CA2611867A1 - Substituted cyclohexyl derivatives as nk-3 receptor antagonists - Google Patents
Substituted cyclohexyl derivatives as nk-3 receptor antagonists Download PDFInfo
- Publication number
- CA2611867A1 CA2611867A1 CA002611867A CA2611867A CA2611867A1 CA 2611867 A1 CA2611867 A1 CA 2611867A1 CA 002611867 A CA002611867 A CA 002611867A CA 2611867 A CA2611867 A CA 2611867A CA 2611867 A1 CA2611867 A1 CA 2611867A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- compound
- optionally substituted
- optionally
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title claims description 9
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title description 108
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 238000000034 method Methods 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 230000001404 mediated effect Effects 0.000 claims abstract description 9
- 229910052796 boron Inorganic materials 0.000 claims abstract description 3
- -1 hydroxy, oxo, phenyl Chemical group 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 68
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 150000002367 halogens Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000005586 smoking cessation Effects 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 165
- 239000000203 mixture Substances 0.000 description 156
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 92
- 239000002904 solvent Substances 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 230000002829 reductive effect Effects 0.000 description 74
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- 101150041968 CDC13 gene Proteins 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 37
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 31
- 239000007787 solid Substances 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- 239000012267 brine Substances 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 23
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 125000001309 chloro group Chemical group Cl* 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- 239000010410 layer Substances 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 14
- 125000001246 bromo group Chemical group Br* 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 206010010904 Convulsion Diseases 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 239000011737 fluorine Chemical group 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 8
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000460 chlorine Chemical group 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- DDPWVABNMBRBFI-UHFFFAOYSA-N tert-butylhydrazine;hydron;chloride Chemical compound Cl.CC(C)(C)NN DDPWVABNMBRBFI-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- XSLHQJJTBVYMJX-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-yl methanesulfonate Chemical compound C1CC(OS(=O)(=O)C)CCC21OCCO2 XSLHQJJTBVYMJX-UHFFFAOYSA-N 0.000 description 3
- LDAMTMVNAGXEDU-UHFFFAOYSA-N 2,2-bis(2-iodoethyl)-1,3-dioxolane Chemical compound ICCC1(CCI)OCCO1 LDAMTMVNAGXEDU-UHFFFAOYSA-N 0.000 description 3
- TZLVUWBGUNVFES-UHFFFAOYSA-N 2-ethyl-5-methylpyrazol-3-amine Chemical compound CCN1N=C(C)C=C1N TZLVUWBGUNVFES-UHFFFAOYSA-N 0.000 description 3
- IHQCJRPOUHFCKA-UHFFFAOYSA-N 4-(2-ethyl-5-methylpyrazol-3-yl)piperidine Chemical compound CCN1N=C(C)C=C1C1CCNCC1 IHQCJRPOUHFCKA-UHFFFAOYSA-N 0.000 description 3
- IIBICWISPHAQIF-UHFFFAOYSA-N 4-(4-bromophenyl)-4-(4-chlorophenyl)sulfonylcyclohexan-1-one Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1(C=2C=CC(Br)=CC=2)CCC(=O)CC1 IIBICWISPHAQIF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010026749 Mania Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000012536 storage buffer Substances 0.000 description 3
- AKTJBXNKJJLHFG-UHFFFAOYSA-N tert-butyl 4-(3-oxobutanoyl)piperidine-1-carboxylate Chemical compound CC(=O)CC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 AKTJBXNKJJLHFG-UHFFFAOYSA-N 0.000 description 3
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LNDNYVIGTNFPLI-UHFFFAOYSA-N 1-(2,4,5-trimethylpyrazol-3-yl)piperidine Chemical compound CN1N=C(C(=C1N1CCCCC1)C)C LNDNYVIGTNFPLI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OKRROXQXGNEUSS-UHFFFAOYSA-N 1h-imidazol-1-ium-1-carboxylate Chemical compound OC(=O)N1C=CN=C1 OKRROXQXGNEUSS-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 2
- RKIKXXMPHKCOTB-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-5h-1,3-thiazol-4-ol Chemical compound CC1=NC(O)(CCl)CS1 RKIKXXMPHKCOTB-UHFFFAOYSA-N 0.000 description 2
- WCMLRSZJUIKVCW-UHFFFAOYSA-N 4-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=C(S)C=C1 WCMLRSZJUIKVCW-UHFFFAOYSA-N 0.000 description 2
- MRTDGZQNSRZPLL-UHFFFAOYSA-N 4-[4-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]butanoic acid Chemical compound OC(=O)CCCC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1 MRTDGZQNSRZPLL-UHFFFAOYSA-N 0.000 description 2
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- RZVZAKMUFYRBQP-UHFFFAOYSA-N 8-(4-chlorophenyl)sulfonyl-8-(4-fluorophenyl)-1,4-dioxaspiro[4.5]decane Chemical compound C1=CC(F)=CC=C1C1(S(=O)(=O)C=2C=CC(Cl)=CC=2)CCC2(OCCO2)CC1 RZVZAKMUFYRBQP-UHFFFAOYSA-N 0.000 description 2
- MQVUWXYWEASWJX-UHFFFAOYSA-N 8-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dioxaspiro[4.5]decane Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)C1CCC2(OCCO2)CC1 MQVUWXYWEASWJX-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 206010024419 Libido decreased Diseases 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910017711 NHRa Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 208000020186 Schizophreniform disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100028651 Tenascin-N Human genes 0.000 description 2
- 101710087911 Tenascin-N Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001934 cyclohexanes Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000017020 hypoactive sexual desire disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 208000022610 schizoaffective disease Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- CTOWDODPISMMHP-UHFFFAOYSA-M (1-benzhydrylazetidin-3-yl)methanesulfonate Chemical compound C1C(CS(=O)(=O)[O-])CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 CTOWDODPISMMHP-UHFFFAOYSA-M 0.000 description 1
- ZZCHUBZBYAFNPJ-UHFFFAOYSA-N (1-benzylpiperidin-4-yl)hydrazine;dihydrochloride Chemical compound Cl.Cl.C1CC(NN)CCN1CC1=CC=CC=C1 ZZCHUBZBYAFNPJ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- GKQXPTHQTXCXEV-UHFFFAOYSA-N (4-chlorophenyl)methanethiol Chemical compound SCC1=CC=C(Cl)C=C1 GKQXPTHQTXCXEV-UHFFFAOYSA-N 0.000 description 1
- FWJLUEHXVHEMRE-UHFFFAOYSA-N (8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)methanol Chemical compound C1CC(CO)(C=2C=CC=CC=2)CCC21OCCO2 FWJLUEHXVHEMRE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YWRXDGYUFPGSDH-MDZDMXLPSA-N (e)-n-methyl-n-[(1-methylindol-2-yl)methyl]-3-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide Chemical compound N1CCCC2=CC(/C=C/C(=O)N(CC=3N(C4=CC=CC=C4C=3)C)C)=CN=C21 YWRXDGYUFPGSDH-MDZDMXLPSA-N 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 description 1
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 1
- HZZGAJXJLNSFQF-UHFFFAOYSA-N 1-(2-ethyl-5-methylpyrazol-3-yl)piperazin-2-one Chemical compound CCN1N=C(C)C=C1N1C(=O)CNCC1 HZZGAJXJLNSFQF-UHFFFAOYSA-N 0.000 description 1
- QCUGIYZOLYUHMH-UHFFFAOYSA-N 1-(2-ethyl-5-methylpyrazol-3-yl)piperidin-4-one Chemical compound CCN1N=C(C)C=C1N1CCC(=O)CC1 QCUGIYZOLYUHMH-UHFFFAOYSA-N 0.000 description 1
- GQPZDFMCHBGNBO-UHFFFAOYSA-N 1-(2-tert-butyl-5-methylpyrazol-3-yl)piperidine Chemical compound CC(C)(C)N1N=C(C=C1N1CCCCC1)C GQPZDFMCHBGNBO-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- UCFJRTISDOOYEC-UHFFFAOYSA-N 1-[(4-chlorophenyl)sulfonylmethyl]-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1CS(=O)(=O)C1=CC=C(Cl)C=C1 UCFJRTISDOOYEC-UHFFFAOYSA-N 0.000 description 1
- GDXQJIASGIISRK-UHFFFAOYSA-N 1-[5-methyl-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]piperidine Chemical compound FC(CN1N=C(C=C1N1CCCCC1)C)(F)F GDXQJIASGIISRK-UHFFFAOYSA-N 0.000 description 1
- NKKISYTZTUFASU-UHFFFAOYSA-N 1-benzyl-3-(4-methyl-1,2,4-triazol-3-yl)piperidine Chemical compound CN1C=NN=C1C1CN(CC=2C=CC=CC=2)CCC1 NKKISYTZTUFASU-UHFFFAOYSA-N 0.000 description 1
- RCDZDBAOFAJUIH-UHFFFAOYSA-N 1-benzyl-4-(3,5-diethylpyrazol-1-yl)piperidine Chemical compound N1=C(CC)C=C(CC)N1C1CCN(CC=2C=CC=CC=2)CC1 RCDZDBAOFAJUIH-UHFFFAOYSA-N 0.000 description 1
- PUMACRRPYCJKEV-UHFFFAOYSA-N 1-benzyl-4-(3,5-diethylpyrazol-1-yl)piperidine;n,n-diethylethanamine Chemical compound CCN(CC)CC.N1=C(CC)C=C(CC)N1C1CCN(CC=2C=CC=CC=2)CC1 PUMACRRPYCJKEV-UHFFFAOYSA-N 0.000 description 1
- WUDDEGZXFZWRKR-UHFFFAOYSA-N 1-benzylpiperidine-3-carbohydrazide Chemical compound C1C(C(=O)NN)CCCN1CC1=CC=CC=C1 WUDDEGZXFZWRKR-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- KIUQWWIOPQFHGW-UHFFFAOYSA-N 1-chloro-4-[(4-fluorophenyl)methylsulfanyl]benzene Chemical compound C1=CC(F)=CC=C1CSC1=CC=C(Cl)C=C1 KIUQWWIOPQFHGW-UHFFFAOYSA-N 0.000 description 1
- OWVFIESJSXRRPZ-UHFFFAOYSA-N 1-chloro-4-[(4-fluorophenyl)methylsulfanyl]benzene N,N-diethylethanamine Chemical compound C(C)N(CC)CC.ClC1=CC=C(C=C1)SCC1=CC=C(C=C1)F OWVFIESJSXRRPZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NSECJXCOETXUHS-UHFFFAOYSA-N 1-methylsulfonylspiro[2h-indole-3,4'-piperidine] Chemical compound C12=CC=CC=C2N(S(=O)(=O)C)CC21CCNCC2 NSECJXCOETXUHS-UHFFFAOYSA-N 0.000 description 1
- QRSIDPLQHZJSAA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-(4-methoxy-4-oxobutyl)piperidine-1,4-dicarboxylate Chemical compound COC(=O)CCCC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1 QRSIDPLQHZJSAA-UHFFFAOYSA-N 0.000 description 1
- CUMYSCMQRWBFKE-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-(4-oxobutyl)piperidine-1,4-dicarboxylate Chemical compound O=CCCCC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1 CUMYSCMQRWBFKE-UHFFFAOYSA-N 0.000 description 1
- BDRPQFXTMDADSO-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl 4-pent-4-enylpiperidine-1,4-dicarboxylate Chemical compound C=CCCCC1(C(=O)OC)CCN(C(=O)OC(C)(C)C)CC1 BDRPQFXTMDADSO-UHFFFAOYSA-N 0.000 description 1
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HKCFTGZESMCKJA-UHFFFAOYSA-N 1-pyridin-4-ylimidazolidin-2-one Chemical group O=C1NCCN1C1=CC=NC=C1 HKCFTGZESMCKJA-UHFFFAOYSA-N 0.000 description 1
- XHODPIGLBGDPHW-UHFFFAOYSA-N 2-(4-methyl-1-piperidin-1-ylimidazol-2-yl)propan-2-ol Chemical compound OC(C)(C)C=1N(C=C(N1)C)N1CCCCC1 XHODPIGLBGDPHW-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- KYZXNTUFRCGZOU-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methylsulfanyl]phenyl]propan-2-ol Chemical compound C1=CC(C(C)(O)C)=CC=C1SCC1=CC=C(Cl)C=C1 KYZXNTUFRCGZOU-UHFFFAOYSA-N 0.000 description 1
- OCRDJNWEKNYCGD-UHFFFAOYSA-N 2-aminoethanol;1-(3-fluorophenyl)piperazin-2-one;hydrochloride Chemical compound Cl.NCCO.FC1=CC=CC(N2C(CNCC2)=O)=C1 OCRDJNWEKNYCGD-UHFFFAOYSA-N 0.000 description 1
- JRMVLHGCVIAPAE-UHFFFAOYSA-N 2-aminoethanol;n-(2-ethyl-5-methylpyrazol-3-yl)-2-(2-hydroxyethylamino)acetamide Chemical compound NCCO.CCN1N=C(C)C=C1NC(=O)CNCCO JRMVLHGCVIAPAE-UHFFFAOYSA-N 0.000 description 1
- OVNHSFQANYEQSS-UHFFFAOYSA-N 2-bromo-n-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(NC(=O)CBr)=C1 OVNHSFQANYEQSS-UHFFFAOYSA-N 0.000 description 1
- ZIDFWUZLZOVUJM-UHFFFAOYSA-N 2-bromoacetyl bromide 2-bromo-N-(3-fluorophenyl)acetamide Chemical compound BrCC(=O)Br.BrCC(=O)NC1=CC(=CC=C1)F ZIDFWUZLZOVUJM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- FYMDXGOUIFUQKZ-UHFFFAOYSA-N 2-chloro-n-(2-ethyl-5-methylpyrazol-3-yl)acetamide Chemical compound CCN1N=C(C)C=C1NC(=O)CCl FYMDXGOUIFUQKZ-UHFFFAOYSA-N 0.000 description 1
- WOOKLLIJIBEXSY-UHFFFAOYSA-N 2-chloroacetyl chloride;2-chloro-n-(2-ethyl-5-methylpyrazol-3-yl)acetamide Chemical compound ClCC(Cl)=O.CCN1N=C(C)C=C1NC(=O)CCl WOOKLLIJIBEXSY-UHFFFAOYSA-N 0.000 description 1
- NTLAIPNGSZBJBB-UHFFFAOYSA-N 2-ethyl-3-piperidin-4-yl-5,6-dihydro-4h-cyclopenta[c]pyrazole Chemical compound CCN1N=C2CCCC2=C1C1CCNCC1 NTLAIPNGSZBJBB-UHFFFAOYSA-N 0.000 description 1
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- RZWRPESYZFJDIU-UHFFFAOYSA-N 2-methyl-4-(piperazin-1-ylmethyl)-1,3-thiazole Chemical compound S1C(C)=NC(CN2CCNCC2)=C1 RZWRPESYZFJDIU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NFBZQFGNDBOQAP-UHFFFAOYSA-N 2-tert-butyl-4-(2-tert-butyl-5-methylpyrazol-3-yl)piperidine-1-carboxylic acid Chemical compound CC1=NN(C(=C1)C2CCN(C(C2)C(C)(C)C)C(=O)O)C(C)(C)C NFBZQFGNDBOQAP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HYCKBFLTZGORKA-HNPMAXIBSA-N 3,7-dihydropurin-6-one;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HYCKBFLTZGORKA-HNPMAXIBSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- FJTAGGCEUHTDGA-UHFFFAOYSA-N 3-methyl-4-piperazin-1-yl-1,2,5-oxadiazole;hydrochloride Chemical compound Cl.CC1=NON=C1N1CCNCC1 FJTAGGCEUHTDGA-UHFFFAOYSA-N 0.000 description 1
- PTXJSRZKZYPHQJ-UHFFFAOYSA-N 4-(2,4,5-trimethylpyrazol-3-yl)piperidine Chemical compound CC1=NN(C)C(C2CCNCC2)=C1C PTXJSRZKZYPHQJ-UHFFFAOYSA-N 0.000 description 1
- IFRZVQGNTASXKO-UHFFFAOYSA-N 4-(2-tert-butyl-5-methylpyrazol-3-yl)piperidine Chemical compound CC(C)(C)N1N=C(C)C=C1C1CCNCC1 IFRZVQGNTASXKO-UHFFFAOYSA-N 0.000 description 1
- HMQVWIUAMNGURO-UHFFFAOYSA-N 4-(4-chlorophenyl)sulfonyl-4-(4-fluorophenyl)cyclohexan-1-one 4-methylbenzenesulfonic acid hydrate Chemical compound O.C1(=CC=C(C=C1)S(=O)(=O)O)C.ClC1=CC=C(C=C1)S(=O)(=O)C1(CCC(CC1)=O)C1=CC=C(C=C1)F HMQVWIUAMNGURO-UHFFFAOYSA-N 0.000 description 1
- YGKDISJLDVGNOR-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole;hydrochloride Chemical compound Cl.CC1=NC(CCl)=CS1 YGKDISJLDVGNOR-UHFFFAOYSA-N 0.000 description 1
- RBASZOXLGJCZLD-UHFFFAOYSA-N 4-[5-methyl-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]piperidine Chemical compound FC(F)(F)CN1N=C(C)C=C1C1CCNCC1 RBASZOXLGJCZLD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- DXJKRLHHCGXHMB-UHFFFAOYSA-N 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine Chemical compound C1NCCN2N=CN=C21 DXJKRLHHCGXHMB-UHFFFAOYSA-N 0.000 description 1
- FYSZGPHWOURLRU-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylsulfanyl]-2-(trifluoromethyl)pyridine Chemical compound C1=NC(C(F)(F)F)=CC=C1SCC1=CC=C(Cl)C=C1 FYSZGPHWOURLRU-UHFFFAOYSA-N 0.000 description 1
- RPFAUCIXZGMCFN-UHFFFAOYSA-N 5-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)C=N1 RPFAUCIXZGMCFN-UHFFFAOYSA-N 0.000 description 1
- LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
- OVVBXVJFGCFEFK-UHFFFAOYSA-N 6-chloro-2-methoxy-3-nitropyridine Chemical compound COC1=NC(Cl)=CC=C1[N+]([O-])=O OVVBXVJFGCFEFK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- UDVSDISNCKEMHE-UHFFFAOYSA-N 8-(2-ethyl-5-methylpyrazol-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound CCN1N=C(C)C=C1N1CCC2(OCCO2)CC1 UDVSDISNCKEMHE-UHFFFAOYSA-N 0.000 description 1
- QQRKZYWRDVOVKS-UHFFFAOYSA-N 8-(4-bromophenyl)-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCC21OCCO2 QQRKZYWRDVOVKS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LUMLSQRRKPUAHH-UHFFFAOYSA-N 8-[4-(trifluoromethyl)phenyl]sulfanyl-1,4-dioxaspiro[4.5]decane Chemical compound C1=CC(C(F)(F)F)=CC=C1SC1CCC2(OCCO2)CC1 LUMLSQRRKPUAHH-UHFFFAOYSA-N 0.000 description 1
- PXHKBKJQKDEHLN-UHFFFAOYSA-N 8-o-tert-butyl 3-o-methyl 4-oxo-8-azaspiro[4.5]decane-3,8-dicarboxylate Chemical compound O=C1C(C(=O)OC)CCC11CCN(C(=O)OC(C)(C)C)CC1 PXHKBKJQKDEHLN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010001022 Acute psychosis Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006362 Brief psychotic disorder, with postpartum onset Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OFDFGBYVWJTHSY-UHFFFAOYSA-N C(=O)(N1C=NC=C1)N1C=NC=C1.N1(C=NC=C1)C(=O)O Chemical compound C(=O)(N1C=NC=C1)N1C=NC=C1.N1(C=NC=C1)C(=O)O OFDFGBYVWJTHSY-UHFFFAOYSA-N 0.000 description 1
- NZOUTMAVRFBTEC-UHFFFAOYSA-N C(=O)[O-].[NH4+].C(C)C1=NN(C(=C1)CC)C1CCNCC1 Chemical compound C(=O)[O-].[NH4+].C(C)C1=NN(C(=C1)CC)C1CCNCC1 NZOUTMAVRFBTEC-UHFFFAOYSA-N 0.000 description 1
- GTDLAMQHFKBIQT-UHFFFAOYSA-N C(C)N1N=C(C=C1N1CCC2(OCCO2)CC1)C.C(C)N1N=C(C=C1N1CCC(CC1)=O)C Chemical compound C(C)N1N=C(C=C1N1CCC2(OCCO2)CC1)C.C(C)N1N=C(C=C1N1CCC(CC1)=O)C GTDLAMQHFKBIQT-UHFFFAOYSA-N 0.000 description 1
- XBYBDGBHCHKTHG-UHFFFAOYSA-N CC(=O)C.CC(C)(C)C1N(CCC(C1)C(CC(C)=O)=O)C(=O)O Chemical compound CC(=O)C.CC(C)(C)C1N(CCC(C1)C(CC(C)=O)=O)C(=O)O XBYBDGBHCHKTHG-UHFFFAOYSA-N 0.000 description 1
- UVFWCTIETZIGJH-UHFFFAOYSA-N CNC(NNC(=O)C1CN(CCC1)CC1=CC=CC=C1)=S Chemical compound CNC(NNC(=O)C1CN(CCC1)CC1=CC=CC=C1)=S UVFWCTIETZIGJH-UHFFFAOYSA-N 0.000 description 1
- SDIWAGXAQHWOOL-UHFFFAOYSA-N C[Si](C)(C)C=[N+]=[N-].CC(C)(OC(=O)N1CCC(CC1)(CCCC(=O)OC)C(=O)OC)C Chemical compound C[Si](C)(C)C=[N+]=[N-].CC(C)(OC(=O)N1CCC(CC1)(CCCC(=O)OC)C(=O)OC)C SDIWAGXAQHWOOL-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OHNXQTNNMRJMHY-UHFFFAOYSA-N ClC1=CC(=CC=C1)C(=O)OO.ClC1=CC=C(C=C1)S(=O)(=O)CC1=CC=C(C=C1)F Chemical compound ClC1=CC(=CC=C1)C(=O)OO.ClC1=CC=C(C=C1)S(=O)(=O)CC1=CC=C(C=C1)F OHNXQTNNMRJMHY-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- XMZANEBWXPVPQR-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.CC(C)N1C(C2(C3=CC=CC=C13)CCNCC2)=O Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.CC(C)N1C(C2(C3=CC=CC=C13)CCNCC2)=O XMZANEBWXPVPQR-UHFFFAOYSA-N 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N Hydrazide-Acetic acid Natural products C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000030431 Male orgasmic disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- GSYLBLRTHYZQNB-UHFFFAOYSA-N N-(1-hydroxyimino-1-piperazin-1-ylpropan-2-ylidene)hydroxylamine Chemical compound ON=C(C(C)=NO)N1CCNCC1 GSYLBLRTHYZQNB-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- YYLLOZJPNBMSIS-UHFFFAOYSA-N N-hydroxy-2-hydroxyiminopropanimidoyl chloride Chemical compound ON=C(C)C(Cl)=NO YYLLOZJPNBMSIS-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- QNPNWCKRKVTZFK-UHFFFAOYSA-N N1CCNCC1.ON=C(C(C)=NO)N1CCNCC1 Chemical compound N1CCNCC1.ON=C(C(C)=NO)N1CCNCC1 QNPNWCKRKVTZFK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010052276 Pseudodementia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- OHWNKRFFJPWWGT-UHFFFAOYSA-N S(=O)(Cl)Cl.Cl.ClCC=1N=C(SC1)C Chemical compound S(=O)(Cl)Cl.Cl.ClCC=1N=C(SC1)C OHWNKRFFJPWWGT-UHFFFAOYSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000030047 Sexual desire disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- IUPNQHHNDSJGIC-UHFFFAOYSA-M [F-].[Cs+].FC(C1=CC=C(C=C1)SC1CCC2(OCCO2)CC1)(F)F Chemical compound [F-].[Cs+].FC(C1=CC=C(C=C1)SC1CCC2(OCCO2)CC1)(F)F IUPNQHHNDSJGIC-UHFFFAOYSA-M 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- QRMWZBFMVQSGHC-UHFFFAOYSA-N acetyl chloride;dihydrochloride Chemical compound Cl.Cl.CC(Cl)=O QRMWZBFMVQSGHC-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- XJHCXCQVJFPJIK-UHFFFAOYSA-M cesium fluoride Substances [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FLSQYHQDVJHORC-UHFFFAOYSA-N chloromethylbenzene ethyl 1-benzylpiperidine-3-carboxylate Chemical compound C(C1=CC=CC=C1)Cl.C1(=CC=CC=C1)CN1CC(CCC1)C(=O)OCC FLSQYHQDVJHORC-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclo-pentanone Natural products O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 1
- 150000001924 cycloalkanes Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PRZPVJOTGOLXRT-UHFFFAOYSA-N cyclohexanone;sodium Chemical compound [Na].O=C1CCCCC1 PRZPVJOTGOLXRT-UHFFFAOYSA-N 0.000 description 1
- MZUPWNMULGRONZ-UHFFFAOYSA-N cyclohexylsulfonylcyclohexane Chemical class C1CCCCC1S(=O)(=O)C1CCCCC1 MZUPWNMULGRONZ-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CDMAVYOAEITWFQ-UHFFFAOYSA-N ethyl 1-benzylpiperidine-3-carboxylate Chemical compound C1C(C(=O)OCC)CCCN1CC1=CC=CC=C1 CDMAVYOAEITWFQ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DGCTVLNZTFDPDJ-UHFFFAOYSA-N heptane-3,5-dione Chemical compound CCC(=O)CC(=O)CC DGCTVLNZTFDPDJ-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000021731 hypoalgesia Diseases 0.000 description 1
- 230000036032 hypoalgesia Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000004197 inhibited female orgasm Diseases 0.000 description 1
- 201000000068 inhibited male orgasm Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000006738 locomotor deficit Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 208000015421 male orgasm disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- JQVZNVXMZKNDSP-UHFFFAOYSA-N methyl 4-[(4-chlorophenyl)methylsulfanyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1SCC1=CC=C(Cl)C=C1 JQVZNVXMZKNDSP-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- AWWOVAYRSZUQAZ-UHFFFAOYSA-N methylhydrazine;oxalic acid Chemical group CNN.OC(=O)C(O)=O AWWOVAYRSZUQAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- IJDIONYCFIJYLK-UHFFFAOYSA-N n,n-diethylethanamine;propan-2-ol Chemical compound CC(C)O.CCN(CC)CC IJDIONYCFIJYLK-UHFFFAOYSA-N 0.000 description 1
- RRPNXMBOBPNLJY-UHFFFAOYSA-N n-(2-ethyl-5-methylpyrazol-3-yl)-2-(2-hydroxyethylamino)acetamide Chemical compound CCN1N=C(C)C=C1NC(=O)CNCCO RRPNXMBOBPNLJY-UHFFFAOYSA-N 0.000 description 1
- NWACHNGGNDLSRX-UHFFFAOYSA-N n-(azetidin-3-yl)-2-ethyl-5-methylpyrazol-3-amine Chemical compound CCN1N=C(C)C=C1NC1CNC1 NWACHNGGNDLSRX-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- RFARBXDEFNSTBA-UHFFFAOYSA-N oxalic acid;2,2,2-trifluoroethylhydrazine Chemical group OC(=O)C(O)=O.NNCC(F)(F)F RFARBXDEFNSTBA-UHFFFAOYSA-N 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical compound [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- JLPGSSHHLKZYMJ-UHFFFAOYSA-N piperidin-4-amine;hydrochloride Chemical compound Cl.NC1CCNCC1 JLPGSSHHLKZYMJ-UHFFFAOYSA-N 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000021011 postpartum psychosis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000026961 psychosexual disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000009155 sensory pathway Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- SXOVJOBXZPCKRA-UHFFFAOYSA-N spiro[1h-indole-3,4'-piperidine]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CCNCC1 SXOVJOBXZPCKRA-UHFFFAOYSA-N 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- JTTMPFFTPWIZRS-UHFFFAOYSA-N tert-butyl 2-oxo-1-propan-2-ylspiro[indole-3,4'-piperidine]-1'-carboxylate Chemical compound C12=CC=CC=C2N(C(C)C)C(=O)C21CCN(C(=O)OC(C)(C)C)CC2 JTTMPFFTPWIZRS-UHFFFAOYSA-N 0.000 description 1
- YEJCWMVHDBKPBN-UHFFFAOYSA-N tert-butyl 2-oxospiro[1h-indole-3,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C1=CC=CC=C1NC2=O YEJCWMVHDBKPBN-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- RLMUBIZOFHUHBI-UHFFFAOYSA-N trifluoromethyl hypochlorite Chemical group FC(F)(F)OCl RLMUBIZOFHUHBI-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/30—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the compounds of formula (I): wherein A,B, n, X, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
Description
Substituted cyclohexyl derivatives as NK-3 receptor anta2onists The present invention relates to substituted cyclohexyl derivatives, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.
Background information on NK-3 receptor antagonists can be found in literature reviews such as Giardina and Raveglia, Exp. Opin. Ther. Patents (1997) 7(4): 307-323 and Giardina et al., Exp. Opin.
Ther. Patents (2000) 10(6): 939-960. These references also contain pertinent information on preclinical validation of therapies that can be treated with NK-3 antagonists.
Representative examples of compounds prepared in the art as NK-3 antagonists are to be found in WO-A-9719926 (SmithKline Beecham S.p.a.) and US-A-5741910 (Sanofi).
Substituted cyclohexyl derivatives are known in the art. For instance, published International applications WO 2004/031137 and WO 2004/031139 (both Merck Sharp & Dohme Limited) disclose cyclohexyl sulfones as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease.
However, neither document discloses that substituted cyclohexyl derivatives are useful as NK-3 antagonists and are thus useful in the treatment of diseases such as schizophrenia.
The present invention thus provides a compound of Formula (I):
S(O),-X Z-N ~I) R2 Y R$
B
wherein:
rings A and B are independently aryl or heteroaryl;
n is 0, 1 or 2;
X and Y are independently selected from a bond, -CH2-, -C(C,-4alkyl)2- and N(C,_4alkyly;
Z is a bond, -CH2- or -C(C,-4alkyl)2-;
R' is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl, hydroxy, C,_6alkoxy, halogen, CN, C02(C,_6alkyl) or C(CH3)20H, optionally substituted by 1 to 8 halogen atoms;
RZ is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl or halogen;
R3 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 8 halogen atoms;
R4 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl or halogen;
R5 and R6 are independently selected from hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_ 8cycloalkyl, hydroxy, C,_6alkoxy or halogen;
Background information on NK-3 receptor antagonists can be found in literature reviews such as Giardina and Raveglia, Exp. Opin. Ther. Patents (1997) 7(4): 307-323 and Giardina et al., Exp. Opin.
Ther. Patents (2000) 10(6): 939-960. These references also contain pertinent information on preclinical validation of therapies that can be treated with NK-3 antagonists.
Representative examples of compounds prepared in the art as NK-3 antagonists are to be found in WO-A-9719926 (SmithKline Beecham S.p.a.) and US-A-5741910 (Sanofi).
Substituted cyclohexyl derivatives are known in the art. For instance, published International applications WO 2004/031137 and WO 2004/031139 (both Merck Sharp & Dohme Limited) disclose cyclohexyl sulfones as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease.
However, neither document discloses that substituted cyclohexyl derivatives are useful as NK-3 antagonists and are thus useful in the treatment of diseases such as schizophrenia.
The present invention thus provides a compound of Formula (I):
S(O),-X Z-N ~I) R2 Y R$
B
wherein:
rings A and B are independently aryl or heteroaryl;
n is 0, 1 or 2;
X and Y are independently selected from a bond, -CH2-, -C(C,-4alkyl)2- and N(C,_4alkyly;
Z is a bond, -CH2- or -C(C,-4alkyl)2-;
R' is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl, hydroxy, C,_6alkoxy, halogen, CN, C02(C,_6alkyl) or C(CH3)20H, optionally substituted by 1 to 8 halogen atoms;
RZ is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl or halogen;
R3 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 8 halogen atoms;
R4 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl or halogen;
R5 and R6 are independently selected from hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_ 8cycloalkyl, hydroxy, C,_6alkoxy or halogen;
R7 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl, C3_8cycloalkyl, (CH2)0_2ary1, (CH2)0_ 2heteroaryl or Het, optionally substituted by 1 to 8 halogen atoms, C,-4alkyl, hydroxy, C,-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 to 3 groups selected from C,-4alkyl;
R8 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl or C3_8cycloalkyl;
or R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle, optionally containing 1, 2 or 3 further heteroatoms selected from N, 0 and S, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,_ 6alkyl, C2_ 6alkenyl, C2_6alkynyl or C3_8cycloalkyl, hydroxy, oxo, (CH2)0_3C,_6alkoxy, (CH2)0--3Oary1, (CH2)0--3ary1, (CH2)0--3heteroaryl, (CH2)0_3Het, or (CH2)0_3NRaRb, wherein said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_6alkyl, hydroxy, oxo, C,_6alkoxy or halogen, which C,_6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said aryl, heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1, 2 or 3 heteroatoms selected from N, 0 or S and which ring is optionally substituted by C,-4alkyl, hydroxy, oxo, C,-4alkoxy or halogen, and which heterocycle may optionally be fused to heteroaryl, which heteroaryl is optionally substituted by CI-6alkyl or trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5- or 10-membered mono- or bi-cyclic ring system optionally containing 1, 2 or 3 heteroatoms selected from N, 0 and S, and further optionally containing 1, 2 or 3 double bonds and also optionally substituted by 1 to 3 groups independently selected from C,_6alkyl, hydroxy, oxo, phenyl and SO2C,_6alkyl;
Ra is hydrogen, C,_6alkyl, C(O)C,_6alkyl, C(O)OC,_6alkyl, C(O)NH(C,_6alkyl), (CH2)0_3ary1, (CH2)0_3heteroaryl or SO2C,_6alkyl, optionally substituted by C,_6alkyl;
Rb is hydrogen, CI-6alkyl or aryl;
and pharmaceutically acceptable salts thereof.
In one embodiment, ring A is phenyl, pyridyl or pyrimidyl. Preferably, ring A
is phenyl or pyridyl.
In another embodiment, ring B is aryl or pyridyl. Preferably, ring B is phenyl.
In another embodiment, n is 1 or 2. Preferably, n is 2.
In another embodiment, X is a bond, -CH2- or -C(C,-4alkyl)2-. Preferably, X is a bond or -CH2-. More preferably, X is a bond.
In another embodiment, Y is a bond, -CH2-- or -C(C,-4alkyl)2-. Preferably, Y
is a bond or -CH2-. More preferably, Y is a bond.
In another embodiment, Z is a bond or -CH2-. Preferably, Z is a bond.
In another embodiment, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, C02(C,_ 4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms.
Preferably, R' is hydrogen, C,_ 4alkyl, C,_4alkoxy, halogen, CN, CO2CH3 or C(CH3)20H, optionally substituted by 1 to 3 halogen atoms.
R8 is hydrogen, C,_6alkyl, C2_6alkenyl, C2_6alkynyl or C3_8cycloalkyl;
or R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle, optionally containing 1, 2 or 3 further heteroatoms selected from N, 0 and S, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,_ 6alkyl, C2_ 6alkenyl, C2_6alkynyl or C3_8cycloalkyl, hydroxy, oxo, (CH2)0_3C,_6alkoxy, (CH2)0--3Oary1, (CH2)0--3ary1, (CH2)0--3heteroaryl, (CH2)0_3Het, or (CH2)0_3NRaRb, wherein said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_6alkyl, hydroxy, oxo, C,_6alkoxy or halogen, which C,_6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said aryl, heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1, 2 or 3 heteroatoms selected from N, 0 or S and which ring is optionally substituted by C,-4alkyl, hydroxy, oxo, C,-4alkoxy or halogen, and which heterocycle may optionally be fused to heteroaryl, which heteroaryl is optionally substituted by CI-6alkyl or trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5- or 10-membered mono- or bi-cyclic ring system optionally containing 1, 2 or 3 heteroatoms selected from N, 0 and S, and further optionally containing 1, 2 or 3 double bonds and also optionally substituted by 1 to 3 groups independently selected from C,_6alkyl, hydroxy, oxo, phenyl and SO2C,_6alkyl;
Ra is hydrogen, C,_6alkyl, C(O)C,_6alkyl, C(O)OC,_6alkyl, C(O)NH(C,_6alkyl), (CH2)0_3ary1, (CH2)0_3heteroaryl or SO2C,_6alkyl, optionally substituted by C,_6alkyl;
Rb is hydrogen, CI-6alkyl or aryl;
and pharmaceutically acceptable salts thereof.
In one embodiment, ring A is phenyl, pyridyl or pyrimidyl. Preferably, ring A
is phenyl or pyridyl.
In another embodiment, ring B is aryl or pyridyl. Preferably, ring B is phenyl.
In another embodiment, n is 1 or 2. Preferably, n is 2.
In another embodiment, X is a bond, -CH2- or -C(C,-4alkyl)2-. Preferably, X is a bond or -CH2-. More preferably, X is a bond.
In another embodiment, Y is a bond, -CH2-- or -C(C,-4alkyl)2-. Preferably, Y
is a bond or -CH2-. More preferably, Y is a bond.
In another embodiment, Z is a bond or -CH2-. Preferably, Z is a bond.
In another embodiment, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, C02(C,_ 4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms.
Preferably, R' is hydrogen, C,_ 4alkyl, C,_4alkoxy, halogen, CN, CO2CH3 or C(CH3)20H, optionally substituted by 1 to 3 halogen atoms.
More preferably, R' is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy, CN, CO2CH3 or C(CH3)20H.
In another embodiment, RZ is hydrogen or C,_6alkyl. Preferably, RZ is hydrogen or methyl.
More preferably, RZ is hydrogen.
In another embodiment, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. Preferably, R3 is hydrogen, C,_4alkyl, C,_4alkoxy, halogen or CN, optionally substituted by 1 to 3 halogen atoms. More preferably, R3 is hydrogen, methyl, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or CN.
In another embodiment, R4 is hydrogen or halogen. Preferably, R4 is hydrogen, fluorine or chlorine.
In another embodiment, R5 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, or halogen. Preferably, R5 is hydrogen, methyl, hydroxy, methoxy or fluorine. More preferably, R5 is hydrogen, hydroxy or fluorine. Most preferably, R5 is hydrogen.
In another embodiment, R6 is hydrogen or C,_6alkyl. Preferably, R6 is hydrogen or methyl.
More preferably, R6 is hydrogen.
In another embodiment, R7 is hydrogen, C,_6alkyl, (CH2)0_2ary1, or Het, optionally substituted by C,-4alkyl, C,-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 or 2 methyl or ethyl groups. Preferably, R7 is hydrogen, benzyl or piperidinyl, optionally substituted by methoxy or pyrazolyl, which pyrazolyl is optionally substituted by 1 or 2 methyl or ethyl groups.
More preferably, R7 is hydrogen, 4-methoxybenzyl or 2-ethyl-5-methyl-2H-pyrazolyl-3-yl.
In another embodiment, R8 is hydrogen or C,_6alkyl. Preferably, R8 is hydrogen or methyl.
More preferably, R8 is hydrogen.
In another embodiment, R7 and R8, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle, optionally containing 1 or 2 further heteroatoms selected from N
and 0, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,-4alkyl, oxo, CH2-O-phenyl, phenyl, heteroaryl, CH2heteroaryl, Het, NH2, (CH2)0_,NHRa or CH2N(phenyl)SO2CH3, where said aryl, heteroaryl, and Het are optionally substituted by 1, 2 or 3 groups selected from C,-4alkyl, oxo or halogen, which C,_4alkyl being optionally substituted by hydroxy or 1 to 3 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5-or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by C,_4alkoxy, and which heterocycle may optionally be fused to pyridyl or triazolyl, optionally substituted by trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5-membered monocyclic or a 8- or 9-membered bicyclic ring system, optionally containing 1 or 2 N atoms, further optionally containing 2 or 3 double bonds and also optionally substituted by C,-4alkyl, oxo, phenyl, or SO2C,-4alkyl, and Ra is as hereinbefore defmed.
In another embodiment, RZ is hydrogen or C,_6alkyl. Preferably, RZ is hydrogen or methyl.
More preferably, RZ is hydrogen.
In another embodiment, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. Preferably, R3 is hydrogen, C,_4alkyl, C,_4alkoxy, halogen or CN, optionally substituted by 1 to 3 halogen atoms. More preferably, R3 is hydrogen, methyl, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or CN.
In another embodiment, R4 is hydrogen or halogen. Preferably, R4 is hydrogen, fluorine or chlorine.
In another embodiment, R5 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, or halogen. Preferably, R5 is hydrogen, methyl, hydroxy, methoxy or fluorine. More preferably, R5 is hydrogen, hydroxy or fluorine. Most preferably, R5 is hydrogen.
In another embodiment, R6 is hydrogen or C,_6alkyl. Preferably, R6 is hydrogen or methyl.
More preferably, R6 is hydrogen.
In another embodiment, R7 is hydrogen, C,_6alkyl, (CH2)0_2ary1, or Het, optionally substituted by C,-4alkyl, C,-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 or 2 methyl or ethyl groups. Preferably, R7 is hydrogen, benzyl or piperidinyl, optionally substituted by methoxy or pyrazolyl, which pyrazolyl is optionally substituted by 1 or 2 methyl or ethyl groups.
More preferably, R7 is hydrogen, 4-methoxybenzyl or 2-ethyl-5-methyl-2H-pyrazolyl-3-yl.
In another embodiment, R8 is hydrogen or C,_6alkyl. Preferably, R8 is hydrogen or methyl.
More preferably, R8 is hydrogen.
In another embodiment, R7 and R8, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle, optionally containing 1 or 2 further heteroatoms selected from N
and 0, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,-4alkyl, oxo, CH2-O-phenyl, phenyl, heteroaryl, CH2heteroaryl, Het, NH2, (CH2)0_,NHRa or CH2N(phenyl)SO2CH3, where said aryl, heteroaryl, and Het are optionally substituted by 1, 2 or 3 groups selected from C,-4alkyl, oxo or halogen, which C,_4alkyl being optionally substituted by hydroxy or 1 to 3 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5-or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by C,_4alkoxy, and which heterocycle may optionally be fused to pyridyl or triazolyl, optionally substituted by trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5-membered monocyclic or a 8- or 9-membered bicyclic ring system, optionally containing 1 or 2 N atoms, further optionally containing 2 or 3 double bonds and also optionally substituted by C,-4alkyl, oxo, phenyl, or SO2C,-4alkyl, and Ra is as hereinbefore defmed.
Preferably, R7 and R8, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, dihydropyridinyl, piperazinyl or morpholinyl ring, which ring is optionally substituted by one or two groups selected from oxo, methyl, phenyl, CH2-O-phenyl, NH2, -N-C-O H IOI Y, -N-C H
> > >
N~ N I
I , H
0 l F
N_ N
tBu CF3 N
. . . N.
N N N N
> > > >
, N /N~
~ - -N
N
/N-l ~N
N -N -OH N N
> > > >
N~
;~~ I I N O' N N -O
N-N N
S N
N N
Na~ N
~ N I %~'/ ~/S
> >
O
~
< ; -N N
~
NN N
N N/
_ > > >
> > >
N~ N I
I , H
0 l F
N_ N
tBu CF3 N
. . . N.
N N N N
> > > >
, N /N~
~ - -N
N
/N-l ~N
N -N -OH N N
> > > >
N~
;~~ I I N O' N N -O
N-N N
S N
N N
Na~ N
~ N I %~'/ ~/S
> >
O
~
< ; -N N
~
NN N
N N/
_ > > >
N)~ N \N'k 0 ~or~*
and which ring is optionally fused to 3-trifluoromethylpyridyl or 1,2,4-triazolyl, and which ring is further optionally spiro-fused to =N~H
N
rN,j N O
N
SO2CHg 5 or where = indicates the spiro-centre.
In one embodiment of the present invention, there is provided the compound of formula (Ia):
Rl R7 ( A rS(O)õ-X Z-N
~ Y R
(Ia) or a pharmaceutically acceptable salt thereof, wherein ring A, n, X, Y, R', R3, R4, R7 and R8 are as defined in relation to formula (I).
Preferably, ring A is phenyl or pyridyl.
Preferably, n is 1 or 2. More preferably, n is 2.
Preferably, X is a bond or -CH2-. More preferably, X is a bond.
Preferably, Y is a bond or -CH2-. More preferably, Y is a bond.
Preferably, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, CO2(C,-4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms. More preferably, R' is hydrogen, C,_4alkyl, C,-4alkoxy, halogen, CN, CO2CH3 or C(CH3)20H, optionally substituted by 1 to 3 halogen atoms. Most preferably, R' is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy, CN, CO2CH3 or C(CH3)20H.
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. More preferably, R3 is hydrogen, C,_4alkyl, C,-4alkoxy, halogen or CN, optionally substituted by 1 to 3 halogen atoms. Most preferably, R3 is hydrogen, methyl, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or CN.
and which ring is optionally fused to 3-trifluoromethylpyridyl or 1,2,4-triazolyl, and which ring is further optionally spiro-fused to =N~H
N
rN,j N O
N
SO2CHg 5 or where = indicates the spiro-centre.
In one embodiment of the present invention, there is provided the compound of formula (Ia):
Rl R7 ( A rS(O)õ-X Z-N
~ Y R
(Ia) or a pharmaceutically acceptable salt thereof, wherein ring A, n, X, Y, R', R3, R4, R7 and R8 are as defined in relation to formula (I).
Preferably, ring A is phenyl or pyridyl.
Preferably, n is 1 or 2. More preferably, n is 2.
Preferably, X is a bond or -CH2-. More preferably, X is a bond.
Preferably, Y is a bond or -CH2-. More preferably, Y is a bond.
Preferably, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, CO2(C,-4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms. More preferably, R' is hydrogen, C,_4alkyl, C,-4alkoxy, halogen, CN, CO2CH3 or C(CH3)20H, optionally substituted by 1 to 3 halogen atoms. Most preferably, R' is hydrogen, methyl, chloro, trifluoromethyl, trifluoromethoxy, CN, CO2CH3 or C(CH3)20H.
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. More preferably, R3 is hydrogen, C,_4alkyl, C,-4alkoxy, halogen or CN, optionally substituted by 1 to 3 halogen atoms. Most preferably, R3 is hydrogen, methyl, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or CN.
Preferably, R4 is hydrogen or halogen. More preferably, R4 is hydrogen, fluorine or chlorine.
Preferably, R7 is hydrogen, benzyl or piperidinyl, optionally substituted by methoxy or pyrazolyl, which pyrazolyl is optionally substituted by 1 or 2 methyl or ethyl groups. More preferably, R7 is hydrogen, 4-methoxybenzyl or 2-ethyl-5-methyl-2H-pyrazolyl-3-yl.
Preferably, R8 is hydrogen.
In an alternative preference, R7 and R8, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle, optionally containing one further heteroatom selected from N and 0, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,-4alkyl, oxo, CH2-O-phenyl, phenyl, heteroaryl, CH2heteroaryl, Het, NH2, (CH2)0_,NHRa or CH2N(phenyl)SO2CH3, where said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups selected from C,_4alkyl, oxo, halogen, which C,_4alkyl being optionally substituted by hydroxy or 1 to 3 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by C,_4alkoxy, and which heterocycle may optionally be fused to pyridyl or triazolyl, optionally substituted by trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5- membered monocyclic or a 8- or 9-membered bicyclic ring system, optionally containing 1 or 2 N atoms, further optionally containing 2 or 3 double bonds and also optionally substituted by C,_4alkyl, oxo, phenyl or SO2C,_4alkyl;
and where Ra is as defined in relation to forrnula (I).
More preferably, R7 and R8, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperazinyl or morpholinyl ring, or an oxo-substituted piperazinyl ring further substituted on the nitrogen atom by thiazolyl, 1-ethy1-3-methyl-1,2 pyrazol-5-yl, fluorophenyl or pyridyl, or a piperidinyl or dihydropyridinyl ring optionally substituted with one or two groups selected from methyl, phenyl, CH2 -0-phenyl, NH2, -N ~ N H I~I
N~ -N-C-O H IOI Y, -N-C-N
> > >
.
:
N
N,,r H \/ I \ ~ ~ / I
tBu CF3 N
. . . ~ N.
N N N /N
> > > >
Preferably, R7 is hydrogen, benzyl or piperidinyl, optionally substituted by methoxy or pyrazolyl, which pyrazolyl is optionally substituted by 1 or 2 methyl or ethyl groups. More preferably, R7 is hydrogen, 4-methoxybenzyl or 2-ethyl-5-methyl-2H-pyrazolyl-3-yl.
Preferably, R8 is hydrogen.
In an alternative preference, R7 and R8, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle, optionally containing one further heteroatom selected from N and 0, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C,-4alkyl, oxo, CH2-O-phenyl, phenyl, heteroaryl, CH2heteroaryl, Het, NH2, (CH2)0_,NHRa or CH2N(phenyl)SO2CH3, where said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups selected from C,_4alkyl, oxo, halogen, which C,_4alkyl being optionally substituted by hydroxy or 1 to 3 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by C,_4alkoxy, and which heterocycle may optionally be fused to pyridyl or triazolyl, optionally substituted by trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5- membered monocyclic or a 8- or 9-membered bicyclic ring system, optionally containing 1 or 2 N atoms, further optionally containing 2 or 3 double bonds and also optionally substituted by C,_4alkyl, oxo, phenyl or SO2C,_4alkyl;
and where Ra is as defined in relation to forrnula (I).
More preferably, R7 and R8, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperazinyl or morpholinyl ring, or an oxo-substituted piperazinyl ring further substituted on the nitrogen atom by thiazolyl, 1-ethy1-3-methyl-1,2 pyrazol-5-yl, fluorophenyl or pyridyl, or a piperidinyl or dihydropyridinyl ring optionally substituted with one or two groups selected from methyl, phenyl, CH2 -0-phenyl, NH2, -N ~ N H I~I
N~ -N-C-O H IOI Y, -N-C-N
> > >
.
:
N
N,,r H \/ I \ ~ ~ / I
tBu CF3 N
. . . ~ N.
N N N /N
> > > >
N / N - ~ -N
~N
/N-I ~ N
;-N ;-N -OH N N
> > > >
N
/ /N O\N N, -N \N ~ O ~ N N
N Na~
> > > >
~ TN
N'N- ' S
, , , O O
)~
-N N
N N N O
N/ \ %~ J~
\I ZtIT1 H3CO , or , and further optionally fused to 3-trifluoromethylpyridyl or 1,2,4-triazolyl, and further optionally spiro-fused to . =N~H
N
rN,j N O
N SO2CH3 or where = indicates the spiro-centre.
In one preferred embodiment of the present invention, there is provided the compound of formula (Iaa):
O
R ~ \ S N R9 _ II
O
(Iaa) or a pharmaceutically acceptable salt thereof, wherein R' and R3 are as defmed in relation to formula (I), and R9 is (CH2)0_3NRaRb, where Ra and Rb are as defined in relation to formula (I), or (CH2)0_3heteroaryl or (CH2)0_3Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_6alkyl, hydroxy, oxo, C,_6alkoxy or halogen, which C,_6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5-or 6-membered ring which optionally contains 1 or 2 heteroatoms selected from N and 0, and which ring is optionally substituted by C,_4alkyl, hydroxy or C,-4alkoxy.
Preferably, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, CO2(C,-4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms. More preferably, R' is hydrogen, methyl, trifluoromethyl, trifluoromethoxy, chlorine, CN, CO2CH3 or C(CH3)20H.
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. More preferably, R3 is methyl, trifluoromethyl, trifluoromethoxy, CN, fluorine, chlorine or bromine.
Preferably, R9 is (CH2)0_,NRaRb, where Ra and Rb are as hereinbefore defined, or heteroaryl or Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_4alkyl or oxo, which C,-4alkyl being optionally substituted by hydroxy or 1 to 3 fluorine atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by methoxy.
Examples of suitable R9 groups include:
SO2CH3 tBu O
H II
N -N-C-O /N N
X-> > > >
~CF3 r , F --N
N' N
/N N
OH
Ol N
N~N
' ~N Na~ N N
> > >
O
~
-N N
~
N
N iN
N'N 0-~
> > >
~N
/N-I ~ N
;-N ;-N -OH N N
> > > >
N
/ /N O\N N, -N \N ~ O ~ N N
N Na~
> > > >
~ TN
N'N- ' S
, , , O O
)~
-N N
N N N O
N/ \ %~ J~
\I ZtIT1 H3CO , or , and further optionally fused to 3-trifluoromethylpyridyl or 1,2,4-triazolyl, and further optionally spiro-fused to . =N~H
N
rN,j N O
N SO2CH3 or where = indicates the spiro-centre.
In one preferred embodiment of the present invention, there is provided the compound of formula (Iaa):
O
R ~ \ S N R9 _ II
O
(Iaa) or a pharmaceutically acceptable salt thereof, wherein R' and R3 are as defmed in relation to formula (I), and R9 is (CH2)0_3NRaRb, where Ra and Rb are as defined in relation to formula (I), or (CH2)0_3heteroaryl or (CH2)0_3Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_6alkyl, hydroxy, oxo, C,_6alkoxy or halogen, which C,_6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5-or 6-membered ring which optionally contains 1 or 2 heteroatoms selected from N and 0, and which ring is optionally substituted by C,_4alkyl, hydroxy or C,-4alkoxy.
Preferably, R' is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen, CN, CO2(C,-4alkyl) or C(CH3)20H, optionally substituted by 1 to 5 halogen atoms. More preferably, R' is hydrogen, methyl, trifluoromethyl, trifluoromethoxy, chlorine, CN, CO2CH3 or C(CH3)20H.
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms. More preferably, R3 is methyl, trifluoromethyl, trifluoromethoxy, CN, fluorine, chlorine or bromine.
Preferably, R9 is (CH2)0_,NRaRb, where Ra and Rb are as hereinbefore defined, or heteroaryl or Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C,_4alkyl or oxo, which C,-4alkyl being optionally substituted by hydroxy or 1 to 3 fluorine atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by methoxy.
Examples of suitable R9 groups include:
SO2CH3 tBu O
H II
N -N-C-O /N N
X-> > > >
~CF3 r , F --N
N' N
/N N
OH
Ol N
N~N
' ~N Na~ N N
> > >
O
~
-N N
~
N
N iN
N'N 0-~
> > >
N)~ N ~ \N'k O
\ I b).
and In another preferred embodiment of the present invention, there is provided the compound of formula (Iab):
N O
F3C ~ \ S N R9 O
(Iab) or a pharmaceutically acceptable salt thereof, wherein R3 is as defmed in relation to formula (I) and R9 is as defmed in relation to formula (Iaa).
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy or halogen. More preferably, R3 is hydrogen or halogen. Most preferably, R3 is fluorine, chlorine or bromine.
Preferably, R9 is heteroaryl, optionally substituted by 1 or 2 groups independently selected from C,-4alkyl, and where said heteroaryl is optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom. Examples of suitable R9 groups include:
~ TN
N'N N/N ~ ~ and The independent syntheses of any optical isomers or their chromatographic separations may be achieved as known in the art. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
The present invention includes within its scope solvates of the compounds of formula (I), for example hydrates, and salts thereof.
The present invention also includes within its scope any enantiomers, diasteromers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.
As used herein, the term "C,_6alkyl" means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "C,-4alkyl" shall be understood in an analogous manner, as shall "C,_6alkoxy" and "C1_4alkoxy".
5 The term "C2_6alkenyl" means linear or branched chain alkenyl groups having from 2 to 6 carbon atoms and includes all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl).
The term "C2_6alkynyl" means linear or branched chain alkynyl groups having from 2 to 6 carbon atoms and includes all of the hexynyl and pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-10 butynyl, 1-propynyl, 2-propynyl, and ethynyl (or acetylenyl).
The term "C3_8cycloalkyl" means a cyclic alkane ring having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl).
The term "halogen" refers to fluorine, chlorine, bromine and iodine.
The term "aryl" refers to phenyl and naphthyl.
The term "heteroaryl" as used herein is intended to include the following groups: furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and pyrrolidinyl.
The term "Het" means a heteroaliphatic ring of 3 to 7 ring atoms, which ring contains 1, 2 or 3 heteroatoms selected from N, 0 or S or a group S(O), S(O)2, NH or NC,-4alkyl.
Examples of Het include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, dioxolanyl, pyran, dioxanyl, morpholine, oxathiolanyl, dithianyl, oxathianyl, thiomorpholinyl, trioxanyl, trithianyl.
The terms "thiophenyl" and "thienyl" have the same meaning herein and are used interchangeably. Similarly, the following pair of terms has the same meaning:
"pyridinyl" and "pyridyl".
Exemplary compounds of the present invention include those listed in the Examples section hereinbelow and their pharmaceutically acceptable salts.
These compounds and those defined by the immediately preceding definitions are useful in therapy, particularly as NK-3 antagonists.
The terms "administration of' and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment.
The term "subject," (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, omithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base. Where a basic group is present, such as amino, an acidic salt, i.e. hydrochloride, hydrobromide, acetate, palmoate, and the like, can be used as the dosage form.
Also, in the case of an alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.
The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
\ I b).
and In another preferred embodiment of the present invention, there is provided the compound of formula (Iab):
N O
F3C ~ \ S N R9 O
(Iab) or a pharmaceutically acceptable salt thereof, wherein R3 is as defmed in relation to formula (I) and R9 is as defmed in relation to formula (Iaa).
Preferably, R3 is hydrogen, C,_6alkyl, hydroxy, C,_6alkoxy or halogen. More preferably, R3 is hydrogen or halogen. Most preferably, R3 is fluorine, chlorine or bromine.
Preferably, R9 is heteroaryl, optionally substituted by 1 or 2 groups independently selected from C,-4alkyl, and where said heteroaryl is optionally fused to a 5- or 6-membered ring which optionally contains a nitrogen atom. Examples of suitable R9 groups include:
~ TN
N'N N/N ~ ~ and The independent syntheses of any optical isomers or their chromatographic separations may be achieved as known in the art. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
The present invention includes within its scope solvates of the compounds of formula (I), for example hydrates, and salts thereof.
The present invention also includes within its scope any enantiomers, diasteromers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.
As used herein, the term "C,_6alkyl" means linear or branched chain alkyl groups having from 1 to 6 carbon atoms and includes all of the hexyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "C,-4alkyl" shall be understood in an analogous manner, as shall "C,_6alkoxy" and "C1_4alkoxy".
5 The term "C2_6alkenyl" means linear or branched chain alkenyl groups having from 2 to 6 carbon atoms and includes all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl).
The term "C2_6alkynyl" means linear or branched chain alkynyl groups having from 2 to 6 carbon atoms and includes all of the hexynyl and pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-10 butynyl, 1-propynyl, 2-propynyl, and ethynyl (or acetylenyl).
The term "C3_8cycloalkyl" means a cyclic alkane ring having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl).
The term "halogen" refers to fluorine, chlorine, bromine and iodine.
The term "aryl" refers to phenyl and naphthyl.
The term "heteroaryl" as used herein is intended to include the following groups: furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and pyrrolidinyl.
The term "Het" means a heteroaliphatic ring of 3 to 7 ring atoms, which ring contains 1, 2 or 3 heteroatoms selected from N, 0 or S or a group S(O), S(O)2, NH or NC,-4alkyl.
Examples of Het include aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, dioxolanyl, pyran, dioxanyl, morpholine, oxathiolanyl, dithianyl, oxathianyl, thiomorpholinyl, trioxanyl, trithianyl.
The terms "thiophenyl" and "thienyl" have the same meaning herein and are used interchangeably. Similarly, the following pair of terms has the same meaning:
"pyridinyl" and "pyridyl".
Exemplary compounds of the present invention include those listed in the Examples section hereinbelow and their pharmaceutically acceptable salts.
These compounds and those defined by the immediately preceding definitions are useful in therapy, particularly as NK-3 antagonists.
The terms "administration of' and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment.
The term "subject," (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" is intended to include all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. Depending on the particular functionality of the compound of the present invention, pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, omithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
These salts may be prepared by standard procedures, e.g. by reacting a free acid with a suitable organic or inorganic base. Where a basic group is present, such as amino, an acidic salt, i.e. hydrochloride, hydrobromide, acetate, palmoate, and the like, can be used as the dosage form.
Also, in the case of an alcohol group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracistemal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans.
The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S.
Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffm. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffm or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.) The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S.
Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffm. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffm or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.) The pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
In the treatment or prevention of conditions which require NK-3 receptor modulation an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A
suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day.
Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
Thus there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
Likewise there is provided the use of a compound of formula (I) for the manufacture of a medicament for treating a neurokinin-3 mediated disease.
There is also disclosed a method of treatment of a subject suffering from a neurokinin-3 mediated disease, which comprises administering to that patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Examples of diseases mediated by neurokinin-3 include CNS disorders such as depression (which term includes bipolar (manic) depression (including type I and type II), unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features (e.g. lethargy, over-eating/obesity, hypersomnia) or postpartum onset, seasonal affective disorder and dysthymia, depression-related anxiety, psychotic depression, and depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion); anxiety disorders (including generalised anxiety disorder (GAD), social anxiety disorder (SAD), agitation, tension, social or emotional withdrawal in psychotic patients, panic disorder, and obsessive compulsive disorder); phobias (including agoraphobia and social phobia);
psychosis and psychotic disorders (including schizophrenia, schizo-affective disorder, schizophreniform-diseases, acute psychosis, alcohol psychosis, autism, delirium, mania (including acute mania), manic depressive psychosis, hallucination, endogenous psychosis, organic psychosyndrome, paranoid and delusional disorders, puerperal psychosis, and psychosis associated with neurodegenerative diseases such as Alzheimer's disease); post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD);
cognitive impairment (e.g. the treatment of impairment of cognitive functions including attention, orientation, memory (memory disorders, amnesia, amnesic disorders and age-associated memory 5 impairment) and language function, and including cognitive impairment as a result of stroke, Alzheimer's disease, Aids-related dementia or other dementia states, as well as other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states)); convulsive disorders such as epilepsy (which includes simple partial seizures, complex partial seizures, secondary generalised seizures, generalised seizures including absence seizures, myoclonic seizures, clonic seizures, 10 tonic seizures, tonic clonic seizures and atonic seizures); psychosexual dysfunction (including inhibited sexual desire (low libido), inhibited sexual arousal or excitement, orgasm dysfunction, inhibited female orgasm and inhibited male orgasm, hypoactive sexual desire disorder (HSDD), female sexual desire disorder (FSDD), and sexual dysfunction side-effects induced by treatment with antidepressants of the SSRI-class); sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep 15 apnea and narcolepsy); disorders of eating behaviours (including anorexia nervosa and bulimia nervosa);
neurodegenerative diseases (such as Alzheimer's disease, ALS, motor neuron disease and other motor disorders such as Parkinson's disease (including relief from locomotor deficits and/or motor disability, including slowly increasing disability in purposeful movement, tremors, bradykinesia, hyperkinesia (moderate and severe), akinesia, rigidity, disturbance of balance and co-ordination, and a disturbance of posture), dementia in Parkinson's disease, dementia in Huntington's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like, and demyelinating diseases such as multiple sclerosis and amyotrophiclateral sclerosis); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities (such as abuse of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine and phencyclidine-like compounds, opiates such as cannabis, heroin, morphine, sedative, hypnotic, amphetamine or amphetamine-related drugs such as dextroamphetamine, methylamphetamine or a combination thereof); pain (which includes neuropathic pain (including diabetic neuropathy; sciatica; non-specific lower back pain;
multiple sclerosis pain; pain associated with fibromyalgia or cancer; AIDS-related and HIV-related neuropathy; chemotherapy-induced neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; sympathetically maintained pain and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis;
reflex sympathetic dystrophy such as shoulder/hand syndrome), acute pain (e.g. musculoskeletal pain, post operative pain and surgical pain), inflammatory pain and chronic pain, pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased, sensitivity, to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia), pain associated with migraine, and non-cardiac chest pain); certain CNS-mediated disorders such as emesis, irritable bowel syndrome, and non-ulcer dyspepsia; COPD, asthma, cough, gastro-oesophageal reflex induced cough, and exacerbated asthma; urinary incontinence; hypertension; and conditions associated with platelet hyperaggregability such as tissue ulceration, nephrotic syndrome, diabetes, migraine, coronary artery disease, pre-eclampsia and stroke. Preferably, the compounds of the invention are useful for the treatment of depression; anxiety disorders; phobias; psychosis and psychotic disorders; post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD);
withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities; and irritable bowel syndrome. More preferably, the compounds of the invention are useful for the treatment of depression;
anxiety disorders; phobias; and psychosis and psychotic disorders (especially schizophrenia, schizo-affective disorder, and schizophreniform diseases. Most preferably, the compounds of the invention are useful for the treatment of schizophrenia.
The compounds for use in the present invention are generally active in the following tests. They normally have an IC50 of less than 1 M and preferably less than 100nM.
Details of the NK-3 receptor and its heterologous expression can be found in Huang et al., BBRC, 1992, 184: 966-972 and Sadowski et al., Neuropeptides, 1993, 24: 317-319.
A membrane preparation is prepared as follows. A 10-layer cell factory is seeded with CHO
cells stably expressing NK-3 receptors. The CHO cells are prepared in a triple T175 flask in 11 growth medium which contains Iscore's modified Dulbecco's medium containing l Oml/1200mM L-Glutamine, 10m1/1 penicillin-streptomycin, one vial of hypoxanthine-thymidine 500x/1, lmg/ml geneticin and 10%
fetal bovine serum (inactivated). The cells are grown for 3 days in an incubator. The medium is washed off and the factory is rinsed twice with 400m1 PBS (Ca, Mg-free). 400m1 enzyme free dissoc. solution (EFDS) is added and the factory is maintained for 10 min at room temperature.
The cells are dislodged and the suspension poured into 500m1 centrifuge bottles. The process is repeated with 200m1 EFDS and the mixtures pooled giving 6 bottles in all, which are spun in a centrifuge for 10 min at 2200 rpm.
The supematants are aspirated and the residual cell pellets are frozen at -80 for 30 min to improve cell lysis and then resuspended in 40m1 Tris with inhibitors per cell factory. The cells are homogenized in 40m1 aliquots with 8 strokes of a glass-teflon grinder at setting 40. The homogenate is transferred to 50m1 centrifuge tubes and placed on a rocker for 15 min at r.t.
The homogenate is rehomogenised and held on ice if necessary before being centrifuged again as above.
The supematant is transferred to Sorvall tubes for an SS-34 roter and held on ice.
40m1 cold Tris with inhibitors is used to resuspend and combine the pellets which are again spun as above. The supematants are again transferred to Sorvall tubes which, with those above, are spun at 18000 rpm for 20 min.
The supematants are discarded and the pellets resuspended in a Storage Buffer consisting of 2.50m1 1M Tris pH7.4, 50 1 1000x protease inhibitors (4mg/ml leupeptin (Sigmo), 40mg/ml Bacitracin (Sigma) and 10mM phosphoranidon (Peninsula) all dissolved in water) plus 0.5m10.5M MnC12 ma.de up to 50m1 with H2Odd. A l Omi syringe is used with 20-, 23- and 25-gauge needles sequentially.
A Bradford protein assay in conducted on 2-10 1 aliquots with BSA as standard before 500-1000 1 aliquots are snap-frozen in liquid nitrogen for storage at -80 C.
The membrane binding assay is carried out as follows. The amount of membranes needed to specifically bind < 10% of 125 I-NeurokinB is predetermined. The frozen stocks are then diluted to allow addition in 50 1.
The test compounds are dissolved in DMSO. An automated apparatus (Tecan) is programmed to add 5 1 of compound or DMSO, approximately 100,000 cpm of isotope in 20 1 buffer which is prepared from 50 MTris, pH7.5, 150 M NaC1, bovine serum albumin to 0.02%, and protease inhibitors as in the storage buffer, made up as 0.5M stock, and 175 1 assay buffer (as the storage buffer but containing 5 M MnC12 and without NaC1) into deep well Marsh boxes (Marsh Biomedical Products) in a 96-well format. Excess unlabelled competing peptide is added by hand for non-specific binding as indicated below. The binding reaction is initiated by adding 50 1 of cell membranes. The tubes are incubated with shaking for lh at r.t. and filtered on a Tomtec 96 well cell harvester using Mach III
filtermats (Tomtec) or using either a Packard 96-well harvester or Tomtec 9600 using Unifilter GF/C
(Packard), presoaked in 0.25% polyethyleneimine and washed five times with 1X
wash buffer (0.1M.Tris, pH7.4 and 1M NaC1, 1X = 100m1 of lOX stock per litre of cold distilled water).
If using Unifilter plates, 60 1 Microscint 20 (Packard) is added to each well and the plate is then heat-sealed before counting in a Packard Topcount. Alternatively the filters from the filtermat are placed in 75x100mm plastic tubes and counted on a Cobra gamma counter.
For the assay, typically 10 g of membrane is used at 25,000 cpm which is filtered over a Unifilter GF/C presoaked in 0.5% BSA.
Compounds of the present invention may be prepared by methods disclosed in the documents hereinbefore referred to and by methods known in the art of organic synthesis and the Schemes set forth below.
According to a general process (A), compounds of formula (I) where Z is a bond may be prepared by the reaction of a compound of formula (II) with a compound of formula (III):
R' ~ R7 ( A rS(O)õ-X O HN/
R2~~J/ ~R8 Y
a (II) (III) where A, B, n, X, Y, R', R2, R3, R4, R5, R6, R7 and R8 are as defined in relation to formula (I). The reaction is conveniently preformed in the presence of a hydride source, such as a sodium triacetoxyborohydride, and a mild acid, such as acetic acid, in a suitable solvent, such as 1,2-dichloroethane.
Where they are not commercially available, the starting materials of formulae (II) and (III) may be prepared by methods illustrated in the following Schemes, by methods analogous to those described in the accompanying Descriptions and Examples, or by standard methods well known from the art. For example, compounds of formula (II) can be made from known compounds using procedures analogous to those found in published International applications WO 2002/081435, WO
2004/031137 and WO
2004/031139 (all Merck Sharp & Dohme Limited).
It will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art.
For instance, a compound of formula (I) where R4 is bromine may be transformed into a compound of formula (I) where R4 is hydrogen by hydrogenation using, for example, a palladium on carbon catalyst and hydrogen gas, in a suitable solvent, such as ethyl acetate.
In addition, a compound of formula (I) where R7 is methoxybenzyl may be transformed into a compound of formula (I) where R7 is hydrogen by treatment with ceric ammonium nitrate in a suitable solvent system such as acetonitrile/water. The resultant compound of formula (I) may be transformed into a different compound of formula (I) by reaction with, for example, a substituted piperidinone in the presence of a hydride source such as sodium triacetoxyborohydride, and acid, such as acetic acid, in a suitable solvent, such as 1,2-dichloroethane.
Also, a compound of formula (Iaa) where R9 is a BOC-protected amine, may be transformed to a compound of formula (Iaa) where R9 is an amine by treatment with acid, such as hydrochloric acid, in a suitable solvent, such as 1,4-dioxane. The resultant compound of formula (Iaa) may be transformed into a compound of formula (Iaa) whereR9 is a urea derivative by reaction with an alkyl isocyanate in the presence of a base, such as triethylamine, in a suitable solvent, such as dichloromethane.
General synthetic schemes:
Scheme 1 R' R' O
E:H ~ 3 i i 2 ~ Br d B
'R' O R' O
S O iv ~ v, vi ~S~
R2 ~- R2 O -~ R2 NRTR$
O
B B B
Cis & Trans Reagents: i) Et3N, CH2C12i ii) mCPBA, CH2C12; iii) 2,2-bis(2-iodoethyl)-1,3-dioxolane, NaH, DMF; iv) pTsOH, AcOH, H20, 50 C; v) R'RBNH, NaBH(OAc)3, AcOH, 1,2-dichloroethane; vi) separate isomers Scheme 2 MeO2CA S HO~ ~S
i B B
Reagents: i) MeMgBr, THF, -78 C.
Scheme 3 R' R3 ~S
-Br + ~~ ~ - Rz Reagents: i) NaH, DMF
Scheme 4 R' R' 0 O
R1 q SH -> R2~S O i-~ R2A -S~
R2- ~OD KXOD
R Br R' 0 O R~ 0 O
~S~'/~ iv S~'/~~ O~
R2 x ~O ~- R2 x x Y~ ~/ Y ~--/ ~O
~ ~
R3 ~ R3 R4 Reagents: i) 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate, CsF, DMF, 60 C;
ii) mCPBA, CH2C12i iii) nBuLi, THF; iv) pTsOH, AcOH, H20, 50 C.
Scheme 5 Rs Rs R' Rs Rs 1 Rs Rs HO-X R2~.J S-X~ '--' OJ \/ O\ R2~X / O
Y'-' O R' Y ~,/'C~
R3~~R4 R2~SH R3,&,R4 R3,, s R6 iii R2~S-Y
R3,'=', R4 Reagents: i) BF3.OEt2, CH2C12i ii) pTsOH, AcOH, H20, 50 C; iii) NaIO4, MeOH, H20.
Scheme 6 R5 R6 R5 R6 R' HO-X \ I O MeO2SO-X OD ii R2 ~ 6 Y~~/ 'O~ Y~~/ 'O S-X O
R~ Y~ ~/ 'OD
R 3~ R4 R3,~R4 A $H
iii, iv R~
A Rs Rs R2~ -O'~ XO
Y
R3,, R4 Reagents: i) MeSO2C1, Et3N, CH2C12i ii), Et3N, DMF, 80 C; iii) mCPBA, CH2C12;
iv) pTsOH, AcOH, H20, 50 C.
Scheme 7 ~ HN HN~ ~ H NN~
H2NC ~ 1-4 G HN-@
OH
ring C = aryl, heteroaryl Reagents: i) haloacetyl chloride, ii) ethanolamine, iii) di-tert-butyl azodicarboxylate, nBu3P, EtOAc.
The following abbreviations are used in the Schemes, Descriptions and Examples: DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; Et20: diethyl ether; EtOAc: ethyl acetate; h: hour(s);
MeCN: acetonitrile; MeOH: methanol; min: minute(s); RT: room temperature; THF:
tetrahydrofuran The following Descriptions and Examples illustrate the present invention.
Description 1: 1-Chloro-4-[(4-fluorobenzyl)thio] benzene Triethylamine (6.3 mL, 45.1 mmol) was added dropwise to a stirred solution of 4-chlorothiophenol (5 g, 34.7 mmol) and 4-fluorobenzyl bromide (6.9 g, 36.4 mmol) in CH2C12 (60 mL) over 5 min. The mixture was stirred for lh at ambient temperature then partitioned between CH2C12 and water. The organic extracts were washed with brine, dried (Na2S04) and concentrated in vacuo to give the title compound (8.78 g, 100%).
'H NMR (500MHz, CDC13): 6 7.23-7.19 (6H, m), 6.96 (2H, t, J 8.6), 4.04 (2H, s).
Description 2: 2-[4-(4-Chlorobenzylsulfanyl)phenyl]propan-2-ol A solution of 4-(4-chlorobenzylsulfanyl)benzoic acid methyl ester (prepared according to the method of Description 1) (3 g, 10.2 mmol) in THF (50 mL) was cooled to -78 *C. Methyl magnesium bromide (3M
in Et2O, 10 mL, 30 mmol) was added dropwise. The mixture was stirred at this temperature for 30 min, then warmed to RT. Water and EtOAc were added and the phases separated. The organic layer was washed with brine, dried over Na2S04, filtered and evaporated in vacuo. The title compound (2.71 g, 90%) was obtained after column chromatography on silica gel (Gradient: EtOAc in hexanes 10% to 30%).
'H NMR (360MHz, CDC13): 6 7.37 (d, J 8.4, 2H); 7.24 (m, 6H); 4.05 (s, 2H);
1.55 (s, 6H).
Description 3: 5-{[(4-Chlorophenyl)methyl]thio}-2-(trifluoromethyl) pyridine NaH (60% dispersion in mineral oil, 1.2 g, 30 mmol) was added to a stirred, cooled (0 C) solution of 4-chlorobenzenemethanethiol (4.22 g, 26.5 mmol) in DMF (50 mL). The mixture was stirred at 0 C for 10 min, then 5-bromo-2-(trifluoromethyl)pyridine (5 g, 22.1 mmol) was added.
The mixture was stirred at RT for 4 h, then water was added. The mixture was extracted with EtOAc and the combined organic fractions were washed with water and brine, dried (Na2S04) and the solvent was evaporated under reduced pressure to give the title compound (6.74 g, 100%). m/z (ES) 304 (M+1).
The following compounds were prepared according to the method of Description 3.
Description Compound Br N
F
Description 6: 1-Chloro-4-[(4-fluorobenzyl)sulfonyl]benzene 3-Chloroperbenzoic acid (15.1 g, 87.5 mmol) was added in portions to a stirred, cooled (0 C) solution of 1-chloro-4-[(4-fluorobenzyl)thio]benzene (Description 1; 8.78 g, 34.7 mmol) in CH2C12 (80 mL). The mixture was warmed to RT and stirred overnight. The mixture was cooled in ice and Ca(OH)2 (9.7 g, 131 mmol) was added. The mixture was stirred for 20 min, filtered through HyfloTM and the solvent was evaporated under reduced pressure to give the title compound (9.34 g, 95%).
'H NMR (500MHz, CDC13): 6 7.55 (d, J 8.6, 2H); 7.43 (d, J 8.6, 2H); 7.08 (dd, J 5.4, 8.7, 2H); 7.00-6.94 (m, 2H); 4.27 (s, 2H).
Description 7: 8-[(4-Chlorophenyl)sulfonyl]-8-(4-fluorophenyl)-1,4-dioxaspiro[4.5]decane NaH (60% in mineral oil, 1.53 g, 39 mmol) was added to a solution of 1-chloro-4-[(4-fluorobenzyl)sulfonyl]benzene (Description 6; 4.67 g, 16.3 mmol) in DMF (120 mL) and the mixture was stirred at RT for 10 min. 2,2-Bis(2-iodoethyl)-1,3-dioxolane (6.85 g, 17.9 mmol) was added and the mixture was stirred at RT overnight. The mixture was cooled in ice and water was added. Aqueous NaHCO3 (saturated) was added and the mixture was extracted with EtOAc. The combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel, eluting with 15 - 20% EtOAc/hexane to give the title compound (4.00 g, 59%).
'H NMR (500MHz, CDC13): 6 7.33 (d, J 8.5, 2H); 7.23 (m, 4H); 7.00 (t, J 8.6, 2H); 3.95 (t, J 6.0, 2H);
3.88 (t, J5.9, 2H); 2.59-2.53 (m, 2H); 2.48 (d, J 12.9, 2H); 1.75 (d, J 13.1, 2H); 1.44-1.38 (m, 2H).
Description 8: 4-[(4-Chlorophenyl)sulfonyl]-4-(4-fluorophenyl)cyclohexanone p-Toluenesulfonic acid monohydrate (3.03 g, 15.9 mmol) was added to a stirred, heated (50 C) solution of 8-[(4-chlorophenyl)sulfonyl]-8-(4-fluorophenyl)-1,4-dioxaspiro[4.5]decane (Description 7; 4.00 g, 9.73 mmol) in acetic acid (90 mL) and water (10 mL) and the mixture was stirred at 50 C overnight. The mixture was cooled, diluted with EtOAc and neutralised with K2C03. The mixture was extracted with EtOAc. The combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (3.3 g, 90%).
'H NMR (500MHz, CDC13): 6 7.37-7.30 (m, 4H); 7.25 (m, 2H); 7.10-7.04 (m, 2H);
2.80 (m, 2H); 2.72-2.66 (m, 2H); 2.50 (m, 2H); 2.22-2.15 (m, 2H).
The following compounds were prepared according to the methods of Descriptions 1-8.
R~ 0 O
O
R' Description R R' 9 H 4-Br 3-Cl 4-Br 11 3-CF3 4-Br 12 4-Cl 3-F
13 4-Cl 4-F
14 4-Cl 4-Br 4-Cl 4-CN
16 4-Cl 4-Me 17 4-Cl 4-CF3 18 4-Cl 4-(OCF3) 19 4-Cl 2,5-F2 4-Cl 3,4-C12 21 4-Cl 2-F, 4-Br 22 4-CN 4-Br 23 4-Me 4-Br 24 4-CF3 3-Br 26 4-CF3 4-Cl 27 4-CF3 4-Br 28 4-CF3 3,4-C12 29 4-CF3 3-F, 4-Cl 30 4-(OCF3) 4-Br 31 4-C(Me)20H 4-Cl 32 4-CO2Me 4-Cl The following compounds were prepared according to the methods of Descriptions 1-8.
F3C N S'O
O
0::::
Description R' 34 4-Cl 35 4-Br Description 36: 8-[4-(Trifluoromethyl)phenylthio] -1,4-dioxa-spiro [4.5]
decane Cesium fluoride (10.2 g, 67.7 mmol) was heated to 180 C under vacuum for 2 h, cooled to RT, placed under a N2 atmosphere and 4-(trifluoromethyl)benzenethiol (5.2 g, 29.2 mmol), 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate (J. Med. Chem. 1992, 35, 2243.) (5.3 g, 22.5 mmol) and DMF (44 mL) were added. The mixture was heated to 60 C for 3 h, cooled and water and EtOAc were added. The layers were separated and the organic layer was washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexanes/EtOAc (100:0 increasing to 90:10) to give the title compound (3.51 g, 50%).
'H NMR (500MHz, CDC13): 6 7.52 (d, J 8.1, 2H); 7.42 (d, J 8.1, 2H); 3.93 (s, 4H); 3.31 (m, 1H); 2.02 (m, 2H); 1.85 (m, 2H); 1.75 (m, 2H); 1.62 (m, 2H).
Description 37: 8-[4-(Trifluoromethyl)benzenesulfonyl] -1,4-dioxa-spiro [4.5]
decane Prepared from 8-[4-(trifluoromethyl)phenylthio]-1,4-dioxa-spiro[4.5]decane (Description 36) according to the method of Description 6.
'H NMR (500MHz, CDC13): 6 8.05 (d, J 8.1, 2H); 7.87 (d, J 8.1, 2H); 3.93 (m, 4H); 2.95 (m, 1H); 2.08 (m, 2H); 1.90-1.75 (m, 4H); 1.55 (m, 2H).
Description 38: 8-(4-Bromo)phenylmethyl-8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane n-Butyllithium (1.6M in hexanes, 1.7 mL, 2.7 mmol) was added dropwise to a stirred, cooled (-78 C) solution of 8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane (Description 37, 1 g, 2.86 mmol) in THF (10 mL) and the mixture was stirred at -78 C for 20 min. A
solution of 4-bromobenzyl bromide (1.43 g, 5.7 mmol) in THF (4 mL) was added dropwise and the mixture was stirred 5 at -78 C for 2 h. Water and EtOAc were added, the mixture warmed to RT and the layers were separated. The organic layer was washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexanes/EtOAc (95:5 increasing to 85:15) to give the title compound (1.16 g, 78%).
'H NMR (500MHz, CDC13): 6 7.95 (d, J 8.1, 2H); 7.80 (d, J 8.1, 2H); 7.40 (d, J
8.2, 2H); 7.13 (d, J 8.2, 10 2H); 3.82 (s, 4H); 3.10 (s, 2H); 1.95 (m, 6H); 1.68 (m, 2H).
Description 39: 4-(4-Bromo)phenylmethyl-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexanone Prepared from 8-(4-bromo)phenylmethyl-8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane (Description 38) according to the method of Description 8.
15 'H NMR (500MHz, CDC13): 6 8.09 (d, J 8.1, 2H); 7.90 (d, J 8.1, 2H); 7.42 (d, J 8.2, 2H); 6.98 (d, J 8.2, 2H); 2.96 (s, 2H); 2.84 (m, 2H); 2.43 (m, 2H); 2.15-2.00 (m, 4H).
Description 40: 4-(4-Bromo)phenylmethyl-4-[4-(chloro)benzenesulfonyl]
cyclohexanone Prepared from 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate and 4-chlorobenzenethiol according to the 20 method of Descriptions 36-39.
'H NMR (500MHz, CDC13): 6 7.88 (d, J 8.1, 2H); 7.60 (d, J 8.1, 2H); 7.42 (d, J
8.2, 2H); 6.98 (d, J 8.2, 2H); 2.95 (s, 2H); 2.82 (m, 2H); 2.41 (m, 2H); 2.10 (m, 2H); 2.01 (m, 2H).
Description 41: 8-Phenyl-1,4-dioxaspiro[4.5]decane-8-methyl Methanesulfonate 25 Triethylamine (0.57 g, 0.0056 mol) then methanesulfonyl chloride (0.57 g, 0.00495 mol) were added dropwise to 8-phenyl-1,4-dioxaspiro[4.5]decane-8-methanol (Bioorganic &
Medicinal Chemistry Letters 2002, 12, 1755-1758, 0.82 g, 0.0033 mol) in CH2C12 (10 mL) and the mixture was stirred at RT for 16 h.
The mixture was diluted with CH2C12, washed with water and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound.
'H NMR (360MHz, CDC13): 6 1.52-1.70 (4H, m), 1.88-1.97 (2H, m), 2.30-2.34 (2H, m), 2.55 (3H, s), 3.88-3.97 (4H, m), 4.10 (2H, s), 7.24 (1H, m), 7.35-7.43 (4H, m).
Description 42: 8-Phenyl-8-[(phenylthio)methyl]]-1,4-dioxa-spiro[4.5]decane Thiophenol (0.22 g , 0.002 mol) followed by triethylamine (0.2 g, 0.002 mol) were added to 8-phenyl- 1,4-dioxaspiro[4.5]decane-8-methyl methanesulfonate (Description 41, 0.5 g, 0.0015 mol) in DMF (8 mL) and the mixture was stirred at 80 C for 16 h. The mixture was cooled, diluted with water and extracted with EtOAc. The combined organic fractions were washed with water, and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give the title compound (0.21 g, 42%).
'H NMR (360MHz, CDC13): 6 1.53-1.69 (4H, m), 1.94-2.02 (2H, m), 2.35 (2H, m), 3.16 (2H, s), 3.87-3.96 (4H, m), 7.06-7.41 (10H, m).
Description 43: 4-Phenyl-4-[(phenylsulfonyl)methylllcyclohexanone To an ice-bath-cooled solution of 8-phenyl-8-[(phenylthio)methyl]]-1,4-dioxa-spiro[4.5]decane (Description 42, 0.21 g, 0.00062 mol) in CH2C12 (8 mL) was added portionwise 3-chloroperbenzoic acid (70%, 0.36 g, 0.0015 mol). After allowing the mixture to warm to RT it was stirred for 16 h. Ca(OH)2 (0.068 g, 0.00092 mol) was added and the mixture was stirred at RT for 15 min.
The mixture was filtered through celite and the solvent was evaporated under reduced pressure. The residue was dissolved in acetic acid (5 mL) and water (0.5 mL) andp-toluenesulfonic acid monohydrate (176 mg, 0.00093 mol) was added. The mixture was heated at 50 C for 16 h, cooled and EtOAc and water were added. The layers were separated and the organic layer was washed with water, and aqueous NaHCO3, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash colunm chromatography on silica gel to give the title compound (0.16 g, 80%).
'H NMR (360MHz, CDC13): 6 2.26-2.48 (6H, m), 2.83 (2H, m), 3.45 (2H, m), 7.19-7.60 (10H, m).
Description 44: 8-(4-Bromophenyl)-8-[(4-trifluoromethyl)phenylthiol]-1,4-dioxa-spiro[4.5]decane Boron trifluoride diethyl etherate (1.82 g, 13 mmol) then 4-(trifluoromethyl)thiophenol (2.3 g, 13 mmol) were added dropwise to a stirred, cooled (-10 C) solution of 8-(4-bromo-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (prepared according to Zhang, Y.; Schuster, G.B. J. Org.
Chem. 1994, 59, 1855.) (2 g, 6.4 mmol) in CH2C12 (32 mL) and the mixture was stirred at RT for 2 h.
Water was added, the layers were separated and the organic layer was washed with brine, dried (Na2S04), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc (98:2 increasing to 90:10) to give the title compound (0.4 g, 13%).
'H NMR (400MHz, CDC13): 6 7.40 (m, 4H); 7.15 (d, J 8.4, 2H); 7.05 (d, J 8.4, 2H); 3.96 (m, 4H); 2.20-1.50 (m, 8H).
Description 45: 4-(4-Bromophenyl)-4-[(4-trifluoromethyl)benzenesulfinyl]
cyclohexanone Sodium metaperiodate (131 mg, 0.7 mmol) in water (1 mL) was added to a solution of 4-(4-bromophenyl)-4-[(4-trifluoromethyl)phenylthio]cyclohexanone [prepared from 8-(4-bromophenyl)-8-[(4-trifluoromethyl)phenylthiol]-1,4-dioxa-spiro[4.5]decane (Description 44) according to the method of Description 8] (0.22 g, 0.51 mmol) in methanol (2 mL) and the mixture was stirred at RT overnight. The mixture was filtered and the solvent was evaporated under reduced pressure.
Water and EtOAc were added and the layers were separated. The organic fraction was washed with brine, dried (Na2S04) and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography on silica gel, eluting with hexane/EtOAc (50:50) to give the title compound.
'H NMR (360MHz, CDC13): 6 7.52 (m, 4H); 7.02 (m, 4H); 7.05 (d, J 8.4, 2H);
2.55 (m, 5H); 2.26 (m, 3H).
Description 46: 1-(1,1-Dimethylethyl) 4-Methy11,4-Piperidinedicarboxylate Trimethylsilyldiazomethane (2.OM in hexane, 147 mL, 0.29 mol) was added over 30 min. via an addition funnel to a stirred, cooled (0 C) solution of 1 -(1, 1 -dimethylethyl) 1,4-piperidinedicarboxylate (45.0 g, 0.20 mol) in CH2C12/MeOH (3:1. 1200 mL). The solvent was evaporated under reduced pressure to give the title compound (47 g) as a light yellow oil. This was used directly in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.46 (s, 9H), 1.58-1.68 (m, 2H), 1.86-1.91 (m, 2H), 2.45 (tt, 1H), 2.81-2.87 (m, 2H), 3.70 (s, 3H), 4.00-4.05 (m, 2H).
Description 47: 1-(1,1-Dimethylethyl) 4-Methyl 4-(Pent-4-en-1-yl)-1,4-piperidinedicarboxylate A solution of 1-(1,1-dimethylethyl) 4-methyl 1,4-piperidinedicarboxylate (Description 46, 25 g, 0.10 mol) in THF (250 mL) was added to a stirred, cooled (0 C) solution of potassium bis(trimethylsilyl)amide (30.7 g, 0.15 mol) in THF (750 mL) and the mixture was stirred at 0 C for 1 h.
5-Bromo-l-pentene (19.4 mL, 0.164 mol) was added and the mixture was allowed to warm to RT and stirred for 1.5 h. The mixture was poured into saturated aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure to give the title compound (30.9 g) which was used in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.26-1.40 (m, 4H), 1.46 (s, 9H), 1.50-1.54 (m, 2H), 1.99-2.06 (m, 2H), 2.11-18 (m, 2H), 2.80-2.98 (m, 2H), 3.72 (s, 3H), 3.87-3.95 (m, 2H), 4.95-5.02 (m, 2H), 5.72-5.80 (m, 1H).
Description 48: 1-(1,1-Dimethylethyl) 4-Methyl 4-(4-Oxobut-1-yl)-1,4-piperidinedicarboxylate A solution of 1-(1,1-dimethylethyl) 4-methyl4-(pent-4-en-l-yl)-1,4-piperidinedicarboxylate (Description 47, 29.4 g, 0.0945 mol) in methanol (1000 mL) was cooled to -78 C and ozone was bubbled into the solution until a blue color persisted. The excess ozone was removed with a stream of N2, then methyl sulfide (69 mL, 0.95 mol) was added, the cooling bath was removed, and the mixture was allowed to warm to RT over 1.5 h. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography, eluting with 2:1 heptane/EtOAc, to give the title compound (23.0 g).
'H NMR (400MHz, CDC13) 6 1.29-1.40 (m, 2H), 1.46 (s, 9H), 1.50-1.57 (m, 4H), 2.09-2.13 (m, 2H), 2.41-2.44 (m, 2H), 2.82-2.95 (m, 2H), 3.73 (s, 3H), 3.86-3.89 (m, 2H), 9.74 (s, 1H).
Description 49: 1-[(1,1-Dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoic acid Jones reagent (2.6M , 28.2 mL) was added via syringe to a solution of 1-(1,1-dimethylethyl) 4-methyl4-(4-oxobut-l-yl)-1,4-piperidinedicarboxylate (Description 48, 23.0 g, 0.0734 mol) in acetone (775 mL).
After 5 min, the solvent was evaporated under reduced pressure and the residue was taken up in water.
The mixture was extracted with Et20 (3x) and the combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (23.4 g) which was used in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.33-1.41 (m, 2H), 1.46 (s, 9H), 1.50-1.57 (br s, 4H), 2.09-2.19 (m, 2H), 2.32-2.34 (m, 2H), 2.85-2.89 (m, 2H), 3.73 (s, 3H), 3.81-3.89 (m, 2H).
Description 50: Methyl 1-[(1,1-Dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoate Trimethylsilyldiazomethane (2.OM in hexane, 53 mL, 0.11 mol) was added to a stirred, cooled (0 C) solution of 1-[(1,1-dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoic acid (Description 49, 23.4 g, 0.071 mol) in CH2C12/MeOH (3:1, 480 mL). The mixture was stirred at RT for 15 min, then the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (20.1 g).
'H NMR (400MHz, CDC13) 6 1.33-1.42 (m, 2H), 1.43 (s, 9H), 1.57-1.59 (m, 4H), 2.08-2.14 (m, 2H), 2.26-2.31 (m, 2H), 2.84-2.94 (m, 2H), 3.68 (s, 3H), 3.73 (s, 3H), 3.83-3.90 (m, 2H).
Description 51: (RS')-8-(1,1-Dimethylethyl) 2-Methyll-Oxo-8-azaspiro[4.5]decane-2,8-dicarboxylate Lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexanes, 47 mL, 0.070 mol) was added to a stirred, cooled (-78 C) solution of methyl 1-[(1,1-dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoate (Description 50, 20.1 g, 0.058 mol) in THF (600 mL). The mixture was stirred at -78 C for 25 min., then additional lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexanes, 31 mL) was added and the mixture was stirred at -78 C for 20 min. The mixture was poured into saturated aqueous ammonium chloride and extracted with Et20 (3x).
The combined organic fractions were washed with brine, dried (Na2SO4), and the solvent was evaporated under reduced pressure to give the title compound (19.9 g) which was taken on to the next step without further purification.
Description 52: 1,1-Dimethylethyll-Oxo-8-azaspiro [4.5] decane-8-carboxylate Pulverized lithium hydroxide (26 g, 1.10 mol) was added to a solution of (RS)-8-(1,1-dimethylethyl) 2-methyl 1-oxo-8-azaspiro[4.5]decane-2,8-dicarboxylate (Description 51, 17.2 g, 0.055 mol) in ethanol/THF/water (2:2:1, 555 mL) and the mixture was stirred at 90 C for 60 h. The mixture was cooled and the solvent was evaporated under reduced pressure. Water was added and the mixture was extracted with CH2C12 (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (9.41 g).
'H NMR (400MHz, CDC13) 6 1.29-1.37 (m, 2H), 1.47 (s, 9H), 1.62-1.69 (m, 2H), 1.92-1.95 (m, 4H), 2.30-2.34 (m, 2H), 3.05-3.10 (m, 2H), 3.87-3.92 (m, 2H).
Description 53: (1RS,2RS)-1,1-Dimethylethyl2-(1-Hydroxyprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate 1,1-Dimethylethyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 52, 4.5 g, 17.8 mmol) was dried by adding and evaporating toluene (3 x 10 mL) under reduced pressure, dissolved in THF (100 mL) and cooled to -78 C. Lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexane, 24 mL, 36 mmol) was added and the mixture was stirred at -78 C for 30 min.
Propionaldehyde (2.6 mL, 36 mmol) was added and the mixture was stirred at -78 C for 5 min. The mixture was diluted with Et20, poured into saturated aqueous ammonium chloride and extracted with Et20 (3x).
The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (4.75 g).
'H NMR (400MHz, CDC13) 6 0.97 (t, 3H), 1.33-1.37 (m, 2H), 1.47 (s, 9H), 1.54-1.68 (m, 5H), 1.75-1.78 (m, 1H), 2.07-2.13 (m, 2H), 2.30-2.33 (m, 1H), 2.95-3.15 (m, 2H), 3.62-3.63 (m, 1H), 3.84-3.94 (m, 2H).
Description 54: 1,1-Dimethylethyl2-(1-Oxoprop-1-yl)-1-oxo-8-azaspiro [4.5]
decane-8-carboxylate DMSO (2.6 mL, 37 mmol) was added slowly to a stirred, cooled (-78 C) solution of oxalyl chloride (1.6 mL, 18.3 mmol) in CH2C12 (150 mL) and the mixture was stirred at -78 C
for 5 min. A solution of (1RS,2RS)-1,1-dimethylethyl2-(1-hydroxyprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 53, 4.75 g, 15.3 mmol) in CH2C12 (40 mL) was added via an addition funnel and the mixture was stirred at -78 C for 45 min. Triethylamine (10.2 mL, 73.2 mmol) was added and the mixture was stirred at -78 C for 5 min., then allowed to warm to RT for 1.5 h. The mixture was poured into water and extracted with CH2C12 (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 15% EtOAc in hexanes, to give the title compound (3.98 g) as a pink oil.
Description 55: 1,1-Dimethylethy11,3-Diethyl-4,5-dihydrospiro [cyclopentapyrazole-6(1H),4'-piperidine]-1'-carboxylate Trifluoroacetate and 1,1-Dimethylethy12,3-Diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4'-piperidine]-1'-carboxylate Trifluoroacetate Ethyl hydrazine oxalate (0.096 g, 0.640 mmol) was added to a solution of 1,1-dimethylethyl2-(1-oxoprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 54, 0.165 g, 0.533 mmol) in ethanol (5 mL) and the mixture was stirred at 85 C for 12 h. The mixture was cooled and the solvent was evaporated under reduced pressure. The residue was taken up in a minimal amount of 40:40:20 5 MeCN/water/DMSO solution and purified by Gilson reverse phase HPLC (Column:
YMC-Pack Pro C18, 100 X 20 mm I.D.; Gradient Eluent: 10:90 to 90:10 v/v MeCN/water + 0.1%
trifluoroacetic acid over 12.5 min; Detection: PDA, 210-400 nm; Flow rate: 20 mL/min) to give 1,1-dimethylethyl 1,3-diethyl-4,5-dihydrospiro [cyclopentapyrazole-6(1H),4' piperidine]-1 '-carboxylate tr fluoroacetate (0.220 g); 'H
NMR (400MHz, CDC13) 6 1.23 (t, 3H), 1.42 (t, 3H), 1.50 (s, 9H), 1.60-1.63 (m, 2H), 1.88-1.93 (m, 2H), 10 2.42-2.47 (m, 2H), 2.56-2.61 (m, 4H), 2.86-2.89 (m, 2H), 4.00 (q, 2H), 4.10-4.13 (m, 2H); m/z (ES) 334 (M+1); and 1, 1-dimethylethyl 2,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4' piperidine]-1'-carboxylate trifluoroacetate (0.016 g); 'H NMR (400MHz, CDC13) 6 1.27 (t, 3H), 1.38 (t, 3H), 1.48 (s, 9H), 1.51-1.57 (m, 2H), 1.75-1.79 (m, 2H), 2.22-2.45 (m, 2H), 2.58-2.65 (m, 4H), 3.51-3.60 (m, 2H), 3.64-3.67 (m, 2H), 4.03 (q, 2H); m/z (ES) 334 (M+1).
Description 56: 1,3-Diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4'-piperidine]
Dihydrochloride Acetyl chloride (1.17 mL, 16.4 mmol) was added to a stirred, cooled (0 C) solution of 1,1-dimethylethyl 1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4'-piperidine]-1'-carboxylate trifluoroacetate (Description 55, 0.547 g, 1.64 mmol) in MeOH (16 mL). The mixture was allowed to warm to RT and stirred for 60 h. The solvent was evaporated under reduced pressure to give the title compound.
'H NMR (400MHz, CDC13) 6 1.32 (t, 3H), 1.54 (t, 3H), 2.00 (d, 2H), 2.37-2.45 (m, 2H), 2.66-2.69 (m, 2H), 2.73-2.82 (m, 4H), 3.18-3.24 (m, 2H), 3.47-3.52 (d, 2H), 4.41 (q, 2H).
Description 57: 1-(1,1-Dimethylethyl) 4-piperidinedicarboxylate Anhydride with 1H-Imidazole-l-carboxylic Acid Carbonyldiimidazole (39.4 g, 243 mmol) was added in portions to a stirred solution of 1 -(1, 1 -dimethylethyl) 4-piperidinedicarboxylate (42.5 g, 187 mmol) in CH2C12 (550 mL) and the mixture was stirred at 4 C overnight. The mixture was poured into Et20 (2 L) and ice water (2 L), the layers were separated and the organic layer was washed with cold aqueous NaHCO3 (saturated, 500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (52 g).
Description 58: 1,1-Dimethylethyl4-(1,3-Dioxobutyl)piperidinecarboxylate Acetone (41 mL) in THF (300 mL) was added dropwise to a stirred suspension of KH (30% in mineral oil, 75 g, 561 mmol) in THF (1.4 L) at RT. The mixture was cooled to -78 C
and treated with 1-(1,1-dimethylethyl) 4-piperidinedicarboxylate anhydride with 1H-imidazole-l-carboxylic acid (Description 57, 52 g) in THF (500 mL). The mixture was allowed to warm to RT
and stirred overnight, then ethanol (50 mL) was added dropwise over 5 min. The mixture was poured into hydrochloric acid (1N, 2 L) and extracted with Et20 (2 xl L). The combined organic fractions were washed with aqueous NaHCO3 (saturated, 500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. Isohexane (1 L) and acetonitrile (500 mL) were added, the layers were separated and the isohexane layer was extracted with MeCN (500 mL). The MeCN layers were combined and the solvent was evaporated under reduced pressure. The residue was filtered through a silica pad, eluting with 0-20% EtOAc in hexanes, to give the title compound as a colorless solid (36 g, 72%).
'H NMR (CDC13) 6 5.50 (1H, s), 4.18-4.11 (2H, m), 2.79-2.62 (2H, m), 2.34-2.27 (1H, m), 2.07 (3H, s), 1.80 (2H, brd, J 14.3), 1.60-1.51 (2H, m), 1.46 (9H, s).
Description 59: 1,1-Dimethylethyl4-[1-(1,1-Dimethylethyl)-3-methyl-lH-pyrazol-yl]piperidinecarboxylate t-Butyl hydrazine hydrochloride (14.8 g, 118 mmol) then triethylamine (17 mL, 120 mmol) were added to a solution of 1,1-dimethylethyl 4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58, 8 g, 29.7 mmol) in ethanol (200 mL) and the mixture was stirred at RT overnight. The solvent was evaporated under reduced pressure and the residue was suspended in EtOAc (1 L), washed with aqueous NaOH (1N, 500 mL), water (500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (9.5 g).
'H NMR (CDC13) 6 5.87 (1H, s), 4.27-4.18 (2H, m), 3.09-2.99 (1H, m), 2.79-2.68 (2H, m), 2.20 (3H, s), 1.85 (2H, brd, J 13.3), 1.63 (9H, s), 1.61-1.52 (2H, m), 1.48 (9H, s).
Description 60: 4-[1-(1,1-Dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidine Methanolic HC1(1N, 100 mL) was added to a solution of 1,1-dimethylethyl4-[1-(1,1-dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidinecarboxylate (Description 59, 9.5 g, 29 mmol) in MeOH (100 mL) and the mixture was stirred at RT for 4 h. The solvent was evaporated under reduced pressure and the residue was triturated with EtOAc. The solid was collected, suspended in aqueous NaOH
(4N, 20 mL) and extracted with CH2C12 (2 x 100 mL). The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (6.4 g).
'H NMR (CDC13) 6 5.91 (1H, s), 3.17 (2H, brd, J 13.0), 3.03 (1H, tt, J 13.0, 4.3), 2.69 (2H, dt, J 12.8, 3.5), 2.21 (3H, s), 1.86 (2H, brd, J 13.4), 1.67 (9H, s), 1.68-1.56 (2H, m).
Description 61: 4-[1-(-(2,2,2-Trifluoroethyl))-3-methyl-lH-pyrazol-5-yl]piperidine Prepared from 1,1-dimethylethyl4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58) according to the methods of Descriptions 59 and 60, substituting trifluoroethyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 5.91 (1H, s), 4.58 (2H, dd, J 16.4, 8.6), 3.17 (2H, brd, J
13.2), 2.70 (2H, dt, J 12.5, 2.4), 2.60 (1H, tt, J 12.1, 4.1), 2.23 (3H, s), 1.82 (2H, brd, J 14.4), 1.58 (2H, qd, J 12.5, 3.8).
Description 62: 1,1-Dimethylethyl4-[(2-Oxocyclopentyl)carbonyl]-1-piperidinecarboxylate Prepared from 1-(1,1-dimethylethyl) 4-piperidinedicarboxylate anhydride with 1H-imidazole-l-carboxylic acid (Description 57) according to the method of Description 58, substituting cyclopentanone for acetone.
'H NMR (CDC13) 6 13.75 (1H, brs), 4.27-4.06 (2H, m), 2.78-2.69 (2H, m), 2.57 (2H, t, J6.2), 2.42 (2H, t, J7.2), 2.37-2.30 (1H, m), 1.96-1.89 (2H, m), 1.75-1.63 (4H, m), 1.46 (9H, s).
Description 63: 4-(2-Ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine Prepared from 1,1-dimethylethyl4-[(2-oxocyclopentyl)carbonyl]-1-piperidinecarboxylate (Description 62) according to the methods of Descriptions 59 and 60, substituting ethyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 4.02 (2H, dd, J 14.5, 8.0), 3.18 (2H, brd, J 12.4), 2.72 (2H, dt, J 12.6, 2.5), 2.68-2.63 (5H, m), 2.40-2.33 (2H, m), 1.81 (2H, brd, J 13.6), 1.69 (2H, qd, J 12.6, 4.1), 1.42 (3H, t, J7.4).
Description 64: 1,1-Dimethylethyl4-(1,3-Dioxo-2-methylbutyl)piperidinecarboxylate NaH (60% in mineral oil, 75 mg, 1.9 mmol) was added to 1,1-dimethylethyl4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58, 0.5 g, 1.9 mmol) in DMF (5 mL). The mixture was stirred at RT for 1 h, then added to a solution of iodomethane (0.59 mL, 9.5 mmol) in DMF (5 mL).
Water (500 mL) was added and the mixture was extracted with EtOAc (100 mL).
The organic layer was washed with saturated brine (50 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with 15-25%
EtOAc in hexanes, to give the title compound (175 mg).
Description 65: 4-[1,3,4-Trimethyl-lH-pyrazol-5-yl]piperidine Prepared from 1,1-dimethylethyl4-(1,3-dioxo-2-methylbutyl)piperidinecarboxylate (Description 64) according to the methods of Descriptions 59 and 60, substituting methyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 4.07 (2H, q, J 7.6), 3.19 (2H, brd, J 11.8), 2.77-2.67 (3H, m), 2.14 (3H, s), 2.02 (3H, s), 1.92 (2H, qd, J 11.8, 4.1), 1.69 (2H, brd, J 13.0), 1.36 (3H, t, J7.4).
Description 66: 1-Phenylmethyl-4-(3,5-diethyl-lH-pyrazol-1-yl)piperidine Triethylamine (3.54 mL, 25.5 mmol) was added to a stirred solution of 4-hydrazino-1-(phenylmethyl)piperidine dihydrochloride (3.53 g, 12.7 mmol) in ethanol (50 mL) and the mixture was stirred at RT for 5 min. 3,5-Heptanedione (3.26 g, 25.5 mmol) was added and the mixture was stirred at RT for 4 days. The mixture was diluted with EtOAc, washed with aqueous NaOH
(0.5M), brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with 100% hexane to 100% Et20, to give the title compound (2.7 g, 71 %).
'H NMR (CD3OD) 6 7.35-7.20 (5H, m), 5.85 (1H, s), 4.02-3.94 (1H, m), 3.55 (2H, s), 2.99 (2H, d, J9.2), 2.63-2.51 (4H, m), 2.27-2.12 (4H, m), 1.73 (2H, t, J 11.8), 1.24-1.16 (6H, m).
Description 67: 4-(3,5-Diethyl-lH-pyrazol-1-yl)piperidine Ammonium formate (5.73 g, 90 mmol) and Pd on C (300 mg) were added to a stirred solution of 1-phenylmethyl-4-(3,5-diethyl-lH-pyrazol-l-yl)piperidine (Description 66, 2.7 g, 9 mmol) in methanol (75 mL) and the mixture was stirred under reflux for 3 h. The mixture was cooled, filtered through HyfloTM and the solvent was evaporated under reduced pressure. The residues was dissolved in MeOH
and poured onto SCX cartridges (Varian Bond E1utTM; 10 mL/500 mg). The cartridges were washed with MeOH, then eluted with methanolic ammonia (2M). The solvent was evaporated under reduced pressure to give the title product. (1.6 g, 85%).
'H NMR (CD3OD) 6 5.86 (1H, s), 4.18-4.10 (1H, m), 3.15 (2H, dd, J2.1, 10.9), 2.75-2.53 (6H, m), 2.07-1.97 (2H, m), 1.79 (2H, d, J 14.0), 1.25-1.17 (6H, m).
Description 68: 1,1-Dimethylethy11,2-Dihydro-l-(1-methylethyl)-2-oxospiro[3H-indole-3,4'-piperidine] -1'-carboxylate NaH (60% in mineral oil, 344 mg, 8.6 mmol) was added in portions to a stirred, cooled (0 C) solution of 1,1-dimethylethyl 1,2-dihydro-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate (2.0 g, 6.6 mmol) in DMF (10 mL) and the mixture was stirred at 0 C for 10 min. 2-lodopropane (0.86 mL, 8.6 mmol) was added and the mixture was allowed to warm to RT and stirred overnight. Water (100 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic fractions were dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash colunm chromatography on silica gel, eluting with isohexane/EtOAc (70:30) to give the title compound as a solid (2.3 g).
'H NMR (CDC13) 6 7.29-7.23 (2H, m), 7.06-7.02 (2H, m), 4.68-4.62 (1H, m), 3.88-3.76 (4H, m), 1.82-1.74 (4H, m), 1.50 (9H, s), 1.47 (6H, d, J7.3).
Description 69: 1-(1-Methylethyl)spiro[3H-indole-3,4'-piperidin]-2(1H)-one Trifluoroacetate Trifluoroacetic acid (2 mL) was added dropwise to a solution of 1, 1 -dimethylethyl 1,2-dihydro-l-(1-methylethyl)-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate (Description 68) in CH2C12 (20 mL) and the mixture was stirred at RT for 4 h. The solvent was evaporated under reduced pressure to give the title compound as a tan solid (2.35 g).
'H NMR (CDC13) 6 9.01 (1H, s), 8.54 (1H, s), 7.32-7.28 (2H, m), 7.12 (1H, t, J7.12), 7.04 (1H, d, J
7.12), 4.65-4.59 (1H, m), 4.00 (2H, q, J 11.9), 3.45 (2H, d, J 12.4), 2.39-2.31 (2H, m), 1.90 (2H, d, J
14.8), 1.49 (6H, d, J 7.0).
Description 70: 1,1-Dimethylethyl4-[(6-Methoxy-3-nitro-2-pyridinyl)amino]piperidinecarboxylate 1,1-Dimethylethyl4-amino-l-piperidinecarboxylate (10.01 g, 50 mmol) and triethylamine (34.85 mL, 25.3 g, 250 mmol) were added to a solution of 2-chloro-6-methoxy-5-nitropyridine (9.43 g, 50 mmol) in DMSO (100 mL) and the mixture was stirred at 100 C for 12 h. The mixture was cooled and added dropwise to water (1200 mL). The mixture was stirred at RT for 12 h, then the solid was collected, washed with water and dried in vacuo to give the title compound as a yellow powder (16.70 g, 95%).
'H NMR (360MHz, CDC13) 6 1.48 (9H, s), 1.52-1.62 (2H, m), 2.02-2.1 (2H, br m), 2.95-3.09 (2H, br m), 3.95 (3H, s), 4.00-4.10 (2H, br m), 4.23-4.35 (1H, m), 6.07 (1H, d, J9), 8.28 (1H, d, J9), 8.63 (1H, br d).
Description 71: 1,3-Dihydro-5-methoxy-3-(4-piperidinyl)-2H-imidazo[4,5-b]pyridin-2-one Dihydrochloride Platinum oxide (hydrated, 1.1 g) was added to a suspension of 1,1-dimethylethyl4-[(6-methoxy-3-nitro-2-pyridinyl)amino]piperidinecarboxylate (Description 70, 16.75 g, 47.52 mmol) in ethanol (250 mL) and the mixture was shaken under H2 (25 to 35 psi) for 4 h. CH2C12 (25 mL) was added, the mixture was filtered and the solvent was evaporated under reduced pressure. The residue was dissolved in toluene (125 mL) and treated with N-ethyldiisopropylamine (24.40 mL, 18.42 g, 142.57 mmol) then N,N'-carbonyldiimidazole (8.48 g, 52.28 mmol) were added. The mixture was stirred at 90 C for 24 h, cooled and the solvent was evaporated under reduced pressure. The residue was dissolved in CH2C12 and washed with aqueous Na2CO3 (5%) and HC1(0.01N), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanolic HC1(3M, 200 mL) and stirred at RT for 90 min. The solvent was evaporated under reduced pressure and the residue was triturated with EtOAc.
The solid was collected and dried in vacuo to give the title compound as a purple solid (9.00 g, 59%).
'H NMR (400MHz, D6-DMSO) 6 1.87 (2H, br d, J 13), 2.75 (2H, qd, J 13, 4), 3.08 (2H, br q, J 11), 3.40 (2H, br d, J 13), 3.75 (3H, s), 4.45-4.55 (1H, m), 6.41 (1H, d, J8), 7.29 (1H, d, J8), 8.75 (1 H, br), 9.01 (1 H, br), 10.90 (1H, s).
Description 72: (3RS)-Ethyl 1-(Phenylmethyl)-3-piperidinecarboxylate Benzyl chloride (165 mL, 181 g, 1.43 mol) was added in one portion to an intensively stirred, cooled (0 C) mixture of (3RS')-ethyl3-piperidinecarboxylate (200 mL, 201 g, 1.29 mol) and triethylamine (200 mL, 145 g, 1.43 mol) in MeCN (400 mL) and the mixture was stirred at RT
for 2.5 h. The solid was collected, washed with MeCN (2 x 200 mL) and dried in vacuo. The solid was dissolved in Et20 (300 mL) and washed with water (2 x 300 mL). The organic layer was dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound as an oil (270 g, 85%).
Description 73: (3RS')-1-(Phenylmethyl)-3-piperidinecarboxylic Acid Hydrazide Acetic acid (20 mL) and hydrazine hydrate (136 mL (140 g, 2.8 mol) were added to a solution of (3RS)-ethyl 1-(phenylmethyl)-3-piperidinecarboxylate (Description 72, 270 g, 1.092 mol) in ethanol (310 mL) 5 and the mixture was heated under reflux for 3 days. The mixture was cooled and the solvent was partly evaporated under reduced pressure until a precipitation occurred. The solid was collected, aqueous KOH
(50 g in 100 mL) was added and the mixture was extracted with CHC13 (2 x 300 mL). The combined organic fractions were dried (Na2SO4) the solvent was partly evaporated under reduced pressure until a precipitation occurred. The solid was collected, the filtrate was diluted with Et20 (200 mL) and further 10 solid was collected. The combined solids were washed with Et20 and dried in vacuo to give the title compound as a solid (217 g, 92%).
Description 74: (3RS')-1-(Phenylmethyl)-3-piperidinecarboxylic Acid 2-[(Methylamino)thioxomethyl] hydrazide 15 Methyl isothiocyanate (90 g, 1 43 mol) in toluene (50 mL) was added to a stirred solution of (3RS)-1-(phenylmethyl)-3-piperidinecarboxylic acid hydrazide (Description 73, 210 g, 0.90 mol) in toluene (500 mL) and the mixture was stirred at RT for 1 h. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (245 g, 90%).
20 Description 75: (3RS')-1-(Phenylmethyl)-3-(4-methyl-5-thio-4H-1,2,4-triazol-3-yl)piperidine Sodium (50 g, 2.18 mol) was added in portions to stirred, cooled (0 C) MeOH
(785 mL). Once the sodium had dissolved, (3RS)-1-(phenylmethyl)-3-piperidinecarboxylic acid 2-[(methylamino)thioxomethyl]hydrazide (Description 74, 230 g, 0.76 mol) was added and the mixture was heated under reflux for 1 h. The mixture was cooled in ice and aqueous acetic acid (126 mL, 131 g, 25 2.19 mol) in water (400 mL) was added. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (173 g, 79%).
Description 76: (3RS')-1-(Phenylmethyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine (3RS)-1-(Phenylmethyl)-3-(4-methyl-5-thio-4H-1,2,4-triazol-3-yl)piperidine (Description 75, 160 g, 30 0.56 mol) was dissolved by portions of 15-20 g in stirred, cooled (0 C) concentrated nitric acid (70%, 500 mL). The mixture was stirred at 0 C for 1 h then poured into stirred, cooled (0 C) aqueous KOH
(600 g) with continuing addition of ice. The mixture was divided into 4 portions and each portion of 500 mL was extracted with CHC13 (300 mL). The combined organic fractions were dried (Na2S04) and the solvent was evaporated under reduced pressure to give the title compound.
Description 77: (3RS')-3-(4-Methyl-4H-1,2,4-triazol-3-yl)piperidine Hydrochloride Pd on C (5%) was added to a mixture of (3RS)-1-(phenylmethyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine (Description 76) and hydrochloric acid (conc., 50 mL) in methanol (400 mL) and the mixture was shaken under an atmosphere of H2 (100 atm.) at 90 C for 24 h. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was dissolved at reflux in iso-propanol (100 mL) and hydrochloric acid (conc., 50 mL) was added. The mixture was cooled and stored at 5 C for 3 days. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (103 g, 91%).
'H NMR (D6-DMSO) 6 9.80-9.40 (3H, m), 3.90 (3H, s), 3.80-2.80 (5H, m), 2.20-1.70 (4H, m).
Description 78: 1-(3-Pyridinylmethyl)piperazine Trifluoroacetate Sodium triacetoxyborohydride (254 g, 1.2 mol) was added in portions to a rigorously stirred solution of 1, 1 -dimethylethyl piperazinecarboxylate (186 g, 1 mol), acetic acid (120 mL, 2 mol) and 3-pyridinecarboxaldehyde (107 g, 1 mol) in CH2C12 (700 mL), keeping the mixture at slow reflux. The mixture was stirred overnight at RT, washed with aqueous acetic acid (5%, 2 x 150 mL) and dried (CaC12). The solution was cooled in ice and trifluoroacetic acid (350 mL, 3.5 mol) was added with stirring. The mixture was stirred at RT until thin layer chromatography (silica gel;
chloroform:ethanol:benzene; 7:2:1; ninhydrin development) indicated complete consumption of starting material. The solvent was partially evaporated under reduced pressure at 70 C. The mixture was then allowed to crystallize (Et20 was added to help crystallization if needed). The solid was collected, washed with Et20 (2 x 100 mL), Et2O:EtOAc (2:1, 100 mL), and again with Et20 (100 mL). The solid was dried in vacuo to give the title compound as a solid (390 g, 75%).
'H NMR (D6-DMSO) 6 8.85 (2H, br s), 8.70 (2H, m), 8.12 (1H, d), 7.69 (1H, t), 6.0 (1H, br s), 3.90 (2H, s), 3.20 (4H, m), 2.80 (4H, m).
Description 79: [1,2-Bis(hydroxyimino)propyl]piperazine Piperazine (84 g, 0.96 mol) in distilled water (400 mL) was added dropwise to a solution of N-hydroxy-2-(hydroxyimino)propanimidoyl chloride (33 g, 0.24 mol) in ethanol (100 mL), maintaining the reaction temperature below 30 C. The mixture was stirred at RT for 24 h, then filtered, washing with hot water (150 mL). The solvent was evaporated under reduced pressure to give a mixture of the title compound and piperazine, which was used without further purification.
Description 80: 1-(4-Methyl-1,2,5-oxadiazol-3-yl)piperazine Hydrochloride NaOH (20 g, 0.5 mol) was added slowly to an intensively stirred solution of [1,2-bis(hydroxyimino)propyl]piperazine (Description 79) in water (350 mL). The mixture was placed in an autoclave (0.5 L) and stirred for 5 h at 190 C. The mixture was cooled and stirred overnight. The mixture was extracted with Et20 (5 x 150 mL), and the combined organic fractions were dried (MgS04) and the solvent was evaporated under reduced pressure. The residue was dissolved in MeOH, acidified with hydrochloric acid (1 eq), and the solvent was evaporated under reduced pressure. The residue was recrystallized from isopropanol to give the title compound (5.8 g).
'H NMR (D6-DMSO) 6 9.50 (2H, br s), 3.50 (4H, t), 3.21 (4H, t), 2.38 (3H, s).
Description 81: 4-(Chloromethyl)-4,5-dihydro-2-methyl-4-thiazolol A mixture of thioacetamide (7.5 g, 0.1 mol), 1.3-dichloroacetone (14 g, 0.11 mol), sodium bicarbonate (9.3 g, 0.11 mol) and dichloroethane (60 mL) was stirred at RT for 48 h. The mixture was filtered, washing with dichloroethane (20 mL), to give a solution of the title compound which was used without further purification.
Description 82: 4-(Chloromethyl)-2-methylthiazole Hydrochloride Thionyl chloride (13.1 g, 0.11 mol) in dichloroethane (60 mL) was added to an intensively stirred solution of 4-(chloromethyl)-4,5-dihydro-2-methyl-4-thiazolol in dichloroethane (Description 81), maintaining the reaction temperature below 30 C. The mixture was stirred at 65-70 C for 30 min, cooled and the solvent was evaporated under reduced pressure. The residue was crystallized from EtOAc to give the title compound as a crystalline solid (17.12 g, 93%).
Description 83: 1-[(2-Methyl-4-thiazolyl)methyllpiperazine 4-(Chloromethyl)-2-methylthiazole hydrochloride (Description 82, 92 g, 0.5 mol) in MeOH (400 mL) was added slowly to a stirred solution of piperazine (500 g, 5.81 mol) in methanol (800 mL) and the mixture was heated under reflux for 3 h. The mixture was cooled and methanolic KOH (1 mol in 400 mL) was added. The mixture was stirred at RT overnight, filtered and the solvent was evaporated under reduced pressure. The residue was dissolved in iso-propanol, filtered and purified by flash column chromatography on silica gel, eluting with iso-propanol-triethylamine (5:1) and the residue was vacuum distilled. A fraction with b.p. 123-127 C/-1 torr was collected to give the title compound as a light-yellow dense oil which formed hygroscopic low melting (-30 C) crystals on standing (57.1 g, 58%).
'H NMR (D6-DMSO) 6 7.20 (1H, s), 3.45 (2H, s), 3.15 (1H, br s), 2.60 (4H, t), 2.50 (3H, s), 2.30 (4H, m).
Description 84: 1,1-Dimethylethyl4-[2-(1-Hydroxy-l-methylethyl)-4-methyl-lH-imidazol-1-yl]-1-piperidinecarboxylate n-Butyllithium (1.6M in hexanes, 5.7 mL, 9.0 mmol) was added dropwise to a stirred, cooled (-78 C) solution of 1,1-dimethylethyl4-(4-methyl-lH-imidazol-l-yl)-1-piperidinecarboxylate (as prepared in W093/19059, 2 g, 7.5 mmol) in THF (50 mL) and the mixture was stirred at -78 C for 1 h. Ethyl bromide (0.7 mL, 9.0 mmol) was added and the mixture was stirred at RT for 5 h. Acetone (1.1 mL, 0.88 g, 15 mmol) was added and the mixture was stirred at RT overnight. Water was added and the mixture was extracted with EtOAc. The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2C12/MeOH (100:0 increasing to 98:2), to give the title compound (0.9 g, 37%).
m/z (ES) 324 (M+1).
Description 85: 4-[2-(1-Hydroxy-l-methylethyl)-4-methyl-lH-imidazol-1-yl]piperidine 1,1-Dimethylethyl4-[2-(1-hydroxy-l-methylethyl)-4-methyl-1 H-imidazol-l-yl]-1-piperidinecarboxylate (Description 84, 450 mg, 1.4 mmol) was dissolved in ethanolic HC1(4M, 6 mL) and stirred at RT
overnight. The solvent was evaporated under reduced pressure, aqueous NaHCO3 (saturated) was added and the mixture was extracted with CHC13/ iPrOH (85:15). The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (257 mg, 83%).
'H NMR (500MHz, CDC13) 6 6.84, 6.53 (total 1H, each s), 5.25, 4.83 (total 1H, each s), 3.16 (2H, m), 2.69 (2H, s), 2.18 (1H, m), 2.11 (3H, s), 1.98-1.79 (3H, m), 1.60, 1.59 (total 6H, each s).
Description 86: 2-Chloro-N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)acetamide Chloroacetyl chloride (3.1 mL, 40 mmol) was added to a stirred mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (4.5 g, 36 mmol) and K2C03 (9.9 g, 72 mmol) in CH2C12 (75 mL). The mixture was stirred at RT for 15 min, diluted with MeOH and filtered. The solvent was evaporated under reduced pressure to give the title compound (5.6 g, 77%).
'H NMR (CD3OD) 6 6.72 (1H, s), 4.33 (4H, dd, J0.0, 7.0), 2.43 (3H, s), 1.47 (3H, t, J7.3).
Description 87: N-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(2-hydroxyethyl)amino]acetamide Ethanolamine (1.04 mL, 17 mmol) was added to a stirred mixture of 2-chloro-N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)acetamide (Description 86, 872 mg, 4.3 mmol) and Nal (50 mg) in MeCN (15 mL) and the mixture was stirred at 80 C for 4.5 h. The mixture was cooled and CHC13/
isopropyl alcohol (3:1) and water were added. The layers were separated and the aqueous layer was extracted with CHC13/ isopropyl alcohol. The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (0.534 g, 54%).
'H NMR (CD3OD) 6 6.08 (1H, s), 3.99 (2H, q, J7.2), 3.67-3.63 (2H, m), 3.46 (2H, s), 2.79-2.73 (2H, m), 2.19 (3H, s), 1.33 (3H, t, J7.2).
Description 88: 1-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)piperazin-2-one Di-tert-butyl azodicarboxylate (0.915 g, 4 mmol) and tri-n-butyl phosphine (1 mL, 4 mmol) were added to a stirred solution of N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(2-hydroxyethyl)amino]acetamide (Description 87, 0.3 g, 1.3 mmol) in EtOAc (10 mL) and the mixture was stirred at RT for 6 h. The mixture was poured onto SCX cartridges (Varian Bond E1utTM; 10 mL/500 mg). The cartridges were washed with MeOH, then eluted with methanolic ammonia (2M). The solvent was evaporated under reduced pressure and the residue was purified by chromatography on silica gel, eluting with CH2C12/MeOH (100:0 increasing to 90:10), to give the title compound (190 mg, 40%).
'H NMR (CDC13) 6 5.89 (1H, s), 3.92-3.86 (2H, m), 3.69 (2H, s), 3.60-3.56 (2H, m), 3.20 (2H, t, J 5.5), 2.25 (3H, s), 1.43-1.39 (3H, m).
Description 89: 2-Bromo-N-(3-fluorophenyl)acetamide Bromoacetyl bromide (23.5 mL, 0.27 mol) was added slowly to a stirred, cooled mixture of 3-fluoroaniline (25 g, 0.225 mol) in EtOAc (250 mL) and aqueous KHCO3 (20%, 250m1). The mixture was allowed to warm to RT and the layers were separated. The organic layer was diluted with EtOAc, washed with aqueous citric acid (10%) and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (51.72 g, 92%).
'H NMR (360MHz, CD3OD) 6 7.54 (1H, dt, J 11, 2), 7.34-7.24 (2H, m), 6.84 (1H, t, J 7), 3.96 (2H, s).
Description 90: 1-(3-Fluorophenyl)piperazinone Hydrochloride Ethanolamine (4.5 mL, 75 mmol) was added to stirred 2-bromo-N-(3-fluorophenyl)acetamide (Description 89, 5.0 g, 21 mmol) in EtOAc (25 mL) and the mixture was stirred at 60 C for 2 h. The mixture was cooled, EtOAc and water were added and the layers were separated.
The organic layer was dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was suspended in EtOAc (135 mL) and tributylphosphine (5.3 mL, 21 mmol) was added. The mixture was cooled to 0 C
and di-tert-butylazodicarboxylate (4.8 g, 21 mmol) was added dropwise over 1 h. The mixture was stirred at 0 C for 0.5 h, then at 40 C for 1.5 h. The mixture was cooled and ethanolic HC1(4M, 4.7 mL) was added. The mixture was stored at 0 C for 0.5 h., and the solid was collected, washing with cold EtOAc, and dried in vacuo to give the title compound.
'H NMR (400MHz, CD3OD) 6 3.68-3.71 (2H, m), 3.97-4.00 (2H, m), 4.02 (2H, s), 7.12 (1H, m), 7.18-7.22 (2H, m), 7.48 (1H, m).
Description 91: N-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-3-azetidinamine A mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (1.0 g, 8.0 mmol), 1-(diphenylmethyl)-3-azetidinyl methanesulfonate (2.5 g, 8.0 mmol) and K2C03 (2.2 g, 16.0 mmol) in DMF (10 mL) was stirred at 60 C
for 24 h. The mixture was cooled, poured into water (50 mL) and extracted with EtOAc (3 x 20 mL).
The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol (10 mL), palladium hydroxide (200 mg) was added and the mixture was shaken under H2 (45 psi) for 72 h. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2C12/MeOH (90:10), to give the title compound as an oil.
(168 mg, 12%).
'H NMR (CD3OD) 6 5.15 (1H, s), 4.17-4.15 (1H, m), 3.90-3.81 (4H, m), 3.58 (2H, m), 2.09 (1H, s), 1.28 (3H, t, J7.1).
Description 92: 8-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-1,4-dioxa-8-azaspiro [4.5] decane A mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (1 g, 8 mmol), 2,2-bis(2-iodoethyl)-1,3-dioxolane (3 g, 8 mmol) and K2C03 were dissolved in MeCN (15 mL) and heated under reflux for 4 days. The 5 mixture was cooled and the solvent was evaporated under reduced pressure.
The residue was suspended in EtOAc (100 mL) and washed with water (50 mL). The organic fraction was dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexanes/EtOAc (80:20), to give the title compound (470 mg).
10 Description 93: 1-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-4-piperidinone 8-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-1,4-dioxa-8-azaspiro[4.5]decane (Description 92) in aqueous acetic acid (75%, 16 mL) was heated under reflux for 16 h. The mixture was cooled and aqueous NaHCO3 (saturated, 300 mL) was added slowly. The mixture was extracted with EtOAc (2 x 200 mL) and the combined organic fractions were washed with brine (100 mL), dried (MgSO4) and the solvent was 15 evaporated under reduced pressure. Heptane was added and evaporated under reduced pressure to give the title compound as an oil (0.3 g).
'H NMR (CDC13) 6 5.69 (1H, s), 4.05 (2H, g, J7.2), 3.19 (4H, m), 2.59 (4H, m), 2.23 (3H, s), 1.42 (3H, t, J 7.3).
20 Example 1: Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Sodium triacetoxyborohydride (0.3 g, 1.4 mmol) and acetic acid (62 mg, 1 mmol) were added to a mixture of 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone (Description 14, 0.44 g, 1 mmol) and 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine (0.2 g, 1 mmol) in 1,2-dichloroethane 25 (8 mL) and the mixture was stirred at RT for 16 h. Water and EtOAc were added and the layers were separated. The organic layer was washed with aqueous NaHCO3 (saturated), water, and brine, dried (MgS04), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with EtOAc/isohexane mixtures, to give the title compound.
'H NMR (360MHz, CDC13) 6 1.185 (2H, m), 1.36 (3H, t, J7.2), 1.60 (2H, m), 1.79-1.93 (2H, m), 2.14 30 (2H, t, J 11.3), 2.19 (3H, s), 2.30 (2H, t, J 13.7), 2.35-2.50 (2H, m), 2.58 (2H, m), 2.86 (2H, m), 3.96 (2H, q, J 7.2), 5.73 (1H, s), 7.09 (2H, d, J 8.7), 7.22 (2H, d, J 8.7), 7.34 (2H, d, J 8.7), 7.43 (2H, d, J 8.7). m/z (ES) 603, 605 (M+1).
The following compounds were prepared according to the method of Example 1 substituting a suitable 35 cyclohexanone for 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone and a suitable amine for 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine.
x. ame ES MS
+1 Cis & Trans-l-[4-(2-Fluoro-4-bromophenyl)-4-(4- 622, 624 hlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine Trans-1'-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-1,3-diethyl-644, 646 ,5-dihydrospiro[cyclopentapyrazole-6(1 H),4'-piperidine]
Trans-l-{4-[4-(Trifluoromethyl)phenyl]-4-(4-chlorobenzenesulfonyl)cyclohexyl}-2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(3,4-Dichlorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl- 594 5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(2,5-Difluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl- 562 5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-[1-(1,1-632, 634 Idimethylethyl)-3-methyl-IH-pyrazol-5-yl]piperidine 8 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-[1-(-(2,2,2- 658/660 trifluoroethyl))-3-methyl-IH-pyrazol-5-yl]piperidine Trans-l-{4-[4-(Trifluoromethoxy)phenyl]-4-(4-chlorobenzenesulfonyl)cyclohexyl}--(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine Trans-l-[4-(4-Fluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-ethyl-2H-pyrazol-3-yl)piperidine 11 Trans-l-[4-(4-Methylphenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 541,543 ethyl-2H-pyrazol-3 -yl)piperidine 12 Trans-l-[4-(4-Cyanophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 551 ethyl-2H-pyrazol-3 -yl)piperidine 13 Trans-l-[4-(4-Bromophenyl)-4-(benzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl- 570 H-pyrazol-3-yl)piperidine 14 Trans-l-[4-(3-Fluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 544 ethyl-2H-pyrazol-3 -yl)piperidine Trans-l-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4-638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 16 Trans-l-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 595, 597 ethyl-2H-pyrazol-3 -yl)piperidine 17 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(3,5-diethyl- 618,620 1 H-pyrazol-l-yl)piperidine 18 Trans-l-{4-(4-Bromophenyl)-4-[3-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4- 638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 19 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(4H-1,2,4- 563/565 triazol-4-yl)piperidine x. ame ES MS
+1 0 Trans-4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 678, 680 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 1 Trans-l-{4-(3-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4- 638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 2 Trans-l-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 594 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 636, 638 2-ethyl-5-methyl-2H-pyrazol-3-yl)-1,2,3,6-tetrahydropyridine 4 Cis-1-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-604, 606 ethyl-2H-pyrazol-3 -yl)piperidine Cis-4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl}
678, 680 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 Cis-1-[4-(3,4-Dichlorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 594 ethyl-2H-pyrazol-3 -yl)piperidine 7 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 638, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 8 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 636, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)-1,2,3,6-tetrahydropyridine 9 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-604, 606 thyl-5-methyl-2H-pyrazol-3-y1)piperidine 0 Cis-1-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 594, hiazolyl)piperazinone 1 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 594, hiazolyl)piperazinone 2 Trans-l-[4-(4-Bromophenyl)-4-(4-methylbenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 584, 586 ethyl-2H-pyrazol-3 -yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethoxy)benzenesulfonyl)cyclohexyl]-4- 654, 656 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 4 Trans-l-[4-(4-Bromophenyl)-4-(3-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 604, 606 ethyl-2H-pyrazol-3 -yl)piperidine 5 Trans-4-[1-{4-(4-Chlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 634 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 R)-Cis-1-[4-(3,4-Dichlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 628 yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 7 Trans-l-[4-(3,4-Dichlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 628 -(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine x. ame ES MS
+1 8 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 711, 713 1,2-dihydro-l-(methylsulfonyl)spiro[3H-indole-3,4'-piperidine]
9 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 689, 691 1 -methylethyl)spiro [3H-indole-3,4'-piperidin]-2(1 H)-one 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 612, 614 3-methyl-1,2,4-oxadiazol-5-yl)piperidine 1 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 597, 599 4H-1,2,4-triazol-4-yl)piperidine 2 RS)-Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 597, 599 -(1 H-1,2,4-triazol-1-yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 597, 599 1 H-tetrazol-1-yl)piperidine 4 Trans-8-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 676, 678 henyl-1,3,8-triazaspiro[4.5]decan-4-one Trans-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 693, 695 iperidin-4-yl]-1,3-dihydro-5-methoxy-2H-imidazo[4,5-b]pyridin-2-one 6 Trans-N-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 713, 715 iperidin-4-yl } methyl-N-phenylmethanesulfonamide 7 Trans-N-[4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 677, yclohexyl } -4-phenylpiperidin-4-yl } -methyl] acetamide 8 RS')-Trans-4-[4-(4-Bromophenyl)-4-(4- 638, 640 trifluoromethyl)benzenesulfonyl)cyclohexyl]-2-(phenoxymethyl)morpholine 9 Trans-l-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 677, 679 iperidin-4-yl]-1,4-dihydro-2H-3,1-benzoxazin-2-one 50 Trans-6-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 569, 571 5,6,7,8-tetrahydro-[ 1,2,4]triazolo[ 1,5-a]pyrazine 51 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 611, yclohexyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine 52 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 622, 624 3-pyridinylmethyl)piperazine 53 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 613, 615 4-methyl-1,2,5-oxadiazol-3-yl)piperazine 54 S)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 635, 637 -(phenylmethyl)-3-pyrrolidinemethanamine 55 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 642, 644 [(2-methyl-4-thiazolyl)methyl]piperazine x. ame ES MS
+1 56 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4-[(2- 642, 644 ethyl-4-thiazolyl)methyl]piperazine 57 S)-Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N- 635, 637 henylmethyl)-3-pyrrolidinemethanamine 58 Cis-N-[4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 677, yclohexyl } -4-phenylpiperidin-4-yl } -methyl] acetamide 59 Cis-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 693, 695 iperidin-4-yl]-1,3-dihydro-5-methoxy-2H-imidazo[4,5-b]pyridin-2-one 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-3- 569, 571 1 H-1,2,4-triazol-3 -yl)azetidine 1 Cis-8-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-676, 678 henyl-1,3,8-triazaspiro[4.5]decan-4-one 2 Cis-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1,2- 711, 713 ydro-l-(methylsulfonyl)spiro [3H-indole-3,4'-piperidine]
3 Trans-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 676, 678 iperidin-4-yl]-3,4-dihydro-2(1 H)-quinazolinone 4 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4- 597, 599 trifluoromethyl)benzenesulfonyl)cyc lohexyl] -3 -(1 H-1,2,4-triazol-1-yl)piperidine Cis-4-[1-{4-(3,4-Dichlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 668 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 Trans-4-[1-{4-(3,4-Dichlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 7 Cis-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1,3- 678/680 ethyl-4, 5-dihydrospiro [cyclopentapyrazole-6(1 H),4'-piperidine]
8 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 678/680 1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1 H),4'-piperidine]
9 -[Trans-4-(4-Bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl]-4- 582, 584 methoxy)benzenemethanamine 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 692, 694 [ 1-(2,2,2-trifluoroethyl)-3 -methyl-1 H-pyrazol-5 -yl]piperidine 1 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 668, 670 [2-(1-hydroxy-l-methylethyl)-4-methyl-1 H-imidazol-1-yl]piperidine 2 Cis-4-[1-{4-(4-Fluororophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 618 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 3 Trans-4-[1-{4-(4-Fluororophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 618 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine x. ame ES MS
+1 4 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-2,6- 560, 562 methylmorpholine 5 Cis-1-[4-(4-Fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4-(2- 578 thyl-5-methyl-2H-pyrazol-3-y1)piperidine 6 Trans-l-[4-(4-Fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 578 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 7 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 653, 655 1-ethyl-3-methyl-1 H-pyrazol-5-yl)piperazin-2-one 8 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(1- 653, 655 thyl-3-methyl-1 H-pyrazol-5-yl)piperazin-2-one 9 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 652, 654 [ 1,3,4-Trimethyl-1 H-pyrazol-5-yl]piperidine 80 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-2,6- 560, 562 Idimethylmorpholine 81 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 652, 654 [ 1,3,4-trimethyl-1 H-pyrazol-5 -yl]piperidine 82 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 639, 641 3-fluorophenyl)piperazinone 83 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N-(1- 625, 627 thyl-3-methyl-1 H-pyrazol-5-yl)-3-azetidinamine 84 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N- 625, 627 1-ethyl-3-methyl-1 H-pyrazol-5-yl)-3-azetidinamine 85 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 666, 668 [ 1-(1,1-dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidine 86 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(3- 639,641 uorophenyl)piperazinone 87 Cis-4-{1-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]piperidin-4- 635, 637 1} -2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 88 Trans-4-{1-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]piperidin-4- 635, 637 1} -2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 89 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 664, 666 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 0 Trans-l-[4-(4-Chloro-3-fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 1 Cis-1-[4-(4-Chloro-3-fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine x. ame ES MS
+1 2 Cis-4-[1-{4-(4-Chloro-3-fluorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
652, 654 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 3 Trans-4-[1-{4-(4-Chloro-3-fluorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 652, 654 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 4 Cis-6-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,6-naphthyridine Trans-6-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,6-naphthyridine 6 Trans-4-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 578 2-pyridinyl)piperazinone 7 Cis-4-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(2- 578 yridinyl)piperazinone 8 Trans-l-{4-(4-Chlorophenyl)-4-[4-(1-hydroxy-l-methylethyl)benzenesulfonyl]
yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 9 Trans-Methyl4-({1-(4-Chlorophenyl)-4-[4-(2-ethyl-5-methyl-2H-pyrazol-3- 584 1)piperidinyl]cyclohexyl} sulfonyl)benzoate-100 1,1-Dimethylethyl [ 1-(Trans-4-(4-chlorophenyl)-4- { [4- 601 trifluoromethyl)phenyl] sulfonyl} cyclohexyl)-4-piperidinyl] carbamate 101 Trans-l-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 639, 641 -(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 102 Cis-1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 639, 641 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 103 Trans-4-[1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]
679,681 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 104 Cis-4-[1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 679, 681 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 105 Cis-4-[1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 635 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 106 Trans-4-[1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]
yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 107 Cis-1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 595 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 108 Trans-l-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 595 -(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 109 Cis-1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 665, 667 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine x. ame ES MS
+1 110 Trans-l-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 665, 667 -(2-ethy1-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 111 Trans-4-[1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 619 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 112 Cis-4-[1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 619 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 113 Trans-l-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 579 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 114 Trans-l-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 605 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 115 Cis-1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 605 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 116 Cis-1-[4-(4-Bromophenylmethyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-618, 620 thyl-5-methyl-2H-pyrazol-3-yl)piperidine 117 Trans-l-[4-(4-Bromophenylmethyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 618, 620 thyl-5-methyl-2H-pyrazol-3-yl)piperidine 118 Cis-1-{4-(4-Bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 652, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 119 Trans-l-{4-(4-Bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
652, 654 yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 120 Cis & Trans-l-[4-Phenyl-4-(phenylsulfonylmethyl)cyclohexyl]-4-(2-ethyl-5-methyl- 506 H-pyrazol-3-yl)piperidine 121 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfinyl) 622, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Example 122: Trans-1-{4-Phenylmethyl-4-[4-(trifluoromethyl)benzenesulfonyl]
cyclohexyll-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Pd on C (30 mg) was added to a solution of trans-1-{4-(4-bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine (Example 119, 57 mg, 87 mol) in EtOAc (5 mL) and the mixture was vigorously stirred under a H2 atmosphere overnight. The mixture was filtered through HyfloTM and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography on silica gel, eluting with EtOAc/MeOH/NH3(Aq.) (98:2:0.2) to give the title compound (10 mg, 20%).
'H NMR (500MHz, CD3OD): 6 7.99 (d, J 8.1, 2H); 7.89 (d, J 8.1, 2H); 7.36 (d, J
8.2, 2H); 7.24 (m, 3H);
5.83 (s, 1H); 4.02 (q, J7.2, 2H); 3.26 (s, 2H); 3.01 (d, J 11.3, 2H); 2.63 (m, 1H); 2.35 (m, 3H); 2.16 (s, 3H); 2.10 (d, J 13.1, 2H); 1.90 (m, 6H); 1.63 (m, 4H); 1.33 (t, J7.2, 3H).
Example 123: Trans-4-(4-Bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexanamine Ceric ammonium nitrate (232 mg, 0.423 mmol) was added to a stirred suspension of N-[trans-4-(4-bromophenyl)-4- { [4-(trifluoromethyl)phenyl] sulfonyl} cyclohexyl] -4-(methoxy)benzenemethanamine (Example 69, 99 mg, 0.17 mmol) in MeCN (1.0 ml) and water (0.35 ml) at RT. The mixture was stirred overnight and a further portion of ceric ammonium nitrate (29 mg, 0.053 mmol) was added. After stirring at RT for a further 1 h, the mixture was diluted with EtOAc and water. The aqueous layer was separated and re-extracted with EtOAc. The combined organic layers were dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography, eluting with 10% MeOH in CH2C12, to give the title compound (48 mg, 62%).
'H NMR (400MHz, CDC13 S 1.02 (2H, q, J 12.4), 1.88 (2H, d, J 12.3), 2.32 (2H, m), 2.53 (2H, d, J 13), 2.84 (1H, m), 7.09 (2H, d, J 8.2), 7.43 (4H, d, J 8.1), 7.63 (2H, d, J 8.0).
The following compound was prepared according to the method of Example 1 substituting trans-4-(4-bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexanamine (Example 123) for 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone and 1-(1-ethyl-3-methyl-lH-pyrazol-5-yl)-4-piperidinone (Description 93) for 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine.
x. ame ES MS (M+1) 124 Trans-N-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 653, 655 yclohexyl] -1-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine-4-amine Example 125: 1-(Trans-4-(4-Chlorophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)piperidin-4-amine Hydrochloride Hydrogen chloride in dioxane (4N, 10 mL) was added to a stirred solution of 1, 1 -dimethylethyl [1-(trans-4-(4-chlorophenyl)-4- { [4-(trifluoromethyl)phenyl] sulfonyl } cyclohexyl)-4-piperidinyl] carbamate (Example 100, 2.045 g, 3.4 mmol) in CH2C12 (10 mL) and the mixture was stirred at RT overnight. The solvent was evaporated under reduced pressure to give the title compound (1.73 g, 95%).
'H NMR (360MHz, CD3OD): 6 7.78 (t, 2H), 7.55 (d, 2H), 7.35 (q, 4H), 3.53 (d, 3H), 3.06 (t, 2H), 2.85 (d, 2H), 2.38 (t, 3H), 2.21 (d, 4H), 1.93 (d, 2H), 1.41 (d, 2H).
Example 126: N-(1,1-Dimethylethyl)-N'-[1-(Trans-4-(4-chlorophenyl)-4-{[4-(trifluoromethyl)p henyl] sulfonyl} cyclohexyl)piperidin-4-yl] urea t-Butyl isocyanate (0.0255 mL, 0.224 mmol) was added to a stirred solution of 1-(trans-4-(4-chlorophenyl)-4- {[4-(trifluoromethyl)phenyl] sulfonyl} cyclohexyl) piperidin-4-amine hydrochloride (Example 125, 0.1 g, 0.186 mmol) and triethylamine (0.077 mL, 0.558 mmol) in CH2C12 (5 mL) and the mixture was stirred at RT for 2 h. Water was added and the mixture was extracted with CH2C12. The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure.
The residue was purified by preparative thin layer chromatography on silica gel, eluting with 5% MeOH
in CH2C12, to give the title compound (40 mg, 36%).
'H NMR (500MHz, CD3OD): 6 7.77 (d, 2H), 7.53 (d, 2H), 7.31 (q, 4H), 3.37 (t, 1H), 2.77 (d, 2H), 2.71 (d, 2H), 2.52 (s, 1H), 2.25 (q, 4H), 1.99 (d, 2H), 1.79 (d, 2H), 1.29 (t, 2H), 1.26 (s, 9H), 1.21-1.13 (m, 2H).
suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day.
Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
Thus there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
Likewise there is provided the use of a compound of formula (I) for the manufacture of a medicament for treating a neurokinin-3 mediated disease.
There is also disclosed a method of treatment of a subject suffering from a neurokinin-3 mediated disease, which comprises administering to that patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Examples of diseases mediated by neurokinin-3 include CNS disorders such as depression (which term includes bipolar (manic) depression (including type I and type II), unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features (e.g. lethargy, over-eating/obesity, hypersomnia) or postpartum onset, seasonal affective disorder and dysthymia, depression-related anxiety, psychotic depression, and depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion); anxiety disorders (including generalised anxiety disorder (GAD), social anxiety disorder (SAD), agitation, tension, social or emotional withdrawal in psychotic patients, panic disorder, and obsessive compulsive disorder); phobias (including agoraphobia and social phobia);
psychosis and psychotic disorders (including schizophrenia, schizo-affective disorder, schizophreniform-diseases, acute psychosis, alcohol psychosis, autism, delirium, mania (including acute mania), manic depressive psychosis, hallucination, endogenous psychosis, organic psychosyndrome, paranoid and delusional disorders, puerperal psychosis, and psychosis associated with neurodegenerative diseases such as Alzheimer's disease); post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD);
cognitive impairment (e.g. the treatment of impairment of cognitive functions including attention, orientation, memory (memory disorders, amnesia, amnesic disorders and age-associated memory 5 impairment) and language function, and including cognitive impairment as a result of stroke, Alzheimer's disease, Aids-related dementia or other dementia states, as well as other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states)); convulsive disorders such as epilepsy (which includes simple partial seizures, complex partial seizures, secondary generalised seizures, generalised seizures including absence seizures, myoclonic seizures, clonic seizures, 10 tonic seizures, tonic clonic seizures and atonic seizures); psychosexual dysfunction (including inhibited sexual desire (low libido), inhibited sexual arousal or excitement, orgasm dysfunction, inhibited female orgasm and inhibited male orgasm, hypoactive sexual desire disorder (HSDD), female sexual desire disorder (FSDD), and sexual dysfunction side-effects induced by treatment with antidepressants of the SSRI-class); sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep 15 apnea and narcolepsy); disorders of eating behaviours (including anorexia nervosa and bulimia nervosa);
neurodegenerative diseases (such as Alzheimer's disease, ALS, motor neuron disease and other motor disorders such as Parkinson's disease (including relief from locomotor deficits and/or motor disability, including slowly increasing disability in purposeful movement, tremors, bradykinesia, hyperkinesia (moderate and severe), akinesia, rigidity, disturbance of balance and co-ordination, and a disturbance of posture), dementia in Parkinson's disease, dementia in Huntington's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like, and demyelinating diseases such as multiple sclerosis and amyotrophiclateral sclerosis); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities (such as abuse of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine and phencyclidine-like compounds, opiates such as cannabis, heroin, morphine, sedative, hypnotic, amphetamine or amphetamine-related drugs such as dextroamphetamine, methylamphetamine or a combination thereof); pain (which includes neuropathic pain (including diabetic neuropathy; sciatica; non-specific lower back pain;
multiple sclerosis pain; pain associated with fibromyalgia or cancer; AIDS-related and HIV-related neuropathy; chemotherapy-induced neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; sympathetically maintained pain and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis;
reflex sympathetic dystrophy such as shoulder/hand syndrome), acute pain (e.g. musculoskeletal pain, post operative pain and surgical pain), inflammatory pain and chronic pain, pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased, sensitivity, to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia), pain associated with migraine, and non-cardiac chest pain); certain CNS-mediated disorders such as emesis, irritable bowel syndrome, and non-ulcer dyspepsia; COPD, asthma, cough, gastro-oesophageal reflex induced cough, and exacerbated asthma; urinary incontinence; hypertension; and conditions associated with platelet hyperaggregability such as tissue ulceration, nephrotic syndrome, diabetes, migraine, coronary artery disease, pre-eclampsia and stroke. Preferably, the compounds of the invention are useful for the treatment of depression; anxiety disorders; phobias; psychosis and psychotic disorders; post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD);
withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities; and irritable bowel syndrome. More preferably, the compounds of the invention are useful for the treatment of depression;
anxiety disorders; phobias; and psychosis and psychotic disorders (especially schizophrenia, schizo-affective disorder, and schizophreniform diseases. Most preferably, the compounds of the invention are useful for the treatment of schizophrenia.
The compounds for use in the present invention are generally active in the following tests. They normally have an IC50 of less than 1 M and preferably less than 100nM.
Details of the NK-3 receptor and its heterologous expression can be found in Huang et al., BBRC, 1992, 184: 966-972 and Sadowski et al., Neuropeptides, 1993, 24: 317-319.
A membrane preparation is prepared as follows. A 10-layer cell factory is seeded with CHO
cells stably expressing NK-3 receptors. The CHO cells are prepared in a triple T175 flask in 11 growth medium which contains Iscore's modified Dulbecco's medium containing l Oml/1200mM L-Glutamine, 10m1/1 penicillin-streptomycin, one vial of hypoxanthine-thymidine 500x/1, lmg/ml geneticin and 10%
fetal bovine serum (inactivated). The cells are grown for 3 days in an incubator. The medium is washed off and the factory is rinsed twice with 400m1 PBS (Ca, Mg-free). 400m1 enzyme free dissoc. solution (EFDS) is added and the factory is maintained for 10 min at room temperature.
The cells are dislodged and the suspension poured into 500m1 centrifuge bottles. The process is repeated with 200m1 EFDS and the mixtures pooled giving 6 bottles in all, which are spun in a centrifuge for 10 min at 2200 rpm.
The supematants are aspirated and the residual cell pellets are frozen at -80 for 30 min to improve cell lysis and then resuspended in 40m1 Tris with inhibitors per cell factory. The cells are homogenized in 40m1 aliquots with 8 strokes of a glass-teflon grinder at setting 40. The homogenate is transferred to 50m1 centrifuge tubes and placed on a rocker for 15 min at r.t.
The homogenate is rehomogenised and held on ice if necessary before being centrifuged again as above.
The supematant is transferred to Sorvall tubes for an SS-34 roter and held on ice.
40m1 cold Tris with inhibitors is used to resuspend and combine the pellets which are again spun as above. The supematants are again transferred to Sorvall tubes which, with those above, are spun at 18000 rpm for 20 min.
The supematants are discarded and the pellets resuspended in a Storage Buffer consisting of 2.50m1 1M Tris pH7.4, 50 1 1000x protease inhibitors (4mg/ml leupeptin (Sigmo), 40mg/ml Bacitracin (Sigma) and 10mM phosphoranidon (Peninsula) all dissolved in water) plus 0.5m10.5M MnC12 ma.de up to 50m1 with H2Odd. A l Omi syringe is used with 20-, 23- and 25-gauge needles sequentially.
A Bradford protein assay in conducted on 2-10 1 aliquots with BSA as standard before 500-1000 1 aliquots are snap-frozen in liquid nitrogen for storage at -80 C.
The membrane binding assay is carried out as follows. The amount of membranes needed to specifically bind < 10% of 125 I-NeurokinB is predetermined. The frozen stocks are then diluted to allow addition in 50 1.
The test compounds are dissolved in DMSO. An automated apparatus (Tecan) is programmed to add 5 1 of compound or DMSO, approximately 100,000 cpm of isotope in 20 1 buffer which is prepared from 50 MTris, pH7.5, 150 M NaC1, bovine serum albumin to 0.02%, and protease inhibitors as in the storage buffer, made up as 0.5M stock, and 175 1 assay buffer (as the storage buffer but containing 5 M MnC12 and without NaC1) into deep well Marsh boxes (Marsh Biomedical Products) in a 96-well format. Excess unlabelled competing peptide is added by hand for non-specific binding as indicated below. The binding reaction is initiated by adding 50 1 of cell membranes. The tubes are incubated with shaking for lh at r.t. and filtered on a Tomtec 96 well cell harvester using Mach III
filtermats (Tomtec) or using either a Packard 96-well harvester or Tomtec 9600 using Unifilter GF/C
(Packard), presoaked in 0.25% polyethyleneimine and washed five times with 1X
wash buffer (0.1M.Tris, pH7.4 and 1M NaC1, 1X = 100m1 of lOX stock per litre of cold distilled water).
If using Unifilter plates, 60 1 Microscint 20 (Packard) is added to each well and the plate is then heat-sealed before counting in a Packard Topcount. Alternatively the filters from the filtermat are placed in 75x100mm plastic tubes and counted on a Cobra gamma counter.
For the assay, typically 10 g of membrane is used at 25,000 cpm which is filtered over a Unifilter GF/C presoaked in 0.5% BSA.
Compounds of the present invention may be prepared by methods disclosed in the documents hereinbefore referred to and by methods known in the art of organic synthesis and the Schemes set forth below.
According to a general process (A), compounds of formula (I) where Z is a bond may be prepared by the reaction of a compound of formula (II) with a compound of formula (III):
R' ~ R7 ( A rS(O)õ-X O HN/
R2~~J/ ~R8 Y
a (II) (III) where A, B, n, X, Y, R', R2, R3, R4, R5, R6, R7 and R8 are as defined in relation to formula (I). The reaction is conveniently preformed in the presence of a hydride source, such as a sodium triacetoxyborohydride, and a mild acid, such as acetic acid, in a suitable solvent, such as 1,2-dichloroethane.
Where they are not commercially available, the starting materials of formulae (II) and (III) may be prepared by methods illustrated in the following Schemes, by methods analogous to those described in the accompanying Descriptions and Examples, or by standard methods well known from the art. For example, compounds of formula (II) can be made from known compounds using procedures analogous to those found in published International applications WO 2002/081435, WO
2004/031137 and WO
2004/031139 (all Merck Sharp & Dohme Limited).
It will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art.
For instance, a compound of formula (I) where R4 is bromine may be transformed into a compound of formula (I) where R4 is hydrogen by hydrogenation using, for example, a palladium on carbon catalyst and hydrogen gas, in a suitable solvent, such as ethyl acetate.
In addition, a compound of formula (I) where R7 is methoxybenzyl may be transformed into a compound of formula (I) where R7 is hydrogen by treatment with ceric ammonium nitrate in a suitable solvent system such as acetonitrile/water. The resultant compound of formula (I) may be transformed into a different compound of formula (I) by reaction with, for example, a substituted piperidinone in the presence of a hydride source such as sodium triacetoxyborohydride, and acid, such as acetic acid, in a suitable solvent, such as 1,2-dichloroethane.
Also, a compound of formula (Iaa) where R9 is a BOC-protected amine, may be transformed to a compound of formula (Iaa) where R9 is an amine by treatment with acid, such as hydrochloric acid, in a suitable solvent, such as 1,4-dioxane. The resultant compound of formula (Iaa) may be transformed into a compound of formula (Iaa) whereR9 is a urea derivative by reaction with an alkyl isocyanate in the presence of a base, such as triethylamine, in a suitable solvent, such as dichloromethane.
General synthetic schemes:
Scheme 1 R' R' O
E:H ~ 3 i i 2 ~ Br d B
'R' O R' O
S O iv ~ v, vi ~S~
R2 ~- R2 O -~ R2 NRTR$
O
B B B
Cis & Trans Reagents: i) Et3N, CH2C12i ii) mCPBA, CH2C12; iii) 2,2-bis(2-iodoethyl)-1,3-dioxolane, NaH, DMF; iv) pTsOH, AcOH, H20, 50 C; v) R'RBNH, NaBH(OAc)3, AcOH, 1,2-dichloroethane; vi) separate isomers Scheme 2 MeO2CA S HO~ ~S
i B B
Reagents: i) MeMgBr, THF, -78 C.
Scheme 3 R' R3 ~S
-Br + ~~ ~ - Rz Reagents: i) NaH, DMF
Scheme 4 R' R' 0 O
R1 q SH -> R2~S O i-~ R2A -S~
R2- ~OD KXOD
R Br R' 0 O R~ 0 O
~S~'/~ iv S~'/~~ O~
R2 x ~O ~- R2 x x Y~ ~/ Y ~--/ ~O
~ ~
R3 ~ R3 R4 Reagents: i) 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate, CsF, DMF, 60 C;
ii) mCPBA, CH2C12i iii) nBuLi, THF; iv) pTsOH, AcOH, H20, 50 C.
Scheme 5 Rs Rs R' Rs Rs 1 Rs Rs HO-X R2~.J S-X~ '--' OJ \/ O\ R2~X / O
Y'-' O R' Y ~,/'C~
R3~~R4 R2~SH R3,&,R4 R3,, s R6 iii R2~S-Y
R3,'=', R4 Reagents: i) BF3.OEt2, CH2C12i ii) pTsOH, AcOH, H20, 50 C; iii) NaIO4, MeOH, H20.
Scheme 6 R5 R6 R5 R6 R' HO-X \ I O MeO2SO-X OD ii R2 ~ 6 Y~~/ 'O~ Y~~/ 'O S-X O
R~ Y~ ~/ 'OD
R 3~ R4 R3,~R4 A $H
iii, iv R~
A Rs Rs R2~ -O'~ XO
Y
R3,, R4 Reagents: i) MeSO2C1, Et3N, CH2C12i ii), Et3N, DMF, 80 C; iii) mCPBA, CH2C12;
iv) pTsOH, AcOH, H20, 50 C.
Scheme 7 ~ HN HN~ ~ H NN~
H2NC ~ 1-4 G HN-@
OH
ring C = aryl, heteroaryl Reagents: i) haloacetyl chloride, ii) ethanolamine, iii) di-tert-butyl azodicarboxylate, nBu3P, EtOAc.
The following abbreviations are used in the Schemes, Descriptions and Examples: DMF: N,N-dimethylformamide; DMSO: dimethylsulfoxide; Et20: diethyl ether; EtOAc: ethyl acetate; h: hour(s);
MeCN: acetonitrile; MeOH: methanol; min: minute(s); RT: room temperature; THF:
tetrahydrofuran The following Descriptions and Examples illustrate the present invention.
Description 1: 1-Chloro-4-[(4-fluorobenzyl)thio] benzene Triethylamine (6.3 mL, 45.1 mmol) was added dropwise to a stirred solution of 4-chlorothiophenol (5 g, 34.7 mmol) and 4-fluorobenzyl bromide (6.9 g, 36.4 mmol) in CH2C12 (60 mL) over 5 min. The mixture was stirred for lh at ambient temperature then partitioned between CH2C12 and water. The organic extracts were washed with brine, dried (Na2S04) and concentrated in vacuo to give the title compound (8.78 g, 100%).
'H NMR (500MHz, CDC13): 6 7.23-7.19 (6H, m), 6.96 (2H, t, J 8.6), 4.04 (2H, s).
Description 2: 2-[4-(4-Chlorobenzylsulfanyl)phenyl]propan-2-ol A solution of 4-(4-chlorobenzylsulfanyl)benzoic acid methyl ester (prepared according to the method of Description 1) (3 g, 10.2 mmol) in THF (50 mL) was cooled to -78 *C. Methyl magnesium bromide (3M
in Et2O, 10 mL, 30 mmol) was added dropwise. The mixture was stirred at this temperature for 30 min, then warmed to RT. Water and EtOAc were added and the phases separated. The organic layer was washed with brine, dried over Na2S04, filtered and evaporated in vacuo. The title compound (2.71 g, 90%) was obtained after column chromatography on silica gel (Gradient: EtOAc in hexanes 10% to 30%).
'H NMR (360MHz, CDC13): 6 7.37 (d, J 8.4, 2H); 7.24 (m, 6H); 4.05 (s, 2H);
1.55 (s, 6H).
Description 3: 5-{[(4-Chlorophenyl)methyl]thio}-2-(trifluoromethyl) pyridine NaH (60% dispersion in mineral oil, 1.2 g, 30 mmol) was added to a stirred, cooled (0 C) solution of 4-chlorobenzenemethanethiol (4.22 g, 26.5 mmol) in DMF (50 mL). The mixture was stirred at 0 C for 10 min, then 5-bromo-2-(trifluoromethyl)pyridine (5 g, 22.1 mmol) was added.
The mixture was stirred at RT for 4 h, then water was added. The mixture was extracted with EtOAc and the combined organic fractions were washed with water and brine, dried (Na2S04) and the solvent was evaporated under reduced pressure to give the title compound (6.74 g, 100%). m/z (ES) 304 (M+1).
The following compounds were prepared according to the method of Description 3.
Description Compound Br N
F
Description 6: 1-Chloro-4-[(4-fluorobenzyl)sulfonyl]benzene 3-Chloroperbenzoic acid (15.1 g, 87.5 mmol) was added in portions to a stirred, cooled (0 C) solution of 1-chloro-4-[(4-fluorobenzyl)thio]benzene (Description 1; 8.78 g, 34.7 mmol) in CH2C12 (80 mL). The mixture was warmed to RT and stirred overnight. The mixture was cooled in ice and Ca(OH)2 (9.7 g, 131 mmol) was added. The mixture was stirred for 20 min, filtered through HyfloTM and the solvent was evaporated under reduced pressure to give the title compound (9.34 g, 95%).
'H NMR (500MHz, CDC13): 6 7.55 (d, J 8.6, 2H); 7.43 (d, J 8.6, 2H); 7.08 (dd, J 5.4, 8.7, 2H); 7.00-6.94 (m, 2H); 4.27 (s, 2H).
Description 7: 8-[(4-Chlorophenyl)sulfonyl]-8-(4-fluorophenyl)-1,4-dioxaspiro[4.5]decane NaH (60% in mineral oil, 1.53 g, 39 mmol) was added to a solution of 1-chloro-4-[(4-fluorobenzyl)sulfonyl]benzene (Description 6; 4.67 g, 16.3 mmol) in DMF (120 mL) and the mixture was stirred at RT for 10 min. 2,2-Bis(2-iodoethyl)-1,3-dioxolane (6.85 g, 17.9 mmol) was added and the mixture was stirred at RT overnight. The mixture was cooled in ice and water was added. Aqueous NaHCO3 (saturated) was added and the mixture was extracted with EtOAc. The combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel, eluting with 15 - 20% EtOAc/hexane to give the title compound (4.00 g, 59%).
'H NMR (500MHz, CDC13): 6 7.33 (d, J 8.5, 2H); 7.23 (m, 4H); 7.00 (t, J 8.6, 2H); 3.95 (t, J 6.0, 2H);
3.88 (t, J5.9, 2H); 2.59-2.53 (m, 2H); 2.48 (d, J 12.9, 2H); 1.75 (d, J 13.1, 2H); 1.44-1.38 (m, 2H).
Description 8: 4-[(4-Chlorophenyl)sulfonyl]-4-(4-fluorophenyl)cyclohexanone p-Toluenesulfonic acid monohydrate (3.03 g, 15.9 mmol) was added to a stirred, heated (50 C) solution of 8-[(4-chlorophenyl)sulfonyl]-8-(4-fluorophenyl)-1,4-dioxaspiro[4.5]decane (Description 7; 4.00 g, 9.73 mmol) in acetic acid (90 mL) and water (10 mL) and the mixture was stirred at 50 C overnight. The mixture was cooled, diluted with EtOAc and neutralised with K2C03. The mixture was extracted with EtOAc. The combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (3.3 g, 90%).
'H NMR (500MHz, CDC13): 6 7.37-7.30 (m, 4H); 7.25 (m, 2H); 7.10-7.04 (m, 2H);
2.80 (m, 2H); 2.72-2.66 (m, 2H); 2.50 (m, 2H); 2.22-2.15 (m, 2H).
The following compounds were prepared according to the methods of Descriptions 1-8.
R~ 0 O
O
R' Description R R' 9 H 4-Br 3-Cl 4-Br 11 3-CF3 4-Br 12 4-Cl 3-F
13 4-Cl 4-F
14 4-Cl 4-Br 4-Cl 4-CN
16 4-Cl 4-Me 17 4-Cl 4-CF3 18 4-Cl 4-(OCF3) 19 4-Cl 2,5-F2 4-Cl 3,4-C12 21 4-Cl 2-F, 4-Br 22 4-CN 4-Br 23 4-Me 4-Br 24 4-CF3 3-Br 26 4-CF3 4-Cl 27 4-CF3 4-Br 28 4-CF3 3,4-C12 29 4-CF3 3-F, 4-Cl 30 4-(OCF3) 4-Br 31 4-C(Me)20H 4-Cl 32 4-CO2Me 4-Cl The following compounds were prepared according to the methods of Descriptions 1-8.
F3C N S'O
O
0::::
Description R' 34 4-Cl 35 4-Br Description 36: 8-[4-(Trifluoromethyl)phenylthio] -1,4-dioxa-spiro [4.5]
decane Cesium fluoride (10.2 g, 67.7 mmol) was heated to 180 C under vacuum for 2 h, cooled to RT, placed under a N2 atmosphere and 4-(trifluoromethyl)benzenethiol (5.2 g, 29.2 mmol), 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate (J. Med. Chem. 1992, 35, 2243.) (5.3 g, 22.5 mmol) and DMF (44 mL) were added. The mixture was heated to 60 C for 3 h, cooled and water and EtOAc were added. The layers were separated and the organic layer was washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexanes/EtOAc (100:0 increasing to 90:10) to give the title compound (3.51 g, 50%).
'H NMR (500MHz, CDC13): 6 7.52 (d, J 8.1, 2H); 7.42 (d, J 8.1, 2H); 3.93 (s, 4H); 3.31 (m, 1H); 2.02 (m, 2H); 1.85 (m, 2H); 1.75 (m, 2H); 1.62 (m, 2H).
Description 37: 8-[4-(Trifluoromethyl)benzenesulfonyl] -1,4-dioxa-spiro [4.5]
decane Prepared from 8-[4-(trifluoromethyl)phenylthio]-1,4-dioxa-spiro[4.5]decane (Description 36) according to the method of Description 6.
'H NMR (500MHz, CDC13): 6 8.05 (d, J 8.1, 2H); 7.87 (d, J 8.1, 2H); 3.93 (m, 4H); 2.95 (m, 1H); 2.08 (m, 2H); 1.90-1.75 (m, 4H); 1.55 (m, 2H).
Description 38: 8-(4-Bromo)phenylmethyl-8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane n-Butyllithium (1.6M in hexanes, 1.7 mL, 2.7 mmol) was added dropwise to a stirred, cooled (-78 C) solution of 8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane (Description 37, 1 g, 2.86 mmol) in THF (10 mL) and the mixture was stirred at -78 C for 20 min. A
solution of 4-bromobenzyl bromide (1.43 g, 5.7 mmol) in THF (4 mL) was added dropwise and the mixture was stirred 5 at -78 C for 2 h. Water and EtOAc were added, the mixture warmed to RT and the layers were separated. The organic layer was washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with hexanes/EtOAc (95:5 increasing to 85:15) to give the title compound (1.16 g, 78%).
'H NMR (500MHz, CDC13): 6 7.95 (d, J 8.1, 2H); 7.80 (d, J 8.1, 2H); 7.40 (d, J
8.2, 2H); 7.13 (d, J 8.2, 10 2H); 3.82 (s, 4H); 3.10 (s, 2H); 1.95 (m, 6H); 1.68 (m, 2H).
Description 39: 4-(4-Bromo)phenylmethyl-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexanone Prepared from 8-(4-bromo)phenylmethyl-8-[4-(trifluoromethyl)benzenesulfonyl]-1,4-dioxa-spiro[4.5]decane (Description 38) according to the method of Description 8.
15 'H NMR (500MHz, CDC13): 6 8.09 (d, J 8.1, 2H); 7.90 (d, J 8.1, 2H); 7.42 (d, J 8.2, 2H); 6.98 (d, J 8.2, 2H); 2.96 (s, 2H); 2.84 (m, 2H); 2.43 (m, 2H); 2.15-2.00 (m, 4H).
Description 40: 4-(4-Bromo)phenylmethyl-4-[4-(chloro)benzenesulfonyl]
cyclohexanone Prepared from 1,4-dioxa-spiro[4.5]dec-8-yl methanesulfonate and 4-chlorobenzenethiol according to the 20 method of Descriptions 36-39.
'H NMR (500MHz, CDC13): 6 7.88 (d, J 8.1, 2H); 7.60 (d, J 8.1, 2H); 7.42 (d, J
8.2, 2H); 6.98 (d, J 8.2, 2H); 2.95 (s, 2H); 2.82 (m, 2H); 2.41 (m, 2H); 2.10 (m, 2H); 2.01 (m, 2H).
Description 41: 8-Phenyl-1,4-dioxaspiro[4.5]decane-8-methyl Methanesulfonate 25 Triethylamine (0.57 g, 0.0056 mol) then methanesulfonyl chloride (0.57 g, 0.00495 mol) were added dropwise to 8-phenyl-1,4-dioxaspiro[4.5]decane-8-methanol (Bioorganic &
Medicinal Chemistry Letters 2002, 12, 1755-1758, 0.82 g, 0.0033 mol) in CH2C12 (10 mL) and the mixture was stirred at RT for 16 h.
The mixture was diluted with CH2C12, washed with water and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound.
'H NMR (360MHz, CDC13): 6 1.52-1.70 (4H, m), 1.88-1.97 (2H, m), 2.30-2.34 (2H, m), 2.55 (3H, s), 3.88-3.97 (4H, m), 4.10 (2H, s), 7.24 (1H, m), 7.35-7.43 (4H, m).
Description 42: 8-Phenyl-8-[(phenylthio)methyl]]-1,4-dioxa-spiro[4.5]decane Thiophenol (0.22 g , 0.002 mol) followed by triethylamine (0.2 g, 0.002 mol) were added to 8-phenyl- 1,4-dioxaspiro[4.5]decane-8-methyl methanesulfonate (Description 41, 0.5 g, 0.0015 mol) in DMF (8 mL) and the mixture was stirred at 80 C for 16 h. The mixture was cooled, diluted with water and extracted with EtOAc. The combined organic fractions were washed with water, and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give the title compound (0.21 g, 42%).
'H NMR (360MHz, CDC13): 6 1.53-1.69 (4H, m), 1.94-2.02 (2H, m), 2.35 (2H, m), 3.16 (2H, s), 3.87-3.96 (4H, m), 7.06-7.41 (10H, m).
Description 43: 4-Phenyl-4-[(phenylsulfonyl)methylllcyclohexanone To an ice-bath-cooled solution of 8-phenyl-8-[(phenylthio)methyl]]-1,4-dioxa-spiro[4.5]decane (Description 42, 0.21 g, 0.00062 mol) in CH2C12 (8 mL) was added portionwise 3-chloroperbenzoic acid (70%, 0.36 g, 0.0015 mol). After allowing the mixture to warm to RT it was stirred for 16 h. Ca(OH)2 (0.068 g, 0.00092 mol) was added and the mixture was stirred at RT for 15 min.
The mixture was filtered through celite and the solvent was evaporated under reduced pressure. The residue was dissolved in acetic acid (5 mL) and water (0.5 mL) andp-toluenesulfonic acid monohydrate (176 mg, 0.00093 mol) was added. The mixture was heated at 50 C for 16 h, cooled and EtOAc and water were added. The layers were separated and the organic layer was washed with water, and aqueous NaHCO3, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash colunm chromatography on silica gel to give the title compound (0.16 g, 80%).
'H NMR (360MHz, CDC13): 6 2.26-2.48 (6H, m), 2.83 (2H, m), 3.45 (2H, m), 7.19-7.60 (10H, m).
Description 44: 8-(4-Bromophenyl)-8-[(4-trifluoromethyl)phenylthiol]-1,4-dioxa-spiro[4.5]decane Boron trifluoride diethyl etherate (1.82 g, 13 mmol) then 4-(trifluoromethyl)thiophenol (2.3 g, 13 mmol) were added dropwise to a stirred, cooled (-10 C) solution of 8-(4-bromo-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol (prepared according to Zhang, Y.; Schuster, G.B. J. Org.
Chem. 1994, 59, 1855.) (2 g, 6.4 mmol) in CH2C12 (32 mL) and the mixture was stirred at RT for 2 h.
Water was added, the layers were separated and the organic layer was washed with brine, dried (Na2S04), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexane/EtOAc (98:2 increasing to 90:10) to give the title compound (0.4 g, 13%).
'H NMR (400MHz, CDC13): 6 7.40 (m, 4H); 7.15 (d, J 8.4, 2H); 7.05 (d, J 8.4, 2H); 3.96 (m, 4H); 2.20-1.50 (m, 8H).
Description 45: 4-(4-Bromophenyl)-4-[(4-trifluoromethyl)benzenesulfinyl]
cyclohexanone Sodium metaperiodate (131 mg, 0.7 mmol) in water (1 mL) was added to a solution of 4-(4-bromophenyl)-4-[(4-trifluoromethyl)phenylthio]cyclohexanone [prepared from 8-(4-bromophenyl)-8-[(4-trifluoromethyl)phenylthiol]-1,4-dioxa-spiro[4.5]decane (Description 44) according to the method of Description 8] (0.22 g, 0.51 mmol) in methanol (2 mL) and the mixture was stirred at RT overnight. The mixture was filtered and the solvent was evaporated under reduced pressure.
Water and EtOAc were added and the layers were separated. The organic fraction was washed with brine, dried (Na2S04) and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography on silica gel, eluting with hexane/EtOAc (50:50) to give the title compound.
'H NMR (360MHz, CDC13): 6 7.52 (m, 4H); 7.02 (m, 4H); 7.05 (d, J 8.4, 2H);
2.55 (m, 5H); 2.26 (m, 3H).
Description 46: 1-(1,1-Dimethylethyl) 4-Methy11,4-Piperidinedicarboxylate Trimethylsilyldiazomethane (2.OM in hexane, 147 mL, 0.29 mol) was added over 30 min. via an addition funnel to a stirred, cooled (0 C) solution of 1 -(1, 1 -dimethylethyl) 1,4-piperidinedicarboxylate (45.0 g, 0.20 mol) in CH2C12/MeOH (3:1. 1200 mL). The solvent was evaporated under reduced pressure to give the title compound (47 g) as a light yellow oil. This was used directly in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.46 (s, 9H), 1.58-1.68 (m, 2H), 1.86-1.91 (m, 2H), 2.45 (tt, 1H), 2.81-2.87 (m, 2H), 3.70 (s, 3H), 4.00-4.05 (m, 2H).
Description 47: 1-(1,1-Dimethylethyl) 4-Methyl 4-(Pent-4-en-1-yl)-1,4-piperidinedicarboxylate A solution of 1-(1,1-dimethylethyl) 4-methyl 1,4-piperidinedicarboxylate (Description 46, 25 g, 0.10 mol) in THF (250 mL) was added to a stirred, cooled (0 C) solution of potassium bis(trimethylsilyl)amide (30.7 g, 0.15 mol) in THF (750 mL) and the mixture was stirred at 0 C for 1 h.
5-Bromo-l-pentene (19.4 mL, 0.164 mol) was added and the mixture was allowed to warm to RT and stirred for 1.5 h. The mixture was poured into saturated aqueous NaHCO3 and extracted with EtOAc (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure to give the title compound (30.9 g) which was used in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.26-1.40 (m, 4H), 1.46 (s, 9H), 1.50-1.54 (m, 2H), 1.99-2.06 (m, 2H), 2.11-18 (m, 2H), 2.80-2.98 (m, 2H), 3.72 (s, 3H), 3.87-3.95 (m, 2H), 4.95-5.02 (m, 2H), 5.72-5.80 (m, 1H).
Description 48: 1-(1,1-Dimethylethyl) 4-Methyl 4-(4-Oxobut-1-yl)-1,4-piperidinedicarboxylate A solution of 1-(1,1-dimethylethyl) 4-methyl4-(pent-4-en-l-yl)-1,4-piperidinedicarboxylate (Description 47, 29.4 g, 0.0945 mol) in methanol (1000 mL) was cooled to -78 C and ozone was bubbled into the solution until a blue color persisted. The excess ozone was removed with a stream of N2, then methyl sulfide (69 mL, 0.95 mol) was added, the cooling bath was removed, and the mixture was allowed to warm to RT over 1.5 h. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography, eluting with 2:1 heptane/EtOAc, to give the title compound (23.0 g).
'H NMR (400MHz, CDC13) 6 1.29-1.40 (m, 2H), 1.46 (s, 9H), 1.50-1.57 (m, 4H), 2.09-2.13 (m, 2H), 2.41-2.44 (m, 2H), 2.82-2.95 (m, 2H), 3.73 (s, 3H), 3.86-3.89 (m, 2H), 9.74 (s, 1H).
Description 49: 1-[(1,1-Dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoic acid Jones reagent (2.6M , 28.2 mL) was added via syringe to a solution of 1-(1,1-dimethylethyl) 4-methyl4-(4-oxobut-l-yl)-1,4-piperidinedicarboxylate (Description 48, 23.0 g, 0.0734 mol) in acetone (775 mL).
After 5 min, the solvent was evaporated under reduced pressure and the residue was taken up in water.
The mixture was extracted with Et20 (3x) and the combined organic fractions were washed with brine, dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (23.4 g) which was used in the next step without further purification.
'H NMR (400MHz, CDC13) 6 1.33-1.41 (m, 2H), 1.46 (s, 9H), 1.50-1.57 (br s, 4H), 2.09-2.19 (m, 2H), 2.32-2.34 (m, 2H), 2.85-2.89 (m, 2H), 3.73 (s, 3H), 3.81-3.89 (m, 2H).
Description 50: Methyl 1-[(1,1-Dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoate Trimethylsilyldiazomethane (2.OM in hexane, 53 mL, 0.11 mol) was added to a stirred, cooled (0 C) solution of 1-[(1,1-dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoic acid (Description 49, 23.4 g, 0.071 mol) in CH2C12/MeOH (3:1, 480 mL). The mixture was stirred at RT for 15 min, then the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (20.1 g).
'H NMR (400MHz, CDC13) 6 1.33-1.42 (m, 2H), 1.43 (s, 9H), 1.57-1.59 (m, 4H), 2.08-2.14 (m, 2H), 2.26-2.31 (m, 2H), 2.84-2.94 (m, 2H), 3.68 (s, 3H), 3.73 (s, 3H), 3.83-3.90 (m, 2H).
Description 51: (RS')-8-(1,1-Dimethylethyl) 2-Methyll-Oxo-8-azaspiro[4.5]decane-2,8-dicarboxylate Lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexanes, 47 mL, 0.070 mol) was added to a stirred, cooled (-78 C) solution of methyl 1-[(1,1-dimethylethoxy)carbonyl]-4-(methoxycarbonyl)-4-piperidinebutanoate (Description 50, 20.1 g, 0.058 mol) in THF (600 mL). The mixture was stirred at -78 C for 25 min., then additional lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexanes, 31 mL) was added and the mixture was stirred at -78 C for 20 min. The mixture was poured into saturated aqueous ammonium chloride and extracted with Et20 (3x).
The combined organic fractions were washed with brine, dried (Na2SO4), and the solvent was evaporated under reduced pressure to give the title compound (19.9 g) which was taken on to the next step without further purification.
Description 52: 1,1-Dimethylethyll-Oxo-8-azaspiro [4.5] decane-8-carboxylate Pulverized lithium hydroxide (26 g, 1.10 mol) was added to a solution of (RS)-8-(1,1-dimethylethyl) 2-methyl 1-oxo-8-azaspiro[4.5]decane-2,8-dicarboxylate (Description 51, 17.2 g, 0.055 mol) in ethanol/THF/water (2:2:1, 555 mL) and the mixture was stirred at 90 C for 60 h. The mixture was cooled and the solvent was evaporated under reduced pressure. Water was added and the mixture was extracted with CH2C12 (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (9.41 g).
'H NMR (400MHz, CDC13) 6 1.29-1.37 (m, 2H), 1.47 (s, 9H), 1.62-1.69 (m, 2H), 1.92-1.95 (m, 4H), 2.30-2.34 (m, 2H), 3.05-3.10 (m, 2H), 3.87-3.92 (m, 2H).
Description 53: (1RS,2RS)-1,1-Dimethylethyl2-(1-Hydroxyprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate 1,1-Dimethylethyl 1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 52, 4.5 g, 17.8 mmol) was dried by adding and evaporating toluene (3 x 10 mL) under reduced pressure, dissolved in THF (100 mL) and cooled to -78 C. Lithium diisopropylamide mono(tetrahydrofuran) (1.5M in cyclohexane, 24 mL, 36 mmol) was added and the mixture was stirred at -78 C for 30 min.
Propionaldehyde (2.6 mL, 36 mmol) was added and the mixture was stirred at -78 C for 5 min. The mixture was diluted with Et20, poured into saturated aqueous ammonium chloride and extracted with Et20 (3x).
The combined organic fractions were washed with brine, dried (Na2SO4), filtered, and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 20-30% EtOAc in hexanes, to give the title compound (4.75 g).
'H NMR (400MHz, CDC13) 6 0.97 (t, 3H), 1.33-1.37 (m, 2H), 1.47 (s, 9H), 1.54-1.68 (m, 5H), 1.75-1.78 (m, 1H), 2.07-2.13 (m, 2H), 2.30-2.33 (m, 1H), 2.95-3.15 (m, 2H), 3.62-3.63 (m, 1H), 3.84-3.94 (m, 2H).
Description 54: 1,1-Dimethylethyl2-(1-Oxoprop-1-yl)-1-oxo-8-azaspiro [4.5]
decane-8-carboxylate DMSO (2.6 mL, 37 mmol) was added slowly to a stirred, cooled (-78 C) solution of oxalyl chloride (1.6 mL, 18.3 mmol) in CH2C12 (150 mL) and the mixture was stirred at -78 C
for 5 min. A solution of (1RS,2RS)-1,1-dimethylethyl2-(1-hydroxyprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 53, 4.75 g, 15.3 mmol) in CH2C12 (40 mL) was added via an addition funnel and the mixture was stirred at -78 C for 45 min. Triethylamine (10.2 mL, 73.2 mmol) was added and the mixture was stirred at -78 C for 5 min., then allowed to warm to RT for 1.5 h. The mixture was poured into water and extracted with CH2C12 (3x). The combined organic fractions were washed with brine, dried (Na2SO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 15% EtOAc in hexanes, to give the title compound (3.98 g) as a pink oil.
Description 55: 1,1-Dimethylethy11,3-Diethyl-4,5-dihydrospiro [cyclopentapyrazole-6(1H),4'-piperidine]-1'-carboxylate Trifluoroacetate and 1,1-Dimethylethy12,3-Diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4'-piperidine]-1'-carboxylate Trifluoroacetate Ethyl hydrazine oxalate (0.096 g, 0.640 mmol) was added to a solution of 1,1-dimethylethyl2-(1-oxoprop-1-yl)-1-oxo-8-azaspiro[4.5]decane-8-carboxylate (Description 54, 0.165 g, 0.533 mmol) in ethanol (5 mL) and the mixture was stirred at 85 C for 12 h. The mixture was cooled and the solvent was evaporated under reduced pressure. The residue was taken up in a minimal amount of 40:40:20 5 MeCN/water/DMSO solution and purified by Gilson reverse phase HPLC (Column:
YMC-Pack Pro C18, 100 X 20 mm I.D.; Gradient Eluent: 10:90 to 90:10 v/v MeCN/water + 0.1%
trifluoroacetic acid over 12.5 min; Detection: PDA, 210-400 nm; Flow rate: 20 mL/min) to give 1,1-dimethylethyl 1,3-diethyl-4,5-dihydrospiro [cyclopentapyrazole-6(1H),4' piperidine]-1 '-carboxylate tr fluoroacetate (0.220 g); 'H
NMR (400MHz, CDC13) 6 1.23 (t, 3H), 1.42 (t, 3H), 1.50 (s, 9H), 1.60-1.63 (m, 2H), 1.88-1.93 (m, 2H), 10 2.42-2.47 (m, 2H), 2.56-2.61 (m, 4H), 2.86-2.89 (m, 2H), 4.00 (q, 2H), 4.10-4.13 (m, 2H); m/z (ES) 334 (M+1); and 1, 1-dimethylethyl 2,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(2H),4' piperidine]-1'-carboxylate trifluoroacetate (0.016 g); 'H NMR (400MHz, CDC13) 6 1.27 (t, 3H), 1.38 (t, 3H), 1.48 (s, 9H), 1.51-1.57 (m, 2H), 1.75-1.79 (m, 2H), 2.22-2.45 (m, 2H), 2.58-2.65 (m, 4H), 3.51-3.60 (m, 2H), 3.64-3.67 (m, 2H), 4.03 (q, 2H); m/z (ES) 334 (M+1).
Description 56: 1,3-Diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4'-piperidine]
Dihydrochloride Acetyl chloride (1.17 mL, 16.4 mmol) was added to a stirred, cooled (0 C) solution of 1,1-dimethylethyl 1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1H),4'-piperidine]-1'-carboxylate trifluoroacetate (Description 55, 0.547 g, 1.64 mmol) in MeOH (16 mL). The mixture was allowed to warm to RT and stirred for 60 h. The solvent was evaporated under reduced pressure to give the title compound.
'H NMR (400MHz, CDC13) 6 1.32 (t, 3H), 1.54 (t, 3H), 2.00 (d, 2H), 2.37-2.45 (m, 2H), 2.66-2.69 (m, 2H), 2.73-2.82 (m, 4H), 3.18-3.24 (m, 2H), 3.47-3.52 (d, 2H), 4.41 (q, 2H).
Description 57: 1-(1,1-Dimethylethyl) 4-piperidinedicarboxylate Anhydride with 1H-Imidazole-l-carboxylic Acid Carbonyldiimidazole (39.4 g, 243 mmol) was added in portions to a stirred solution of 1 -(1, 1 -dimethylethyl) 4-piperidinedicarboxylate (42.5 g, 187 mmol) in CH2C12 (550 mL) and the mixture was stirred at 4 C overnight. The mixture was poured into Et20 (2 L) and ice water (2 L), the layers were separated and the organic layer was washed with cold aqueous NaHCO3 (saturated, 500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound as a colorless solid (52 g).
Description 58: 1,1-Dimethylethyl4-(1,3-Dioxobutyl)piperidinecarboxylate Acetone (41 mL) in THF (300 mL) was added dropwise to a stirred suspension of KH (30% in mineral oil, 75 g, 561 mmol) in THF (1.4 L) at RT. The mixture was cooled to -78 C
and treated with 1-(1,1-dimethylethyl) 4-piperidinedicarboxylate anhydride with 1H-imidazole-l-carboxylic acid (Description 57, 52 g) in THF (500 mL). The mixture was allowed to warm to RT
and stirred overnight, then ethanol (50 mL) was added dropwise over 5 min. The mixture was poured into hydrochloric acid (1N, 2 L) and extracted with Et20 (2 xl L). The combined organic fractions were washed with aqueous NaHCO3 (saturated, 500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. Isohexane (1 L) and acetonitrile (500 mL) were added, the layers were separated and the isohexane layer was extracted with MeCN (500 mL). The MeCN layers were combined and the solvent was evaporated under reduced pressure. The residue was filtered through a silica pad, eluting with 0-20% EtOAc in hexanes, to give the title compound as a colorless solid (36 g, 72%).
'H NMR (CDC13) 6 5.50 (1H, s), 4.18-4.11 (2H, m), 2.79-2.62 (2H, m), 2.34-2.27 (1H, m), 2.07 (3H, s), 1.80 (2H, brd, J 14.3), 1.60-1.51 (2H, m), 1.46 (9H, s).
Description 59: 1,1-Dimethylethyl4-[1-(1,1-Dimethylethyl)-3-methyl-lH-pyrazol-yl]piperidinecarboxylate t-Butyl hydrazine hydrochloride (14.8 g, 118 mmol) then triethylamine (17 mL, 120 mmol) were added to a solution of 1,1-dimethylethyl 4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58, 8 g, 29.7 mmol) in ethanol (200 mL) and the mixture was stirred at RT overnight. The solvent was evaporated under reduced pressure and the residue was suspended in EtOAc (1 L), washed with aqueous NaOH (1N, 500 mL), water (500 mL) and brine (500 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound as a yellow oil (9.5 g).
'H NMR (CDC13) 6 5.87 (1H, s), 4.27-4.18 (2H, m), 3.09-2.99 (1H, m), 2.79-2.68 (2H, m), 2.20 (3H, s), 1.85 (2H, brd, J 13.3), 1.63 (9H, s), 1.61-1.52 (2H, m), 1.48 (9H, s).
Description 60: 4-[1-(1,1-Dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidine Methanolic HC1(1N, 100 mL) was added to a solution of 1,1-dimethylethyl4-[1-(1,1-dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidinecarboxylate (Description 59, 9.5 g, 29 mmol) in MeOH (100 mL) and the mixture was stirred at RT for 4 h. The solvent was evaporated under reduced pressure and the residue was triturated with EtOAc. The solid was collected, suspended in aqueous NaOH
(4N, 20 mL) and extracted with CH2C12 (2 x 100 mL). The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (6.4 g).
'H NMR (CDC13) 6 5.91 (1H, s), 3.17 (2H, brd, J 13.0), 3.03 (1H, tt, J 13.0, 4.3), 2.69 (2H, dt, J 12.8, 3.5), 2.21 (3H, s), 1.86 (2H, brd, J 13.4), 1.67 (9H, s), 1.68-1.56 (2H, m).
Description 61: 4-[1-(-(2,2,2-Trifluoroethyl))-3-methyl-lH-pyrazol-5-yl]piperidine Prepared from 1,1-dimethylethyl4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58) according to the methods of Descriptions 59 and 60, substituting trifluoroethyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 5.91 (1H, s), 4.58 (2H, dd, J 16.4, 8.6), 3.17 (2H, brd, J
13.2), 2.70 (2H, dt, J 12.5, 2.4), 2.60 (1H, tt, J 12.1, 4.1), 2.23 (3H, s), 1.82 (2H, brd, J 14.4), 1.58 (2H, qd, J 12.5, 3.8).
Description 62: 1,1-Dimethylethyl4-[(2-Oxocyclopentyl)carbonyl]-1-piperidinecarboxylate Prepared from 1-(1,1-dimethylethyl) 4-piperidinedicarboxylate anhydride with 1H-imidazole-l-carboxylic acid (Description 57) according to the method of Description 58, substituting cyclopentanone for acetone.
'H NMR (CDC13) 6 13.75 (1H, brs), 4.27-4.06 (2H, m), 2.78-2.69 (2H, m), 2.57 (2H, t, J6.2), 2.42 (2H, t, J7.2), 2.37-2.30 (1H, m), 1.96-1.89 (2H, m), 1.75-1.63 (4H, m), 1.46 (9H, s).
Description 63: 4-(2-Ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine Prepared from 1,1-dimethylethyl4-[(2-oxocyclopentyl)carbonyl]-1-piperidinecarboxylate (Description 62) according to the methods of Descriptions 59 and 60, substituting ethyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 4.02 (2H, dd, J 14.5, 8.0), 3.18 (2H, brd, J 12.4), 2.72 (2H, dt, J 12.6, 2.5), 2.68-2.63 (5H, m), 2.40-2.33 (2H, m), 1.81 (2H, brd, J 13.6), 1.69 (2H, qd, J 12.6, 4.1), 1.42 (3H, t, J7.4).
Description 64: 1,1-Dimethylethyl4-(1,3-Dioxo-2-methylbutyl)piperidinecarboxylate NaH (60% in mineral oil, 75 mg, 1.9 mmol) was added to 1,1-dimethylethyl4-(1,3-dioxobutyl)piperidinecarboxylate (Description 58, 0.5 g, 1.9 mmol) in DMF (5 mL). The mixture was stirred at RT for 1 h, then added to a solution of iodomethane (0.59 mL, 9.5 mmol) in DMF (5 mL).
Water (500 mL) was added and the mixture was extracted with EtOAc (100 mL).
The organic layer was washed with saturated brine (50 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with 15-25%
EtOAc in hexanes, to give the title compound (175 mg).
Description 65: 4-[1,3,4-Trimethyl-lH-pyrazol-5-yl]piperidine Prepared from 1,1-dimethylethyl4-(1,3-dioxo-2-methylbutyl)piperidinecarboxylate (Description 64) according to the methods of Descriptions 59 and 60, substituting methyl hydrazine oxalate for t-butyl hydrazine hydrochloride.
'H NMR (CDC13) 6 4.07 (2H, q, J 7.6), 3.19 (2H, brd, J 11.8), 2.77-2.67 (3H, m), 2.14 (3H, s), 2.02 (3H, s), 1.92 (2H, qd, J 11.8, 4.1), 1.69 (2H, brd, J 13.0), 1.36 (3H, t, J7.4).
Description 66: 1-Phenylmethyl-4-(3,5-diethyl-lH-pyrazol-1-yl)piperidine Triethylamine (3.54 mL, 25.5 mmol) was added to a stirred solution of 4-hydrazino-1-(phenylmethyl)piperidine dihydrochloride (3.53 g, 12.7 mmol) in ethanol (50 mL) and the mixture was stirred at RT for 5 min. 3,5-Heptanedione (3.26 g, 25.5 mmol) was added and the mixture was stirred at RT for 4 days. The mixture was diluted with EtOAc, washed with aqueous NaOH
(0.5M), brine, dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with 100% hexane to 100% Et20, to give the title compound (2.7 g, 71 %).
'H NMR (CD3OD) 6 7.35-7.20 (5H, m), 5.85 (1H, s), 4.02-3.94 (1H, m), 3.55 (2H, s), 2.99 (2H, d, J9.2), 2.63-2.51 (4H, m), 2.27-2.12 (4H, m), 1.73 (2H, t, J 11.8), 1.24-1.16 (6H, m).
Description 67: 4-(3,5-Diethyl-lH-pyrazol-1-yl)piperidine Ammonium formate (5.73 g, 90 mmol) and Pd on C (300 mg) were added to a stirred solution of 1-phenylmethyl-4-(3,5-diethyl-lH-pyrazol-l-yl)piperidine (Description 66, 2.7 g, 9 mmol) in methanol (75 mL) and the mixture was stirred under reflux for 3 h. The mixture was cooled, filtered through HyfloTM and the solvent was evaporated under reduced pressure. The residues was dissolved in MeOH
and poured onto SCX cartridges (Varian Bond E1utTM; 10 mL/500 mg). The cartridges were washed with MeOH, then eluted with methanolic ammonia (2M). The solvent was evaporated under reduced pressure to give the title product. (1.6 g, 85%).
'H NMR (CD3OD) 6 5.86 (1H, s), 4.18-4.10 (1H, m), 3.15 (2H, dd, J2.1, 10.9), 2.75-2.53 (6H, m), 2.07-1.97 (2H, m), 1.79 (2H, d, J 14.0), 1.25-1.17 (6H, m).
Description 68: 1,1-Dimethylethy11,2-Dihydro-l-(1-methylethyl)-2-oxospiro[3H-indole-3,4'-piperidine] -1'-carboxylate NaH (60% in mineral oil, 344 mg, 8.6 mmol) was added in portions to a stirred, cooled (0 C) solution of 1,1-dimethylethyl 1,2-dihydro-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate (2.0 g, 6.6 mmol) in DMF (10 mL) and the mixture was stirred at 0 C for 10 min. 2-lodopropane (0.86 mL, 8.6 mmol) was added and the mixture was allowed to warm to RT and stirred overnight. Water (100 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic fractions were dried (MgSO4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash colunm chromatography on silica gel, eluting with isohexane/EtOAc (70:30) to give the title compound as a solid (2.3 g).
'H NMR (CDC13) 6 7.29-7.23 (2H, m), 7.06-7.02 (2H, m), 4.68-4.62 (1H, m), 3.88-3.76 (4H, m), 1.82-1.74 (4H, m), 1.50 (9H, s), 1.47 (6H, d, J7.3).
Description 69: 1-(1-Methylethyl)spiro[3H-indole-3,4'-piperidin]-2(1H)-one Trifluoroacetate Trifluoroacetic acid (2 mL) was added dropwise to a solution of 1, 1 -dimethylethyl 1,2-dihydro-l-(1-methylethyl)-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate (Description 68) in CH2C12 (20 mL) and the mixture was stirred at RT for 4 h. The solvent was evaporated under reduced pressure to give the title compound as a tan solid (2.35 g).
'H NMR (CDC13) 6 9.01 (1H, s), 8.54 (1H, s), 7.32-7.28 (2H, m), 7.12 (1H, t, J7.12), 7.04 (1H, d, J
7.12), 4.65-4.59 (1H, m), 4.00 (2H, q, J 11.9), 3.45 (2H, d, J 12.4), 2.39-2.31 (2H, m), 1.90 (2H, d, J
14.8), 1.49 (6H, d, J 7.0).
Description 70: 1,1-Dimethylethyl4-[(6-Methoxy-3-nitro-2-pyridinyl)amino]piperidinecarboxylate 1,1-Dimethylethyl4-amino-l-piperidinecarboxylate (10.01 g, 50 mmol) and triethylamine (34.85 mL, 25.3 g, 250 mmol) were added to a solution of 2-chloro-6-methoxy-5-nitropyridine (9.43 g, 50 mmol) in DMSO (100 mL) and the mixture was stirred at 100 C for 12 h. The mixture was cooled and added dropwise to water (1200 mL). The mixture was stirred at RT for 12 h, then the solid was collected, washed with water and dried in vacuo to give the title compound as a yellow powder (16.70 g, 95%).
'H NMR (360MHz, CDC13) 6 1.48 (9H, s), 1.52-1.62 (2H, m), 2.02-2.1 (2H, br m), 2.95-3.09 (2H, br m), 3.95 (3H, s), 4.00-4.10 (2H, br m), 4.23-4.35 (1H, m), 6.07 (1H, d, J9), 8.28 (1H, d, J9), 8.63 (1H, br d).
Description 71: 1,3-Dihydro-5-methoxy-3-(4-piperidinyl)-2H-imidazo[4,5-b]pyridin-2-one Dihydrochloride Platinum oxide (hydrated, 1.1 g) was added to a suspension of 1,1-dimethylethyl4-[(6-methoxy-3-nitro-2-pyridinyl)amino]piperidinecarboxylate (Description 70, 16.75 g, 47.52 mmol) in ethanol (250 mL) and the mixture was shaken under H2 (25 to 35 psi) for 4 h. CH2C12 (25 mL) was added, the mixture was filtered and the solvent was evaporated under reduced pressure. The residue was dissolved in toluene (125 mL) and treated with N-ethyldiisopropylamine (24.40 mL, 18.42 g, 142.57 mmol) then N,N'-carbonyldiimidazole (8.48 g, 52.28 mmol) were added. The mixture was stirred at 90 C for 24 h, cooled and the solvent was evaporated under reduced pressure. The residue was dissolved in CH2C12 and washed with aqueous Na2CO3 (5%) and HC1(0.01N), dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanolic HC1(3M, 200 mL) and stirred at RT for 90 min. The solvent was evaporated under reduced pressure and the residue was triturated with EtOAc.
The solid was collected and dried in vacuo to give the title compound as a purple solid (9.00 g, 59%).
'H NMR (400MHz, D6-DMSO) 6 1.87 (2H, br d, J 13), 2.75 (2H, qd, J 13, 4), 3.08 (2H, br q, J 11), 3.40 (2H, br d, J 13), 3.75 (3H, s), 4.45-4.55 (1H, m), 6.41 (1H, d, J8), 7.29 (1H, d, J8), 8.75 (1 H, br), 9.01 (1 H, br), 10.90 (1H, s).
Description 72: (3RS)-Ethyl 1-(Phenylmethyl)-3-piperidinecarboxylate Benzyl chloride (165 mL, 181 g, 1.43 mol) was added in one portion to an intensively stirred, cooled (0 C) mixture of (3RS')-ethyl3-piperidinecarboxylate (200 mL, 201 g, 1.29 mol) and triethylamine (200 mL, 145 g, 1.43 mol) in MeCN (400 mL) and the mixture was stirred at RT
for 2.5 h. The solid was collected, washed with MeCN (2 x 200 mL) and dried in vacuo. The solid was dissolved in Et20 (300 mL) and washed with water (2 x 300 mL). The organic layer was dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound as an oil (270 g, 85%).
Description 73: (3RS')-1-(Phenylmethyl)-3-piperidinecarboxylic Acid Hydrazide Acetic acid (20 mL) and hydrazine hydrate (136 mL (140 g, 2.8 mol) were added to a solution of (3RS)-ethyl 1-(phenylmethyl)-3-piperidinecarboxylate (Description 72, 270 g, 1.092 mol) in ethanol (310 mL) 5 and the mixture was heated under reflux for 3 days. The mixture was cooled and the solvent was partly evaporated under reduced pressure until a precipitation occurred. The solid was collected, aqueous KOH
(50 g in 100 mL) was added and the mixture was extracted with CHC13 (2 x 300 mL). The combined organic fractions were dried (Na2SO4) the solvent was partly evaporated under reduced pressure until a precipitation occurred. The solid was collected, the filtrate was diluted with Et20 (200 mL) and further 10 solid was collected. The combined solids were washed with Et20 and dried in vacuo to give the title compound as a solid (217 g, 92%).
Description 74: (3RS')-1-(Phenylmethyl)-3-piperidinecarboxylic Acid 2-[(Methylamino)thioxomethyl] hydrazide 15 Methyl isothiocyanate (90 g, 1 43 mol) in toluene (50 mL) was added to a stirred solution of (3RS)-1-(phenylmethyl)-3-piperidinecarboxylic acid hydrazide (Description 73, 210 g, 0.90 mol) in toluene (500 mL) and the mixture was stirred at RT for 1 h. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (245 g, 90%).
20 Description 75: (3RS')-1-(Phenylmethyl)-3-(4-methyl-5-thio-4H-1,2,4-triazol-3-yl)piperidine Sodium (50 g, 2.18 mol) was added in portions to stirred, cooled (0 C) MeOH
(785 mL). Once the sodium had dissolved, (3RS)-1-(phenylmethyl)-3-piperidinecarboxylic acid 2-[(methylamino)thioxomethyl]hydrazide (Description 74, 230 g, 0.76 mol) was added and the mixture was heated under reflux for 1 h. The mixture was cooled in ice and aqueous acetic acid (126 mL, 131 g, 25 2.19 mol) in water (400 mL) was added. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (173 g, 79%).
Description 76: (3RS')-1-(Phenylmethyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine (3RS)-1-(Phenylmethyl)-3-(4-methyl-5-thio-4H-1,2,4-triazol-3-yl)piperidine (Description 75, 160 g, 30 0.56 mol) was dissolved by portions of 15-20 g in stirred, cooled (0 C) concentrated nitric acid (70%, 500 mL). The mixture was stirred at 0 C for 1 h then poured into stirred, cooled (0 C) aqueous KOH
(600 g) with continuing addition of ice. The mixture was divided into 4 portions and each portion of 500 mL was extracted with CHC13 (300 mL). The combined organic fractions were dried (Na2S04) and the solvent was evaporated under reduced pressure to give the title compound.
Description 77: (3RS')-3-(4-Methyl-4H-1,2,4-triazol-3-yl)piperidine Hydrochloride Pd on C (5%) was added to a mixture of (3RS)-1-(phenylmethyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine (Description 76) and hydrochloric acid (conc., 50 mL) in methanol (400 mL) and the mixture was shaken under an atmosphere of H2 (100 atm.) at 90 C for 24 h. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was dissolved at reflux in iso-propanol (100 mL) and hydrochloric acid (conc., 50 mL) was added. The mixture was cooled and stored at 5 C for 3 days. The solid was collected, washed with Et20 and dried in vacuo to give the title compound as a solid (103 g, 91%).
'H NMR (D6-DMSO) 6 9.80-9.40 (3H, m), 3.90 (3H, s), 3.80-2.80 (5H, m), 2.20-1.70 (4H, m).
Description 78: 1-(3-Pyridinylmethyl)piperazine Trifluoroacetate Sodium triacetoxyborohydride (254 g, 1.2 mol) was added in portions to a rigorously stirred solution of 1, 1 -dimethylethyl piperazinecarboxylate (186 g, 1 mol), acetic acid (120 mL, 2 mol) and 3-pyridinecarboxaldehyde (107 g, 1 mol) in CH2C12 (700 mL), keeping the mixture at slow reflux. The mixture was stirred overnight at RT, washed with aqueous acetic acid (5%, 2 x 150 mL) and dried (CaC12). The solution was cooled in ice and trifluoroacetic acid (350 mL, 3.5 mol) was added with stirring. The mixture was stirred at RT until thin layer chromatography (silica gel;
chloroform:ethanol:benzene; 7:2:1; ninhydrin development) indicated complete consumption of starting material. The solvent was partially evaporated under reduced pressure at 70 C. The mixture was then allowed to crystallize (Et20 was added to help crystallization if needed). The solid was collected, washed with Et20 (2 x 100 mL), Et2O:EtOAc (2:1, 100 mL), and again with Et20 (100 mL). The solid was dried in vacuo to give the title compound as a solid (390 g, 75%).
'H NMR (D6-DMSO) 6 8.85 (2H, br s), 8.70 (2H, m), 8.12 (1H, d), 7.69 (1H, t), 6.0 (1H, br s), 3.90 (2H, s), 3.20 (4H, m), 2.80 (4H, m).
Description 79: [1,2-Bis(hydroxyimino)propyl]piperazine Piperazine (84 g, 0.96 mol) in distilled water (400 mL) was added dropwise to a solution of N-hydroxy-2-(hydroxyimino)propanimidoyl chloride (33 g, 0.24 mol) in ethanol (100 mL), maintaining the reaction temperature below 30 C. The mixture was stirred at RT for 24 h, then filtered, washing with hot water (150 mL). The solvent was evaporated under reduced pressure to give a mixture of the title compound and piperazine, which was used without further purification.
Description 80: 1-(4-Methyl-1,2,5-oxadiazol-3-yl)piperazine Hydrochloride NaOH (20 g, 0.5 mol) was added slowly to an intensively stirred solution of [1,2-bis(hydroxyimino)propyl]piperazine (Description 79) in water (350 mL). The mixture was placed in an autoclave (0.5 L) and stirred for 5 h at 190 C. The mixture was cooled and stirred overnight. The mixture was extracted with Et20 (5 x 150 mL), and the combined organic fractions were dried (MgS04) and the solvent was evaporated under reduced pressure. The residue was dissolved in MeOH, acidified with hydrochloric acid (1 eq), and the solvent was evaporated under reduced pressure. The residue was recrystallized from isopropanol to give the title compound (5.8 g).
'H NMR (D6-DMSO) 6 9.50 (2H, br s), 3.50 (4H, t), 3.21 (4H, t), 2.38 (3H, s).
Description 81: 4-(Chloromethyl)-4,5-dihydro-2-methyl-4-thiazolol A mixture of thioacetamide (7.5 g, 0.1 mol), 1.3-dichloroacetone (14 g, 0.11 mol), sodium bicarbonate (9.3 g, 0.11 mol) and dichloroethane (60 mL) was stirred at RT for 48 h. The mixture was filtered, washing with dichloroethane (20 mL), to give a solution of the title compound which was used without further purification.
Description 82: 4-(Chloromethyl)-2-methylthiazole Hydrochloride Thionyl chloride (13.1 g, 0.11 mol) in dichloroethane (60 mL) was added to an intensively stirred solution of 4-(chloromethyl)-4,5-dihydro-2-methyl-4-thiazolol in dichloroethane (Description 81), maintaining the reaction temperature below 30 C. The mixture was stirred at 65-70 C for 30 min, cooled and the solvent was evaporated under reduced pressure. The residue was crystallized from EtOAc to give the title compound as a crystalline solid (17.12 g, 93%).
Description 83: 1-[(2-Methyl-4-thiazolyl)methyllpiperazine 4-(Chloromethyl)-2-methylthiazole hydrochloride (Description 82, 92 g, 0.5 mol) in MeOH (400 mL) was added slowly to a stirred solution of piperazine (500 g, 5.81 mol) in methanol (800 mL) and the mixture was heated under reflux for 3 h. The mixture was cooled and methanolic KOH (1 mol in 400 mL) was added. The mixture was stirred at RT overnight, filtered and the solvent was evaporated under reduced pressure. The residue was dissolved in iso-propanol, filtered and purified by flash column chromatography on silica gel, eluting with iso-propanol-triethylamine (5:1) and the residue was vacuum distilled. A fraction with b.p. 123-127 C/-1 torr was collected to give the title compound as a light-yellow dense oil which formed hygroscopic low melting (-30 C) crystals on standing (57.1 g, 58%).
'H NMR (D6-DMSO) 6 7.20 (1H, s), 3.45 (2H, s), 3.15 (1H, br s), 2.60 (4H, t), 2.50 (3H, s), 2.30 (4H, m).
Description 84: 1,1-Dimethylethyl4-[2-(1-Hydroxy-l-methylethyl)-4-methyl-lH-imidazol-1-yl]-1-piperidinecarboxylate n-Butyllithium (1.6M in hexanes, 5.7 mL, 9.0 mmol) was added dropwise to a stirred, cooled (-78 C) solution of 1,1-dimethylethyl4-(4-methyl-lH-imidazol-l-yl)-1-piperidinecarboxylate (as prepared in W093/19059, 2 g, 7.5 mmol) in THF (50 mL) and the mixture was stirred at -78 C for 1 h. Ethyl bromide (0.7 mL, 9.0 mmol) was added and the mixture was stirred at RT for 5 h. Acetone (1.1 mL, 0.88 g, 15 mmol) was added and the mixture was stirred at RT overnight. Water was added and the mixture was extracted with EtOAc. The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2C12/MeOH (100:0 increasing to 98:2), to give the title compound (0.9 g, 37%).
m/z (ES) 324 (M+1).
Description 85: 4-[2-(1-Hydroxy-l-methylethyl)-4-methyl-lH-imidazol-1-yl]piperidine 1,1-Dimethylethyl4-[2-(1-hydroxy-l-methylethyl)-4-methyl-1 H-imidazol-l-yl]-1-piperidinecarboxylate (Description 84, 450 mg, 1.4 mmol) was dissolved in ethanolic HC1(4M, 6 mL) and stirred at RT
overnight. The solvent was evaporated under reduced pressure, aqueous NaHCO3 (saturated) was added and the mixture was extracted with CHC13/ iPrOH (85:15). The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure to give the title compound (257 mg, 83%).
'H NMR (500MHz, CDC13) 6 6.84, 6.53 (total 1H, each s), 5.25, 4.83 (total 1H, each s), 3.16 (2H, m), 2.69 (2H, s), 2.18 (1H, m), 2.11 (3H, s), 1.98-1.79 (3H, m), 1.60, 1.59 (total 6H, each s).
Description 86: 2-Chloro-N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)acetamide Chloroacetyl chloride (3.1 mL, 40 mmol) was added to a stirred mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (4.5 g, 36 mmol) and K2C03 (9.9 g, 72 mmol) in CH2C12 (75 mL). The mixture was stirred at RT for 15 min, diluted with MeOH and filtered. The solvent was evaporated under reduced pressure to give the title compound (5.6 g, 77%).
'H NMR (CD3OD) 6 6.72 (1H, s), 4.33 (4H, dd, J0.0, 7.0), 2.43 (3H, s), 1.47 (3H, t, J7.3).
Description 87: N-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(2-hydroxyethyl)amino]acetamide Ethanolamine (1.04 mL, 17 mmol) was added to a stirred mixture of 2-chloro-N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)acetamide (Description 86, 872 mg, 4.3 mmol) and Nal (50 mg) in MeCN (15 mL) and the mixture was stirred at 80 C for 4.5 h. The mixture was cooled and CHC13/
isopropyl alcohol (3:1) and water were added. The layers were separated and the aqueous layer was extracted with CHC13/ isopropyl alcohol. The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (0.534 g, 54%).
'H NMR (CD3OD) 6 6.08 (1H, s), 3.99 (2H, q, J7.2), 3.67-3.63 (2H, m), 3.46 (2H, s), 2.79-2.73 (2H, m), 2.19 (3H, s), 1.33 (3H, t, J7.2).
Description 88: 1-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)piperazin-2-one Di-tert-butyl azodicarboxylate (0.915 g, 4 mmol) and tri-n-butyl phosphine (1 mL, 4 mmol) were added to a stirred solution of N-(1-ethyl-3-methyl-lH-pyrazol-5-yl)-2-[(2-hydroxyethyl)amino]acetamide (Description 87, 0.3 g, 1.3 mmol) in EtOAc (10 mL) and the mixture was stirred at RT for 6 h. The mixture was poured onto SCX cartridges (Varian Bond E1utTM; 10 mL/500 mg). The cartridges were washed with MeOH, then eluted with methanolic ammonia (2M). The solvent was evaporated under reduced pressure and the residue was purified by chromatography on silica gel, eluting with CH2C12/MeOH (100:0 increasing to 90:10), to give the title compound (190 mg, 40%).
'H NMR (CDC13) 6 5.89 (1H, s), 3.92-3.86 (2H, m), 3.69 (2H, s), 3.60-3.56 (2H, m), 3.20 (2H, t, J 5.5), 2.25 (3H, s), 1.43-1.39 (3H, m).
Description 89: 2-Bromo-N-(3-fluorophenyl)acetamide Bromoacetyl bromide (23.5 mL, 0.27 mol) was added slowly to a stirred, cooled mixture of 3-fluoroaniline (25 g, 0.225 mol) in EtOAc (250 mL) and aqueous KHCO3 (20%, 250m1). The mixture was allowed to warm to RT and the layers were separated. The organic layer was diluted with EtOAc, washed with aqueous citric acid (10%) and brine, dried (MgSO4) and the solvent was evaporated under reduced pressure to give the title compound (51.72 g, 92%).
'H NMR (360MHz, CD3OD) 6 7.54 (1H, dt, J 11, 2), 7.34-7.24 (2H, m), 6.84 (1H, t, J 7), 3.96 (2H, s).
Description 90: 1-(3-Fluorophenyl)piperazinone Hydrochloride Ethanolamine (4.5 mL, 75 mmol) was added to stirred 2-bromo-N-(3-fluorophenyl)acetamide (Description 89, 5.0 g, 21 mmol) in EtOAc (25 mL) and the mixture was stirred at 60 C for 2 h. The mixture was cooled, EtOAc and water were added and the layers were separated.
The organic layer was dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was suspended in EtOAc (135 mL) and tributylphosphine (5.3 mL, 21 mmol) was added. The mixture was cooled to 0 C
and di-tert-butylazodicarboxylate (4.8 g, 21 mmol) was added dropwise over 1 h. The mixture was stirred at 0 C for 0.5 h, then at 40 C for 1.5 h. The mixture was cooled and ethanolic HC1(4M, 4.7 mL) was added. The mixture was stored at 0 C for 0.5 h., and the solid was collected, washing with cold EtOAc, and dried in vacuo to give the title compound.
'H NMR (400MHz, CD3OD) 6 3.68-3.71 (2H, m), 3.97-4.00 (2H, m), 4.02 (2H, s), 7.12 (1H, m), 7.18-7.22 (2H, m), 7.48 (1H, m).
Description 91: N-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-3-azetidinamine A mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (1.0 g, 8.0 mmol), 1-(diphenylmethyl)-3-azetidinyl methanesulfonate (2.5 g, 8.0 mmol) and K2C03 (2.2 g, 16.0 mmol) in DMF (10 mL) was stirred at 60 C
for 24 h. The mixture was cooled, poured into water (50 mL) and extracted with EtOAc (3 x 20 mL).
The combined organic fractions were dried (Na2SO4) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol (10 mL), palladium hydroxide (200 mg) was added and the mixture was shaken under H2 (45 psi) for 72 h. The mixture was filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with CH2C12/MeOH (90:10), to give the title compound as an oil.
(168 mg, 12%).
'H NMR (CD3OD) 6 5.15 (1H, s), 4.17-4.15 (1H, m), 3.90-3.81 (4H, m), 3.58 (2H, m), 2.09 (1H, s), 1.28 (3H, t, J7.1).
Description 92: 8-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-1,4-dioxa-8-azaspiro [4.5] decane A mixture of 1-ethyl-3-methyl-lH-pyrazol-5-amine (1 g, 8 mmol), 2,2-bis(2-iodoethyl)-1,3-dioxolane (3 g, 8 mmol) and K2C03 were dissolved in MeCN (15 mL) and heated under reflux for 4 days. The 5 mixture was cooled and the solvent was evaporated under reduced pressure.
The residue was suspended in EtOAc (100 mL) and washed with water (50 mL). The organic fraction was dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with hexanes/EtOAc (80:20), to give the title compound (470 mg).
10 Description 93: 1-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-4-piperidinone 8-(1-Ethyl-3-methyl-lH-pyrazol-5-yl)-1,4-dioxa-8-azaspiro[4.5]decane (Description 92) in aqueous acetic acid (75%, 16 mL) was heated under reflux for 16 h. The mixture was cooled and aqueous NaHCO3 (saturated, 300 mL) was added slowly. The mixture was extracted with EtOAc (2 x 200 mL) and the combined organic fractions were washed with brine (100 mL), dried (MgSO4) and the solvent was 15 evaporated under reduced pressure. Heptane was added and evaporated under reduced pressure to give the title compound as an oil (0.3 g).
'H NMR (CDC13) 6 5.69 (1H, s), 4.05 (2H, g, J7.2), 3.19 (4H, m), 2.59 (4H, m), 2.23 (3H, s), 1.42 (3H, t, J 7.3).
20 Example 1: Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Sodium triacetoxyborohydride (0.3 g, 1.4 mmol) and acetic acid (62 mg, 1 mmol) were added to a mixture of 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone (Description 14, 0.44 g, 1 mmol) and 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine (0.2 g, 1 mmol) in 1,2-dichloroethane 25 (8 mL) and the mixture was stirred at RT for 16 h. Water and EtOAc were added and the layers were separated. The organic layer was washed with aqueous NaHCO3 (saturated), water, and brine, dried (MgS04), and the solvent was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel, eluting with EtOAc/isohexane mixtures, to give the title compound.
'H NMR (360MHz, CDC13) 6 1.185 (2H, m), 1.36 (3H, t, J7.2), 1.60 (2H, m), 1.79-1.93 (2H, m), 2.14 30 (2H, t, J 11.3), 2.19 (3H, s), 2.30 (2H, t, J 13.7), 2.35-2.50 (2H, m), 2.58 (2H, m), 2.86 (2H, m), 3.96 (2H, q, J 7.2), 5.73 (1H, s), 7.09 (2H, d, J 8.7), 7.22 (2H, d, J 8.7), 7.34 (2H, d, J 8.7), 7.43 (2H, d, J 8.7). m/z (ES) 603, 605 (M+1).
The following compounds were prepared according to the method of Example 1 substituting a suitable 35 cyclohexanone for 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone and a suitable amine for 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine.
x. ame ES MS
+1 Cis & Trans-l-[4-(2-Fluoro-4-bromophenyl)-4-(4- 622, 624 hlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine Trans-1'-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-1,3-diethyl-644, 646 ,5-dihydrospiro[cyclopentapyrazole-6(1 H),4'-piperidine]
Trans-l-{4-[4-(Trifluoromethyl)phenyl]-4-(4-chlorobenzenesulfonyl)cyclohexyl}-2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(3,4-Dichlorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl- 594 5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(2,5-Difluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl- 562 5-methyl-2H-pyrazol-3-yl)piperidine Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-[1-(1,1-632, 634 Idimethylethyl)-3-methyl-IH-pyrazol-5-yl]piperidine 8 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-[1-(-(2,2,2- 658/660 trifluoroethyl))-3-methyl-IH-pyrazol-5-yl]piperidine Trans-l-{4-[4-(Trifluoromethoxy)phenyl]-4-(4-chlorobenzenesulfonyl)cyclohexyl}--(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine Trans-l-[4-(4-Fluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-ethyl-2H-pyrazol-3-yl)piperidine 11 Trans-l-[4-(4-Methylphenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 541,543 ethyl-2H-pyrazol-3 -yl)piperidine 12 Trans-l-[4-(4-Cyanophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 551 ethyl-2H-pyrazol-3 -yl)piperidine 13 Trans-l-[4-(4-Bromophenyl)-4-(benzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-methyl- 570 H-pyrazol-3-yl)piperidine 14 Trans-l-[4-(3-Fluorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 544 ethyl-2H-pyrazol-3 -yl)piperidine Trans-l-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4-638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 16 Trans-l-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 595, 597 ethyl-2H-pyrazol-3 -yl)piperidine 17 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(3,5-diethyl- 618,620 1 H-pyrazol-l-yl)piperidine 18 Trans-l-{4-(4-Bromophenyl)-4-[3-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4- 638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 19 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(4H-1,2,4- 563/565 triazol-4-yl)piperidine x. ame ES MS
+1 0 Trans-4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 678, 680 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 1 Trans-l-{4-(3-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4- 638, 640 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 2 Trans-l-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 594 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 636, 638 2-ethyl-5-methyl-2H-pyrazol-3-yl)-1,2,3,6-tetrahydropyridine 4 Cis-1-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5-604, 606 ethyl-2H-pyrazol-3 -yl)piperidine Cis-4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl}
678, 680 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 Cis-1-[4-(3,4-Dichlorophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 594 ethyl-2H-pyrazol-3 -yl)piperidine 7 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 638, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 8 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 636, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)-1,2,3,6-tetrahydropyridine 9 Cis & Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-604, 606 thyl-5-methyl-2H-pyrazol-3-y1)piperidine 0 Cis-1-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 594, hiazolyl)piperazinone 1 Trans-l-[4-(4-Bromophenyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 594, hiazolyl)piperazinone 2 Trans-l-[4-(4-Bromophenyl)-4-(4-methylbenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 584, 586 ethyl-2H-pyrazol-3 -yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethoxy)benzenesulfonyl)cyclohexyl]-4- 654, 656 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 4 Trans-l-[4-(4-Bromophenyl)-4-(3-chlorobenzenesulfonyl)cyclohexyl]-4-(2-ethyl-5- 604, 606 ethyl-2H-pyrazol-3 -yl)piperidine 5 Trans-4-[1-{4-(4-Chlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 634 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 R)-Cis-1-[4-(3,4-Dichlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 628 yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 7 Trans-l-[4-(3,4-Dichlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 628 -(2-ethyl-5-methyl-2H-pyrazol-3-y1)piperidine x. ame ES MS
+1 8 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 711, 713 1,2-dihydro-l-(methylsulfonyl)spiro[3H-indole-3,4'-piperidine]
9 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 689, 691 1 -methylethyl)spiro [3H-indole-3,4'-piperidin]-2(1 H)-one 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 612, 614 3-methyl-1,2,4-oxadiazol-5-yl)piperidine 1 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 597, 599 4H-1,2,4-triazol-4-yl)piperidine 2 RS)-Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 597, 599 -(1 H-1,2,4-triazol-1-yl)piperidine 3 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 597, 599 1 H-tetrazol-1-yl)piperidine 4 Trans-8-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 676, 678 henyl-1,3,8-triazaspiro[4.5]decan-4-one Trans-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 693, 695 iperidin-4-yl]-1,3-dihydro-5-methoxy-2H-imidazo[4,5-b]pyridin-2-one 6 Trans-N-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 713, 715 iperidin-4-yl } methyl-N-phenylmethanesulfonamide 7 Trans-N-[4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 677, yclohexyl } -4-phenylpiperidin-4-yl } -methyl] acetamide 8 RS')-Trans-4-[4-(4-Bromophenyl)-4-(4- 638, 640 trifluoromethyl)benzenesulfonyl)cyclohexyl]-2-(phenoxymethyl)morpholine 9 Trans-l-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 677, 679 iperidin-4-yl]-1,4-dihydro-2H-3,1-benzoxazin-2-one 50 Trans-6-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 569, 571 5,6,7,8-tetrahydro-[ 1,2,4]triazolo[ 1,5-a]pyrazine 51 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 611, yclohexyl]-3-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine 52 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 622, 624 3-pyridinylmethyl)piperazine 53 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 613, 615 4-methyl-1,2,5-oxadiazol-3-yl)piperazine 54 S)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 635, 637 -(phenylmethyl)-3-pyrrolidinemethanamine 55 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 642, 644 [(2-methyl-4-thiazolyl)methyl]piperazine x. ame ES MS
+1 56 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4-[(2- 642, 644 ethyl-4-thiazolyl)methyl]piperazine 57 S)-Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N- 635, 637 henylmethyl)-3-pyrrolidinemethanamine 58 Cis-N-[4-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 677, yclohexyl } -4-phenylpiperidin-4-yl } -methyl] acetamide 59 Cis-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 693, 695 iperidin-4-yl]-1,3-dihydro-5-methoxy-2H-imidazo[4,5-b]pyridin-2-one 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-3- 569, 571 1 H-1,2,4-triazol-3 -yl)azetidine 1 Cis-8-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-676, 678 henyl-1,3,8-triazaspiro[4.5]decan-4-one 2 Cis-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1,2- 711, 713 ydro-l-(methylsulfonyl)spiro [3H-indole-3,4'-piperidine]
3 Trans-3-[1-{4-(4-Bromophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 676, 678 iperidin-4-yl]-3,4-dihydro-2(1 H)-quinazolinone 4 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4- 597, 599 trifluoromethyl)benzenesulfonyl)cyc lohexyl] -3 -(1 H-1,2,4-triazol-1-yl)piperidine Cis-4-[1-{4-(3,4-Dichlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 668 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 6 Trans-4-[1-{4-(3,4-Dichlorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 7 Cis-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1,3- 678/680 ethyl-4, 5-dihydrospiro [cyclopentapyrazole-6(1 H),4'-piperidine]
8 Trans-1'-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]- 678/680 1,3-diethyl-4,5-dihydrospiro[cyclopentapyrazole-6(1 H),4'-piperidine]
9 -[Trans-4-(4-Bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl]-4- 582, 584 methoxy)benzenemethanamine 0 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 692, 694 [ 1-(2,2,2-trifluoroethyl)-3 -methyl-1 H-pyrazol-5 -yl]piperidine 1 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 668, 670 [2-(1-hydroxy-l-methylethyl)-4-methyl-1 H-imidazol-1-yl]piperidine 2 Cis-4-[1-{4-(4-Fluororophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl} 618 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 3 Trans-4-[1-{4-(4-Fluororophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 618 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine x. ame ES MS
+1 4 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-2,6- 560, 562 methylmorpholine 5 Cis-1-[4-(4-Fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4-(2- 578 thyl-5-methyl-2H-pyrazol-3-y1)piperidine 6 Trans-l-[4-(4-Fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 578 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 7 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 653, 655 1-ethyl-3-methyl-1 H-pyrazol-5-yl)piperazin-2-one 8 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(1- 653, 655 thyl-3-methyl-1 H-pyrazol-5-yl)piperazin-2-one 9 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 652, 654 [ 1,3,4-Trimethyl-1 H-pyrazol-5-yl]piperidine 80 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-2,6- 560, 562 Idimethylmorpholine 81 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 652, 654 [ 1,3,4-trimethyl-1 H-pyrazol-5 -yl]piperidine 82 Trans-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 639, 641 3-fluorophenyl)piperazinone 83 Cis-1-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N-(1- 625, 627 thyl-3-methyl-1 H-pyrazol-5-yl)-3-azetidinamine 84 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-N- 625, 627 1-ethyl-3-methyl-1 H-pyrazol-5-yl)-3-azetidinamine 85 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 666, 668 [ 1-(1,1-dimethylethyl)-3-methyl-lH-pyrazol-5-yl]piperidine 86 Cis-4-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(3- 639,641 uorophenyl)piperazinone 87 Cis-4-{1-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]piperidin-4- 635, 637 1} -2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 88 Trans-4-{1-[4-(4-Bromophenyl)-4-(4-cyanobenzenesulfonyl)cyclohexyl]piperidin-4- 635, 637 1} -2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 89 Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-4- 664, 666 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 0 Trans-l-[4-(4-Chloro-3-fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 1 Cis-1-[4-(4-Chloro-3-fluorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine x. ame ES MS
+1 2 Cis-4-[1-{4-(4-Chloro-3-fluorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
652, 654 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 3 Trans-4-[1-{4-(4-Chloro-3-fluorophenyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 652, 654 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 4 Cis-6-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,6-naphthyridine Trans-6-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,6-naphthyridine 6 Trans-4-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1- 578 2-pyridinyl)piperazinone 7 Cis-4-[4-(4-Chlorophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl)cyclohexyl]-1-(2- 578 yridinyl)piperazinone 8 Trans-l-{4-(4-Chlorophenyl)-4-[4-(1-hydroxy-l-methylethyl)benzenesulfonyl]
yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 9 Trans-Methyl4-({1-(4-Chlorophenyl)-4-[4-(2-ethyl-5-methyl-2H-pyrazol-3- 584 1)piperidinyl]cyclohexyl} sulfonyl)benzoate-100 1,1-Dimethylethyl [ 1-(Trans-4-(4-chlorophenyl)-4- { [4- 601 trifluoromethyl)phenyl] sulfonyl} cyclohexyl)-4-piperidinyl] carbamate 101 Trans-l-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 639, 641 -(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 102 Cis-1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 639, 641 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 103 Trans-4-[1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]
679,681 yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 104 Cis-4-[1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 679, 681 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 105 Cis-4-[1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 635 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 106 Trans-4-[1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]
yclohexyl}piperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 107 Cis-1-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 595 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 108 Trans-l-{4-(4-Chlorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 595 -(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 109 Cis-1-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 665, 667 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine x. ame ES MS
+1 110 Trans-l-{4-(4-Bromophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}- 665, 667 -(2-ethy1-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 111 Trans-4-[1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 619 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 112 Cis-4-[1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl} 619 iperidin-4-yl]-2-ethyl-4,5,6,7-tetrahydro-3-pyrazolo[ 1,5-a]pyridine 113 Trans-l-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 579 2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 114 Trans-l-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 605 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 115 Cis-1-{4-(4-Fluorophenyl)-4-[2-(trifluoromethyl)pyrid-5-ylsulfonyl]cyclohexyl}-4- 605 2-ethyl-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl)piperidine 116 Cis-1-[4-(4-Bromophenylmethyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2-618, 620 thyl-5-methyl-2H-pyrazol-3-yl)piperidine 117 Trans-l-[4-(4-Bromophenylmethyl)-4-(4-chlorobenzenesulfonyl)cyclohexyl]-4-(2- 618, 620 thyl-5-methyl-2H-pyrazol-3-yl)piperidine 118 Cis-1-{4-(4-Bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl] 652, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 119 Trans-l-{4-(4-Bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl]
652, 654 yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine 120 Cis & Trans-l-[4-Phenyl-4-(phenylsulfonylmethyl)cyclohexyl]-4-(2-ethyl-5-methyl- 506 H-pyrazol-3-yl)piperidine 121 RS)-Trans-l-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfinyl) 622, yclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Example 122: Trans-1-{4-Phenylmethyl-4-[4-(trifluoromethyl)benzenesulfonyl]
cyclohexyll-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine Pd on C (30 mg) was added to a solution of trans-1-{4-(4-bromophenylmethyl)-4-[4-(trifluoromethyl)benzenesulfonyl]cyclohexyl]-4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine (Example 119, 57 mg, 87 mol) in EtOAc (5 mL) and the mixture was vigorously stirred under a H2 atmosphere overnight. The mixture was filtered through HyfloTM and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography on silica gel, eluting with EtOAc/MeOH/NH3(Aq.) (98:2:0.2) to give the title compound (10 mg, 20%).
'H NMR (500MHz, CD3OD): 6 7.99 (d, J 8.1, 2H); 7.89 (d, J 8.1, 2H); 7.36 (d, J
8.2, 2H); 7.24 (m, 3H);
5.83 (s, 1H); 4.02 (q, J7.2, 2H); 3.26 (s, 2H); 3.01 (d, J 11.3, 2H); 2.63 (m, 1H); 2.35 (m, 3H); 2.16 (s, 3H); 2.10 (d, J 13.1, 2H); 1.90 (m, 6H); 1.63 (m, 4H); 1.33 (t, J7.2, 3H).
Example 123: Trans-4-(4-Bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexanamine Ceric ammonium nitrate (232 mg, 0.423 mmol) was added to a stirred suspension of N-[trans-4-(4-bromophenyl)-4- { [4-(trifluoromethyl)phenyl] sulfonyl} cyclohexyl] -4-(methoxy)benzenemethanamine (Example 69, 99 mg, 0.17 mmol) in MeCN (1.0 ml) and water (0.35 ml) at RT. The mixture was stirred overnight and a further portion of ceric ammonium nitrate (29 mg, 0.053 mmol) was added. After stirring at RT for a further 1 h, the mixture was diluted with EtOAc and water. The aqueous layer was separated and re-extracted with EtOAc. The combined organic layers were dried (MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by preparative thin layer chromatography, eluting with 10% MeOH in CH2C12, to give the title compound (48 mg, 62%).
'H NMR (400MHz, CDC13 S 1.02 (2H, q, J 12.4), 1.88 (2H, d, J 12.3), 2.32 (2H, m), 2.53 (2H, d, J 13), 2.84 (1H, m), 7.09 (2H, d, J 8.2), 7.43 (4H, d, J 8.1), 7.63 (2H, d, J 8.0).
The following compound was prepared according to the method of Example 1 substituting trans-4-(4-bromophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexanamine (Example 123) for 4-(4-bromophenyl)-4-[(4-chlorophenyl)sulfonyl]cyclohexanone and 1-(1-ethyl-3-methyl-lH-pyrazol-5-yl)-4-piperidinone (Description 93) for 4-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine.
x. ame ES MS (M+1) 124 Trans-N-[4-(4-Bromophenyl)-4-(4-(trifluoromethyl)benzenesulfonyl) 653, 655 yclohexyl] -1-(2-ethyl-5-methyl-2H-pyrazol-3-yl)piperidine-4-amine Example 125: 1-(Trans-4-(4-Chlorophenyl)-4-{[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)piperidin-4-amine Hydrochloride Hydrogen chloride in dioxane (4N, 10 mL) was added to a stirred solution of 1, 1 -dimethylethyl [1-(trans-4-(4-chlorophenyl)-4- { [4-(trifluoromethyl)phenyl] sulfonyl } cyclohexyl)-4-piperidinyl] carbamate (Example 100, 2.045 g, 3.4 mmol) in CH2C12 (10 mL) and the mixture was stirred at RT overnight. The solvent was evaporated under reduced pressure to give the title compound (1.73 g, 95%).
'H NMR (360MHz, CD3OD): 6 7.78 (t, 2H), 7.55 (d, 2H), 7.35 (q, 4H), 3.53 (d, 3H), 3.06 (t, 2H), 2.85 (d, 2H), 2.38 (t, 3H), 2.21 (d, 4H), 1.93 (d, 2H), 1.41 (d, 2H).
Example 126: N-(1,1-Dimethylethyl)-N'-[1-(Trans-4-(4-chlorophenyl)-4-{[4-(trifluoromethyl)p henyl] sulfonyl} cyclohexyl)piperidin-4-yl] urea t-Butyl isocyanate (0.0255 mL, 0.224 mmol) was added to a stirred solution of 1-(trans-4-(4-chlorophenyl)-4- {[4-(trifluoromethyl)phenyl] sulfonyl} cyclohexyl) piperidin-4-amine hydrochloride (Example 125, 0.1 g, 0.186 mmol) and triethylamine (0.077 mL, 0.558 mmol) in CH2C12 (5 mL) and the mixture was stirred at RT for 2 h. Water was added and the mixture was extracted with CH2C12. The combined organic fractions were dried (MgSO4) and the solvent was evaporated under reduced pressure.
The residue was purified by preparative thin layer chromatography on silica gel, eluting with 5% MeOH
in CH2C12, to give the title compound (40 mg, 36%).
'H NMR (500MHz, CD3OD): 6 7.77 (d, 2H), 7.53 (d, 2H), 7.31 (q, 4H), 3.37 (t, 1H), 2.77 (d, 2H), 2.71 (d, 2H), 2.52 (s, 1H), 2.25 (q, 4H), 1.99 (d, 2H), 1.79 (d, 2H), 1.29 (t, 2H), 1.26 (s, 9H), 1.21-1.13 (m, 2H).
Claims (26)
1. A compound of formula (I):
wherein:
rings A and B are independently aryl or heteroaryl;
n is 0, 1 or 2;
X and Y are independently selected from a bond, -CH2-, -C(C1-4alkyl)2- and N(C1-4alkyl)-;
Z is a bond, -CH2- or -C(C1-4alkyl)2-;
R1 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy, halogen, CN, CO2(C1-6alkyl) or C(CH3)2OH, optionally substituted by 1 to 8 halogen atoms;
R2 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl or halogen;
R3 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy, halogen or CN, optionally substituted by 1 to 8 halogen atoms;
R4 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl or halogen;
R5 and R6 are independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy or halogen;
R7 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, (CH2)0-2ary1, (CH2)0-2heteroaryl or Het, optionally substituted by 1 to 8 halogen atoms, C1-4alkyl, hydroxy, C1-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 to 3 groups selected from C1-4alkyl;
R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C3-8cycloalkyl;
or R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle, optionally containing 1, 2 or 3 further heteroatoms selected from N, O and S, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C3-8cycloalkyl, hydroxy, oxo, (CH2)0-3C1-6alkoxy, (CH2)0-3Oaryl, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3Het, or (CH2)0-3NR a R b, wherein said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C1-6alkyl, hydroxy, oxo, C1-6alkoxy or halogen, which C1-6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said aryl, heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1,
wherein:
rings A and B are independently aryl or heteroaryl;
n is 0, 1 or 2;
X and Y are independently selected from a bond, -CH2-, -C(C1-4alkyl)2- and N(C1-4alkyl)-;
Z is a bond, -CH2- or -C(C1-4alkyl)2-;
R1 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy, halogen, CN, CO2(C1-6alkyl) or C(CH3)2OH, optionally substituted by 1 to 8 halogen atoms;
R2 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl or halogen;
R3 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy, halogen or CN, optionally substituted by 1 to 8 halogen atoms;
R4 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl or halogen;
R5 and R6 are independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, hydroxy, C1-6alkoxy or halogen;
R7 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, (CH2)0-2ary1, (CH2)0-2heteroaryl or Het, optionally substituted by 1 to 8 halogen atoms, C1-4alkyl, hydroxy, C1-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 to 3 groups selected from C1-4alkyl;
R8 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C3-8cycloalkyl;
or R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocycle, optionally containing 1, 2 or 3 further heteroatoms selected from N, O and S, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C3-8cycloalkyl, hydroxy, oxo, (CH2)0-3C1-6alkoxy, (CH2)0-3Oaryl, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3Het, or (CH2)0-3NR a R b, wherein said aryl, heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C1-6alkyl, hydroxy, oxo, C1-6alkoxy or halogen, which C1-6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said aryl, heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1,
2 or 3 heteroatoms selected from N, O or S and which ring is optionally substituted by C1-4alkyl, hydroxy, oxo, C1-4alkoxy or halogen, and which heterocycle may optionally be fused to heteroaryl, which heteroaryl is optionally substituted by C1-6alkyl or trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5- or 10-membered mono- or bi-cyclic ring system optionally containing 1, 2 or 3 heteroatoms selected from N, O and S, and further optionally containing 1, 2 or 3 double bonds and also optionally substituted by 1 to 3 groups independently selected from C1-6alkyl, hydroxy, oxo, phenyl and SO2C1-6alkyl;
R a is hydrogen, C1-6alkyl, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)NH(C1-6alkyl), (CH2)0-3aryl, (CH2)0-3heteroaryl or SO2C1-6alkyl, optionally substituted by C1-6alkyl;
R b is hydrogen, C1-6alkyl or aryl;
and pharmaceutically acceptable salts thereof.
2. A compound as claimed in Claim 1 wherein ring A is phenyl, pyridyl or pyrimidyl.
R a is hydrogen, C1-6alkyl, C(O)C1-6alkyl, C(O)OC1-6alkyl, C(O)NH(C1-6alkyl), (CH2)0-3aryl, (CH2)0-3heteroaryl or SO2C1-6alkyl, optionally substituted by C1-6alkyl;
R b is hydrogen, C1-6alkyl or aryl;
and pharmaceutically acceptable salts thereof.
2. A compound as claimed in Claim 1 wherein ring A is phenyl, pyridyl or pyrimidyl.
3. A compound as claimed in Claim 1 or Claim 2 wherein ring B is aryl or pyridyl.
4. A compound as claimed in any one of Claims 1 to 3 wherein n is 1 or 2.
5. A compound as claimed in any one of Claims 1 to 4 wherein X is a bond, -CH2-or -C(C1-4alkyl)2-.
6. A compound as claimed in any one of Claims 1 to 5 wherein Y is a bond, -CH2-or -C(C1-4alkyl)2-.
7. A compound as claimed in any one of Claims 1 to 6 wherein Z is a bond or -CH2-.
8. A compound as claimed in any one of Claims 1 to 7 wherein R1 is hydrogen, C1-6alkyl, hydroxy, C1-6alkoxy, halogen, CN, CO2(C1-4alkyl) or C(CH3)2OH, optionally substituted by 1 to 5 halogen atoms.
9. A compound as claimed in any one of Claims 1 to 8 wherein R2 is hydrogen or C1-6alkyl.
10. A compound as claimed in any one of Claims 1 to 9 wherein R3 is hydrogen, C1-6alkyl, hydroxy, C1-6alkoxy, halogen or CN, optionally substituted by 1 to 5 halogen atoms.
11. A compound as claimed in any one of Claims 1 to 10 wherein R4 is hydrogen or halogen.
12. A compound as claimed in any one of Claims 1 to 11 wherein R5 is hydrogen, C1-6alkyl, hydroxy, C1-6alkoxy, or halogen.
13. A compound as claimed in any one of Claims 1 to 12 wherein R6 is hydrogen or C1-6alkyl.
14. A compound as claimed in any one of Claims 1 to 13 wherein R7 is hydrogen, C1-6alkyl, (CH2)0-2aryl, or Het, optionally substituted by C1-4alkyl, C1-4alkoxy or heteroaryl, which heteroaryl is optionally substituted by 1 or 2 methyl or ethyl groups.
15. A compound as claimed in any one of Claims 1 to 14 wherein R8 is hydrogen or C1-6alkyl.
16. A compound as claimed in any one of Claims 1 to 13 wherein R7 and R8, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycle, optionally containing 1 or 2 further heteroatoms selected from N and O, which heterocycle may optionally contain one double bond, and which heterocycle may optionally be substituted by one or two groups selected from C1-4alkyl, oxo, CH2-O-phenyl, phenyl, heteroaryl, CH2heteroaryl, Het, NH2, (CH2)0-1NHR a or CH2N(phenyl)SO2CH3, where said aryl, heteroaryl, and Het are optionally substituted by 1, 2 or 3 groups selected from C1-4alkyl, oxo or halogen, which C1-4alkyl being optionally substituted by hydroxy or 1 to 3 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5-or 6-membered ring which optionally contains a nitrogen atom and which ring is optionally substituted by C1-4alkoxy, and which heterocycle may optionally be fused to pyridyl or triazolyl, optionally substituted by trifluoromethyl, and which heterocycle may optionally be spiro-fused to a 5-membered monocyclic or a 8- or 9-membered bicyclic ring system, optionally containing 1 or 2 N atoms, further optionally containing 2 or 3 double bonds and also optionally substituted by C1-4alkyl, oxo, phenyl, or SO2C1-4alkyl, and R a is as defined in Claim 1.
17. A compound as claimed in Claim 1 of formula (Ia):
or a pharmaceutically acceptable salt thereof, wherein ring A, n, X, Y, R1, R3, R4, R7 and R8 are as defined in Claim 1.
or a pharmaceutically acceptable salt thereof, wherein ring A, n, X, Y, R1, R3, R4, R7 and R8 are as defined in Claim 1.
18. A compound as claimed in Claim 17 of formula (Iaa):
or a pharmaceutically acceptable salt thereof, wherein R1 and R3 are as defined in Claim 1, and R9 is (CH2)0-3NR a R b, where R a and R b are as defined in Claim 1, or (CH2)0-3heteroaryl or (CH2)0-3Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C1-6alkyl, hydroxy, oxo, C1-6alkoxy or halogen, which C1-6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1 or 2 heteroatoms selected from N and O, and which ring is optionally substituted by C1-4alkyl, hydroxy or C1-4alkoxy.
or a pharmaceutically acceptable salt thereof, wherein R1 and R3 are as defined in Claim 1, and R9 is (CH2)0-3NR a R b, where R a and R b are as defined in Claim 1, or (CH2)0-3heteroaryl or (CH2)0-3Het, where said heteroaryl and Het are optionally substituted by 1, 2 or 3 groups independently selected from C1-6alkyl, hydroxy, oxo, C1-6alkoxy or halogen, which C1-6alkyl being optionally substituted by hydroxy or 1 to 5 halogen atoms, and where said heteroaryl and Het are also optionally fused to a 5- or 6-membered ring which optionally contains 1 or 2 heteroatoms selected from N and O, and which ring is optionally substituted by C1-4alkyl, hydroxy or C1-4alkoxy.
19. A compound as claimed in Claim 17 of formula (Iab):
or a pharmaceutically acceptable salt thereof, wherein R3 is as defined in Claim 1 and R9 is as defined in Claim 18.
or a pharmaceutically acceptable salt thereof, wherein R3 is as defined in Claim 1 and R9 is as defined in Claim 18.
20. A compound as claimed in Claim 1 which is selected from Examples 1 to 126 or a pharmaceutically acceptable salt thereof.
21. A pharmaceutical composition comprising a compound of any one of Claims 1 to 20 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
22. A compound of any one of Claims 1 to 20 or a pharmaceutically acceptable salt thereof for use in therapy.
23. Use of a compound of any one of Claims 1 to 20 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a NK-3 receptor mediated disease.
24. A method of treatment of a subject suffering from a NK-3 receptor mediated disease, which comprises administering to that patient a therapeutically effective amount of a compound of any one of Claims 1 to 20 or a pharmaceutically acceptable salt thereof.
25. The use of Claim 23 or the method of Claim 24 wherein the NK-3 receptor mediated disease is selected from: depression; anxiety disorders; phobias; psychosis and psychotic disorders; post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities; and irritable bowel syndrome.
26. A method of preparing a compound of Claim 1 where Z is a bond by the reaction of a compound of formula (II) with a compound of formula (III):
where A, B, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in Claim 1.
where A, B, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in Claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513747.6 | 2005-07-06 | ||
GBGB0513747.6A GB0513747D0 (en) | 2005-07-06 | 2005-07-06 | Therapeutic compounds |
PCT/GB2006/050184 WO2007003965A1 (en) | 2005-07-06 | 2006-07-04 | Substituted cyclohexyl derivatives as nk-3 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2611867A1 true CA2611867A1 (en) | 2007-01-11 |
Family
ID=34856682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002611867A Abandoned CA2611867A1 (en) | 2005-07-06 | 2006-07-04 | Substituted cyclohexyl derivatives as nk-3 receptor antagonists |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1907372A1 (en) |
JP (1) | JP2008544978A (en) |
AU (1) | AU2006264652A1 (en) |
CA (1) | CA2611867A1 (en) |
GB (1) | GB0513747D0 (en) |
WO (1) | WO2007003965A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8450304B2 (en) | 2008-12-10 | 2013-05-28 | Janssen Pharmaceutica N.V. | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 |
JP5685581B2 (en) | 2009-04-17 | 2015-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 4-Azetidinyl-1-heteroatom-linked cyclohexane antagonist of CCR2 |
EP2419419B1 (en) | 2009-04-17 | 2014-12-03 | Janssen Pharmaceutica NV | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
EP2568812B1 (en) * | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
BR112012031873A2 (en) | 2010-06-17 | 2016-11-08 | Janssen Pharmaceutica Nv | ccr2 cyclohexyl azetidinyl antagonists |
WO2015103508A1 (en) * | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
CN106061947B (en) * | 2014-01-06 | 2019-12-03 | 百时美施贵宝公司 | Cyclohexyl sulfone ROR gamma modulators |
CN104341389A (en) * | 2014-10-19 | 2015-02-11 | 湖南华腾制药有限公司 | Method for preparing triazolylpiperidine hydrochloride |
WO2019090001A1 (en) * | 2017-11-02 | 2019-05-09 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
CN109608411A (en) * | 2018-12-17 | 2019-04-12 | 上海合全药物研发有限公司 | A kind of preparation method of tert-butyl -1- oxygen subunit -6- oxa- -9- azaspiro [4.5] decane -9- formic acid base ester |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2719311B1 (en) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools. |
GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
GB0223039D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
GB0223038D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
-
2005
- 2005-07-06 GB GBGB0513747.6A patent/GB0513747D0/en not_active Ceased
-
2006
- 2006-07-04 AU AU2006264652A patent/AU2006264652A1/en not_active Abandoned
- 2006-07-04 WO PCT/GB2006/050184 patent/WO2007003965A1/en active Application Filing
- 2006-07-04 EP EP06744364A patent/EP1907372A1/en not_active Withdrawn
- 2006-07-04 CA CA002611867A patent/CA2611867A1/en not_active Abandoned
- 2006-07-04 JP JP2008518986A patent/JP2008544978A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2006264652A1 (en) | 2007-01-11 |
EP1907372A1 (en) | 2008-04-09 |
GB0513747D0 (en) | 2005-08-10 |
JP2008544978A (en) | 2008-12-11 |
WO2007003965A1 (en) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2611867A1 (en) | Substituted cyclohexyl derivatives as nk-3 receptor antagonists | |
EP1891002B1 (en) | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia | |
AU2001283345B2 (en) | Cyclopentyl modulators of chemokine receptor activity | |
ES2586213T3 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
CA2483752C (en) | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | |
AU2005262330B2 (en) | Piperidine derivatives as NK1 antagonists | |
US20200108054A1 (en) | Substituted benzamides and methods of use thereof | |
US20090118332A1 (en) | Therapeutic Agents - 551 | |
AU2003284984B2 (en) | Gamma-aminoamide modulators of chemokine receptor activity | |
JP5813101B2 (en) | Glycine transporter-1 inhibitor, its production method and use method | |
MXPA06001558A (en) | Cyclic amine base-1 inhibitors having a heterocyclic substituent. | |
CA2570637A1 (en) | N-substituted piperidines and their use as pharmaceuticals | |
JP2003528076A (en) | Sulfonamide-substituted bridged bicycloalkyl derivatives | |
CA2607874A1 (en) | Quinoline derivatives as neurokinin receptor antagonists | |
AU2001283345A1 (en) | Cyclopentyl modulators of chemokine receptor activity | |
US20200115354A1 (en) | Therapeutic compounds and methods of use thereof | |
AU2004231087A1 (en) | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | |
CA3011465A1 (en) | Pyridazine derivatives as eaat2 activators | |
WO2008100620A2 (en) | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
JP2018533551A (en) | Therapeutic compounds and methods of use thereof | |
WO2008100635A1 (en) | 1- [3- (monocyclic amino) propyl] - 4, 5, 6, 7-tetrahydro-1h-pyrazolo [4, 3-c] -pyridines as modulators of cathepsin s | |
US20080096885A1 (en) | Quinoline Derivatives as Neurokinin Receptor Antagonists | |
CA3208951A1 (en) | Pyrazolopyridine derivatives and uses thereof | |
US20240239766A1 (en) | 3-amino piperidyl sodium channel inhibitors | |
CA2616547A1 (en) | Quinoline derivatives as neurokinin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |